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ABSTRACT 
 
 
STEPHANY DE SCISCIOLO CAVALLO.  Racial disparities in direct-to-consumer 
pharmaceutical advertising.  (Under the direction of DR. TERESA L. SCHEID) 
 
 
Reducing health disparities by increasing access to health information is a 
national priority.  Research demonstrates that direct-to-consumer advertising (DTCA) is 
effective in educating consumers about health issues.  However, research also identified 
racial disparities in such advertising.  In 2009, the Food and Drug Administration (FDA) 
issued a report that included a number of recommendations for enhancing the ability of 
DTCA to reach disadvantaged populations, including racial and ethnic minorities.  This 
study compared the pharmaceutical advertisements placed in five popular women’s 
magazines published prior to and following the 2009 FDA report to assess the impact of 
these recommendations on the content and appearance of advertisements placed in 
magazines of differing racial orientation. 
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CHAPTER 1:  INTRODUCTION 
 
 
The variability in health status among different population groups in the United 
States remains a much studied issue in health policy.  Despite a significant national 
investment in health care and widespread technological advancement (e.g., new drugs, 
better facilities, state-of-the art equipment), the fact remains that some groups of people 
are healthier than others.  For example, a 2011 report from the Centers for Disease 
Control and Prevention (CDC) indicates that African Americans fare more poorly than 
Caucasians on virtually every morbidity and mortality health outcome measure, with the 
exception of motor-vehicle-related deaths (CDC, 2011).  African Americans, as well as 
other minorities, have less access to health care and preventive services, are more likely 
to live in unhealthy housing and breathe unhealthy air, and are at greater risk for 
developing a chronic disease than Caucasians (CDC, 2011).  As a result, the life 
expectancy of the African American population is 3.8 years less than that for the 
Caucasian population based on 2010 data (Murphy, Xu, & Kochanek, 2013).  In contrast, 
the life expectancy of the Hispanic population is 2.3 years greater than for the Caucasian 
population and 6.1 years greater than for the African American population (Murphy et al., 
2013), suggesting that something other than minority status is negatively impacting the 
health of African Americans in this country. 
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 While the difference in life expectancy between African Americans and 
Caucasians has been declining, the relative risk differences between the African 
American and Caucasian populations for individual diseases remain significant.  For 
example, an African American with hypertension has a far greater risk of dying from the 
disease than does a Caucasian (Murphy et al., 2013).  In fact, for 8 of the 15 leading 
causes of death in the United States in 2010, the rate of death among African Americans 
in the United States was greater than among Caucasians, with Black to White, 
age-adjusted ratios ranging from a low of 1.1 for influenza and pneumonia to a high of 
2.4 for essential hypertension and hypertensive renal disease (Murphy et al., 2013).  
Many reasons have been cited for such disparities.  It is not the goal of this dissertation to 
evaluate either the issue of whether health disparities do in fact exist in the United States 
or the reasons why they exist.  Rather, the purpose of the study was to examine a 
potential source of disparity—direct-to-consumer pharmaceutical advertising (DTCA).   
Advertising pharmaceuticals directly to consumers is big business.  Drug 
companies spent over $4.3 billion in 2010 advertising their products.  Nearly one-third of 
these funds were dedicated to print advertising.  During the mid-2000s, researchers in 
several disciplines studied pharmaceutical advertising using the theoretical constructs 
common to their individual fields of study.  Each study made an important contribution to 
the literature regarding the effectiveness and appropriateness of DTCA, resulting in a 
lively debate about its relative merits.  Communications experts are concerned about the 
ability of consumers to understand the information presented in the advertisements 
(Kaphingst, Rudd, DeJong, & Daltroy, 2003; Stokes, 2005; Rubinelli, Nakamoto, Schulz, 
& de Saussure, 2006; Mackert & Love, 2011), while health economists worry that such 
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advertising will steer patients towards higher priced drugs (Hausman, 2008; Block, 
2007).  Sociologists warn about the medicalization of America as more and more drugs 
are introduced to treat so-called lifestyle conditions (e.g., erectile dysfunction, 
menopause) (Conrad & Leiter, 2008; Payton & Thoits, 2011).  To make sense of the vast 
amount of literature written about DTCA within the context of health policy, this study 
synthesized, integrated, and expanded upon the findings of this earlier research using the 
framework of two popular models of individual health behavior:  social cognitive theory 
and the health belief model. 
Whatever one’s opinion of DTCA, it is clearly one of the most widely recognized 
types of advertising.1  Numerous studies have reported a high degree of awareness of 
pharmaceutical advertising among those surveyed (Bell, Kravitz, & Wilkes, 1999; Calfee, 
2002; Weissman, et al., 2003; Aiken, Swasy, & Braman, 2004; Thomaselli, 2006; Lee & 
Begley, 2010), as well as a tendency to discuss advertised drugs with their doctors 
(Allison-Ottey, Ruffin, and Allison, 2002; Weissman, et al., 2003; Thomaselli, 2006).  
Researchers have also pointed out the potential of DTCA to impact health disparities (Fry 
et al., 2007; Avery, Kenkel, Lillard, Mathios, & Wang, 2008; Ball, Liang, & Lee, 2009; 
Crawley, Hisaw, & Illes, 2009; Young and Eckrich, 2013).  To the extent that DTCA 
serves to motivate individuals to seek additional information from their physicians, racial 
disparities in the frequency and content of such advertising may contribute to the poorer 
health outcomes experienced by the African American population, in particular.  On the 
                                                          
1 See Chapter 2 for a detailed discussion of the advantages and disadvantages of DTCA.  While this 
dissertation is premised on the health promotion potential of pharmaceutical advertising, critics of this form 
of advertising contend that DTCA can have a negative impact on people’s health by manipulating them to 
seek unnecessary, and potentially harmful, medications. 
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other hand, advertising that appeals to a black audience, either through its appearance or 
content, and which prompts individuals to discuss health concerns with their physicians 
can be invaluable to our efforts to improve health outcomes within this community.   
Recognizing the health promotion potential of DTCA, the Food and Drug 
Administration (FDA) issued a series of recommendations in 2009 aimed at enhancing 
the ability of DTCA to reach disadvantaged populations.  Among these 
recommendations, four served as the basis for this study (FDA, 2009, p. 26): 
(1) “Use communicators in the advertisements and channels to disseminate messages 
that the target populations rate as credible.” 
(2) “Produce help-seeking or other ad campaigns concerning diseases and health 
issues that have particular relevance to the target community.” 
(3) “Provide information and relevant nondrug interventions (e.g., diet and exercise) 
that patients should consider.” 
(4) “Provide information on any available discounts or patient assistance programs 
that can help low income individuals obtain medications.” 
To determine the impact of the FDA recommendations on the appearance and 
content of DTCA, research questions (RQs) were designed to specifically evaluate 
differences in advertising that may have resulted from the FDA recommendations.  As 
such, RQs were tied directly to the FDA recommendations as follows:   
RQ1:  Does the frequency of pharmaceutical advertising vary based on the racial 
orientation of the magazine?  (Recommendation 1) 
RQ2:  Did the frequency of pharmaceutical advertising appearing in black-oriented 
women’s magazines increase following the 2009 FDA report?  (Recommendation 1) 
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RQ3:  Do the types of drugs advertised vary by the racial orientation of the magazine? 
(Recommendation 2) 
RQ4:  Have the types of drugs advertised become more concordant with the health risks 
of the race of the magazine’s readers following the 2009 FDA report?  
(Recommendation 2) 
RQ5:  Does the race of the models used in DTCA vary based on the racial orientation of 
the magazine (Recommendation 1) 
RQ6:  Did the percentage of advertisements featuring black models increase following 
the 2009 FDA report?  (Recommendation 1) 
RQ7:  Does the provision of information about nondrug interventions vary based on the 
racial orientation of the magazine?  (Recommendation 3) 
RQ8:  Did the percentage of advertisements that include information about nondrug 
interventions increase following the 2009 FDA study? (Recommendation 3) 
RQ9:  Does the provision of information about available discounts or patient assistance 
programs vary based on the racial orientation of the magazine?  (Recommendation 4) 
RQ10:  Did the percentage of advertisements that include information about available 
discounts or patient assistance programs increase following the 2009 FDA study? 
(Recommendation 4) 
The study focused on pharmaceutical advertising found in print media.  While 
pharmaceutical companies spend a large portion of their budgets on television 
advertising, magazine advertising remains strong.  Bulik (2011) notes that, in 2010, drug 
companies spent the largest portion of their advertising budget on magazines 
(32.5 percent) followed closely by network television at 31.5 percent.  (The industry also 
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spent 12.7 percent of its advertising budget on cable television, 8.1 percent on syndicated 
television, and 2.4 percent on television spots.  All told, the industry dedicated a total of 
55 percent of its advertising dollars on television (Bulik, 2011)).  With respect to  
pharmaceuticals, magazine readers are more likely to have discussed an ad seen in a 
magazine with their doctors than one seen on television (MPA, 2013).  In fact, some 
pharmaceutical companies are considering reducing the amount of television advertising 
they do as a result of regulatory and consumer backlash (Hensley, 2005; Japsen, 2012).  
In addition, people are more likely to buy products seen in magazine ads than products 
advertised on television or the Internet (MPA, 2013).   
Because the FDA recommendations were targeted to improving the ability of 
DTCA to reach minority populations, magazine titles examined in this dissertation 
represented two genres:  magazines that are read primarily by white women (Family 
Circle and Good Housekeeping) and magazines that are read primarily by black women 
(Ebony and Essence).  A fifth magazine, O, The Oprah Magazine, which is read by both 
black and white women, was selected as an additional point of comparison.  The selection 
of women’s magazines2 reflects the fact that women tend to make the medical decisions 
for their families (Keitel, 2000; Kaiser Family Foundation, 2003; Abel, Lee, & Weeks, 
2007; Mastin, Andsager, Choi, & Lee, 2007).  Furthermore, previous research has found 
that women’s magazines contain more DTCA than other magazine genres, and women, 
rather than men, are more likely to pay attention to these ads (Mastin et al., 2007).  
                                                          
2 For the purposes of the study, women’s magazines are defined as those which discuss a broad range of 
issues relevant to women and which possess a predominately female readership.   
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Magazine readership remains strong among African Americans.  According to the 
MPA Factbook 2013/2014, published by The Association of Magazine Media (MPA), 
91 percent of adults surveyed read at least one magazine during the previous six months 
(MPA, 2013).  On average, African Americans read more magazine issues (14.6) 
monthly than the average number of issues (10.0) read by all U.S. adults (MPA, 2013).   
To determine the impact of the FDA recommendations on pharmaceutical 
advertising, DTCA found in magazine issues published between January 2008 and 
December 2009 (i.e., the “before FDA report” period) was compared to DTCA found in 
magazines published between January 2011 and December 2012 (i.e., the “after FDA 
report” period).  Because the FDA report was published in September 2009, magazine 
issues published in 2010 were excluded from the study sample.  It was assumed that 
pharmaceutical companies would need some period of time to implement the FDA report 
recommendations in their ongoing advertising campaigns. 
 Data analysis was conducted in three phases.  The purpose of the first analysis 
phase was to determine whether the frequency and type of pharmaceutical advertising 
varied on the basis of the racial orientation of the magazine in which it appeared and its 
publication date (RQ1 through RQ4).  In this phase, 237 magazine issues were reviewed 
and a total of 1,163 pharmaceutical advertisements were identified.  Of these, 1,090 were 
product claim ads and 73 were help-seeking advertisements.  (The FDA defines a product 
claim ad as one that mentions the name of a drug and the condition that it treats, while 
help-seeking ads describe a particular medical condition but do not mention a specific 
drug (FDA, 2012a).)  Data were compiled by year for each magazine title, and 
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descriptive statistics were used to ascertain the means for each magazine title and year for 
the following variables: 
 total number of magazine pages 
 total number of advertising pages 
 total number of advertising pages dedicated to DTCA 
 percent of advertising pages as a function of total magazine pages 
 percent of DTCA as a function of total magazine pages 
 percent of DTCA as a function of total advertising pages 
Data were filtered by racial orientation to allow the frequency of pharmaceutical 
advertising to be compared based on the racial orientation of magazine.  Data were then 
sorted by the relationship of the magazine’s publication date to the FDA report date (i.e. 
“before” or “after”).  This allowed data from magazines published before the FDA report 
to be compared to data from magazines published after the FDA report.  Independent 
sample t-tests were used to evaluate the significance of differences in means. 
 To evaluate differences in the types of drugs advertised, the name of each drug 
and the medical condition for which it is used to treat were recorded.  Medical conditions 
were grouped into 16 disease categories based on the work of Bell, Wilkes, and Kravitz 
(2000).  Frequency distributions were obtained for the name of the drugs advertised and 
the disease category in which they fell.  Trends in the data were analyzed to determine 
whether differences in the types of drugs advertised pre- and post-FDA report publication 
could be discerned.  These data were also compared to the leading causes of death for 
Caucasians and African Americans to determine how relevant the advertised product was 
to the health issues and diseases of most concern to each group. 
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 The second phase of analysis examined in more depth a subset of 
439 advertisements that promoted drugs used to treat life-threatening conditions, 
including Alzheimer’s disease, cancer, cardiovascular disease, depression, diabetes, and 
respiratory illness.  This analysis phase focused on identifying changes in the appearance 
and content of DTCA published after the FDA report (RQ5 through RQ10).  Each ad was 
coded in terms of whether it used a human model or likeness, a cartoon character, or an 
inanimate object, such as a chart or diagram.  If the ad featured a human model or 
likeness, the race, age, and gender of each model was recorded.  The race of the primary 
model was also noted.   
Next, the type of appeal used in each ad was determined.  Through the use of both 
visual and textual cues, advertisers may appeal to either an individual’s emotions or 
intellect or both (Macias, Pashupati, & Lewis, 2007).  Rational appeals tend to motivate 
individuals through the use of logical and informational arguments (Main, Argo, & 
Huhmann, 2004).  Emotional appeals can be either positive or negative.  Positive 
emotional appeals try to evoke a favorable consumer response by conveying a sense of 
warmth, happiness, or relief (Main et al., 2004).  Negative emotional appeals can inspire 
feelings of anger, fear, or sadness (Main et al., 2004).  Ads can include both rational and 
emotional appeals.  Chapter 4 provides the coding scheme for the type of advertising 
appeal used. 
Ads were also coded for the answers to the following yes/no questions: 
 Is the reader offered help in finding patient support services? 
 Is the reader referred to a Web site for additional information? 
 Is the reader given a telephone contact for additional information? 
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 Is the reader encouraged to talk with a doctor or another individual? 
 Is the reader offered monetary incentives or other financial support? 
 Are alternative therapies, such as diet and exercise, suggested to the reader? 
 Is the reader encouraged to report negative side effects of prescription drugs to the 
FDA? 
This latter information item is a requirement of the Food and Drug Administration 
Amendments Act of 2007.  It was purposely included in the analysis to measure the 
pharmaceutical industry’s responsiveness to a regulatory requirement.  Appendix A 
presents the data collection code sheets used in the two analysis phases described above. 
 A third phase of analysis was conducted to qualitatively compare the appearance 
and content of ads for the same drug placed in different magazine genres during the same 
month and year.  For example, an ad for Januvia, a diabetes medication, which was 
published in the June 2008 issue of Ebony magazine was compared to an ad for Januvia 
that appeared in the June 2008 issue of Good Housekeeping.  A total of 10 drugs, within 
the six disease categories of interest, were advertised in both black-oriented magazines 
and white-oriented magazines during the same month and year.  (Drug ads that appeared 
in the crossover magazine were omitted from this phase of the analysis since its target 
audience is less defined.)  Twenty-seven ad versions were evaluated.  While limited in 
scope, the study was the first to examine this aspect of DTCA, which warrants further 
research.   
 The next chapter of the dissertation reviews the current literature, particularly the 
results of previous content analyses of pharmaceutical advertising in magazines.  A brief 
history of the evolution of DTCA is presented, and current DTCA regulations are 
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discussed.  The debate about the value of DTCA is summarized within the context of its 
potential to reduce health disparities by providing health information to disadvantaged 
populations.  
 Chapters 3 and 4 present the results of the study.  Chapter 3 focuses on the first 
phase of the analysis and looks at the frequency and type of pharmaceutical advertising 
that appeared in the five women’s magazines providing data for this research.  Chapter 4 
discusses the results of the second and third phases of the analysis which examined the 
appearance and content of a subset of the DTCA identified in Phase 1.  Chapter 5 
discusses the implications of the study results on health policy and offers some policy 
recommendations.  Study limitations are identified, and future research opportunities are 
highlighted. 
 
 
 
CHAPTER 2:  LITERATURE REVIEW 
 
 
 The United States is just one of two industrialized countries (New Zealand is the 
other) that currently permits pharmaceutical companies to advertise directly to the 
consumer (Almasi, Stafford, Kravitz, & Mansfield, 2006; Calfee, 2002).  DTCA 
encompasses pharmaceutical companies’ efforts to reach consumers directly via all forms 
of media, including print (magazines, newspapers, billboards), broadcast (radio, 
television), and the Internet (Ventola, 2011; Sokol, Wackowski, & Lewis, 2010).  The 
Food and Drug Administration (FDA), which regulates DTCA in the United States 
recognizes three categories of drug advertisements: product claim ads, reminder ads, and 
help-seeking ads (FDA, 2010; Silver & Stevens, 2009; Ventola, 2011).  Product claim 
ads are defined as those advertisements that “name a drug and the condition it treats”; 
reminder ads are those advertisements that “give the drug’s name, but not the drug’s 
uses”; and help-seeking ads are those advertisements that “describe a disease or 
condition, but don’t recommend or suggest specific drugs” (FDA, 2010).  Only product 
claim ads must provide information regarding both the benefits and the risks associated 
with taking the advertised drug (Silver & Stevens, 2009; Ventola, 2011).   
 This chapter reviews the history of pharmaceutical advertising in the United 
States, including industry spending patterns and government regulation.  A theoretical  
framework is presented, and the advantages and disadvantages of DTCA are discussed. 
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The chapter closes with a summary of previous content analyses of print pharmaceutical 
advertising and identifies how the research presented in this dissertation addresses several 
key gaps in the literature. 
2.1  The Evolution of Direct-to-Consumer Advertising 
A review of the history of DTCA in the United States is fascinating.  Since its 
very beginnings at the turn of the 20th century, pharmaceutical advertising has come full 
circle.  Newspapers in the late 1800s and early 1900s were filled with advertisements for 
various patent medicines claiming to cure a wide variety of ailments (Silver & Stevens, 
2009).  The consumer’s right to self-medicate was considered sacrosanct (Donohue, 
2006).  However, in 1905, the American Medical Association (AMA) created the Council 
of Pharmacy and Chemistry.  The Council’s objectives were to encourage patients to use 
physician-prepared medications and to discourage the use of patent medications 
(Donohue, 2006).  The AMA considered self-medication “a threat to the medical 
profession” (Donohue, 2006, p. 665).   
 Early attempts to discourage self-medication by the AMA led to an increase in 
information provided to consumers, based on the assumption that, given the right 
information, consumers could identify effective medications (Donohue, 2006).  By World 
War II, physicians had asserted their authority over patient decisions, and DTCA was 
virtually nonexistent (Donohue, 2006).  By the 1960s, 90 percent of the advertising 
money spent by pharmaceutical companies was directed at physicians rather than the 
public (Donohue, 2006).   
 The focus of pharmaceutical advertising started to turn in the 1970s with the birth 
of the patients’ rights movement (Donohue, 2006).  Consumer groups began to demand 
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more information about prescription drugs, voicing their concerns that physicians did not 
adequately explain the possible side effects of the drugs that they prescribed to their 
patients (Donohue, 2006).  In response to these concerns, as well as its own research, the 
FDA ultimately adopted a plan to encourage drug companies to voluntarily provide 
information to consumers (Donohue, 2006).  Soon afterward, pharmaceutical companies 
began targeting their advertising efforts at consumers (Donohue, 2006; Wilkes, Bell, & 
Kravitz, 2000).  Initially limited to print media (Donohue, 2006), pharmaceutical 
advertising is now ubiquitous as consumers are exposed to advertisements in newspapers, 
magazines, television, and on the Internet. 
 One interesting aspect of the history of DTCA in the United States is the changing 
positions taken by the key stakeholders over time, particularly the pharmaceutical 
companies.  Early opponents to DTCA included not only physicians, but the drug 
companies as well (Donohue, 2006).  In the early 1980s, executives of pharmaceutical 
groups advocated “strict limits, if not an outright ban on prescription drug advertising to 
the public” (Donohue, 2006, p. 678).  Consumer groups, who had demanded that patients 
to be given more information about their prescription drugs, also opposed DTCA, 
preferring instead for such information to be provided in patient package inserts 
(Donohue, 2006).  And consumers themselves disagreed with the notion that DTCA 
would better inform their medical decision making.  Donohue (2006) reported that 
surveys of consumers conducted during this time period indicated the following: 
More than three-quarters of consumers disagreed with the statement that 
they could decide about using a drug, and 63 percent disagreed with the 
statement that patients could tell whether a prescription drug ad was 
misleading (p. 677). 
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 Today, consumers and physicians appear to have softened their stance against 
DTCA.  As people strive to become better educated consumers of medical services, 
DTCA is one readily accessible source of health information (Huh & Becker, 2002).  An 
FDA survey conducted in 2002 found that 43 percent of those who responded said they 
had sought more information about either a drug or their health based on a 
pharmaceutical advertisement (FDA, 2004).  Thirty-two percent said that DTCA helped 
them “make better health decisions” (FDA, 2004).  In addition, many physicians now 
recognize that DTCA can provide their patients with important information and may 
serve as a means to encourage dialog about conditions that they might otherwise feel too 
embarrassed to discuss (Donohue, 2006; Finlayson & Mullner, 2005).  In 2000, the AMA 
acknowledged that DTCA could “increase patient awareness about treatment options and 
enhance patient-physician communication” (Calfee, 2002).  The AMA further conceded 
that “[a]dvertising directly to the public educates patients, enabling them to better 
understand and participate in medical care” (Calfee, 2002). 
Pharmaceutical companies have similarly embraced direct-to-consumer 
advertising.  Since the FDA relaxed its pharmaceutical advertising guidelines in 1997 
(see the following section), the amount of money expended by drug companies on DTCA 
has risen exponentially from about $700 million in 1996 to a peak of $5.4 billion in 2006 
(Bulik, 2011).  In 2010, the industry spent about $4.3 billion, with nearly 60 percent of 
the resources dedicated to advertising drugs associated with the following conditions: 
stomach; sleep disorder; contraception; impotence; allergy and asthma; arthritis; heart, 
blood pressure, and cholesterol; and mental health (Bulik, 2011).  Well over half of this 
amount was spent to advertise a mere 25 drugs (Bulik, 2011).  Magazine advertising 
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accounted for roughly 30 percent of expenditures, while advertising on all forms of 
television outlets (including network TV, syndicated TV, cable TV, and spot TV) 
accounted for approximately 55 percent (Bulik, 2011).  Advertising on the Internet 
accounted for about 5 percent of expenditures (Bulik, 2011).  Figures 2-1 through 2-3 
offer a graphical presentation of this information. 
 
Figure 2-1:  DTCA spending over time 
(Bulik, 2011, p. 5) 
 
Figure 2-2:  DTCA spending in 2010 by drug category 
(Bulik, 2011, p. 7) 
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Figure 2-3:  Percentage of DTCA spending in 2010 by medium 
(Bulik, 2011, p. 9) 
2.2  Regulating Pharmaceutical Advertising 
 Despite their popularity, the safety and efficacy of patent medications was 
questionable.  Many of these concoctions contained less-than-healthful ingredients, such 
as alcohol, formaldehyde, mercury, and morphine (Silver & Stevens, 2009).  In 1906, 
Congress passed the first of what would become a long string of laws aimed at regulating 
the promotion and distribution of pharmaceuticals.  Figure 2-4 provides a timeline of 
Federal action, beginning with the 1906 Pure Food and Drugs Act and ending with the 
Food and Drug Administration Amendments Act (FDAAA) of 2007.  Table 2-1 
highlights the significant aspects of each piece of legislation, as well as actions taken by 
the FDA to specifically regulate DTCA. 
 As mentioned before, the issuance of the FDA’s guidelines for broadcast 
advertisements led to a proliferation in the amount of DTCA to which consumers are 
exposed, as well as the amount of money spent on advertising aimed at the consumer by 
the pharmaceutical companies.  Particularly relevant to the proposed study is the FDAAA 
of 2007.  Section 901 of the Act requires the FDA to submit to Congress a report on the 
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ability of DTCA to communicate to subsets of the general population, including “racial 
and ethnic minority communities” (FDA, 2009, p. i).  The Act went on to direct the 
Secretary of Health and Human Services as follows: 
The Secretary shall utilize the Advisory Committee on Risk 
Communication established under this Act to advise the Secretary with 
respect to such report.  The Advisory Committee shall study direct-to-
consumer advertising as it relates to increased access to health information 
and decreased health disparities for these populations.  (FDA, 2009, p. i). 
 
In this charge to the Secretary of Health and Human Services, Congress recognized the 
potential of DTCA to increase access to health information and decrease health 
disparities within specific population subsets.  Inherent within this direction is the 
concern that DTCA may not be reaching these population subsets in a sufficient manner.   
In its report to Congress, the Secretary noted that “[r]esearch on DTC advertising of 
prescription medications has shown that this advertising can educate consumers about 
health issues” (FDA, 2009, p. iv).  However, the Secretary further acknowledged that 
“research also shows that DTC advertising can have negative consequences and that 
improvements can be made to increase its effectiveness as a communication tool for 
population subgroups” (FDA, 2009, p. iv).  The report provided a number of 
recommendations for enhancing the ability of DTCA to reach disadvantaged populations 
and called for further research into the potential impact of DTCA on “improving access 
to health information and reducing health disparities” (FDA, 2009, p. iv.). 
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Table 2-1:  Significant events in the history of DTCA regulation 
 
Event Purpose 
1906 Pure Food and 
Drugs Act1 
 Prohibited the sale across state lines of illegal food and 
drugs. 
 Implemented product labeling standards. 
Sherley Amendment 
(1912) 
 Prohibited drug labels from making inaccurate 
therapeutic claims. 
1938 Food, Drug, and 
Cosmetic Act (FDCA) 
 Established the Food and Drug Administration. 
 Required drugs to be safe and to be approved by the 
FDA before marketed. 
 Expanded drug labeling requirements. 
Wheeler Lea Act (1938)  Awarded the Federal Trade Commission (FTC) 
jurisdiction over drug advertising. 
 Exempted advertisements in medical journals from 
regulatory authority. 
Durham Humphrey 
Amendments (1951) 
 Created a “statutory definition” of prescription drugs. 
Kefauver-Harris 
Amendments to the 
FDCA (1962)2 
 Required that drugs be proven safe and effective before 
marketed. 
 Required that drugs meet a “high standard of scientific 
evidence.” 
 Transferred regulatory authority over prescription drug 
advertising from FTC to FDA. 
FDA Final Advertising 
Regulations (1969) 
 Required advertisements to present “information in brief 
summary relating to side effects, contraindications, and 
effectiveness.”3 
 Required advertisements to present a “fair balance” of 
information about the drug’s benefits and side effects.4  
 Required print advertisements to include a “brief 
summary” conveying the risk information found in 
drug’s package labeling.5 
 Required broadcast advertisements to convey a drug’s 
major risks and provide a brief summary or make 
“adequate provision…for dissemination of the approved 
or permitted package labeling in connection with the 
broadcast presentation.”6 
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Table 2-1:  (continued) 
 
Event Purpose 
FDA Draft Guidelines 
(1997) and Final 
Guidelines (1999) for 
Consumer-Directed 
Broadcast 
Advertisements 
 Clarified the phrase “adequate provision.” 
 Provided guidance on how advertisers could fulfill the 
adequate provision requirement. 
 Exempted certain advertisement types (reminder, help 
seeking) from regulatory requirements. 
Food and Drug 
Administration 
Amendments Act 
(FDAAA) of 2007 
 Requires FDA to report to Congress on DTCA and “its 
ability to communicate to subsets of the general 
population, including elderly populations, children, and 
racial and ethnic minority communities.”7 
1 Unless otherwise noted, the majority of information presented in this table was taken from Donohue 
(2006) and Gellad and Lyles (2007). 
2 Donohue (2006), p. 670. 
3 FDA (1999), p. 1. 
4 Donohue (2006), p. 671. 
5 FDA (1999), p. 1. 
6 FDA (1999), p. 1. 
7 FDA (2009), p. i. 
 
 
 Among the recommendations contained in this report (FDA, 2009, p. 26), the 
following four are particularly applicable to the proposed study: 
(1) Use communicators in the advertisements and channels to disseminate 
messages that the target populations rate as credible. 
(2) Produce help-seeking or other ad campaigns concerning diseases and 
health issues that have particular relevance to the target community. 
(3) Provide information about relevant nondrug interventions (e.g., diet and 
exercise) that patients should consider. 
(4) Provide information on any available discounts or patient assistance 
programs that can help low income individuals obtain medications. 
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2.3  Theoretical Framework 
 Researchers from several disciplines have examined DTCA using the organizing 
frameworks common to their fields.  In a review of the health policy literature, two 
models stand out as being particularly relevant to the proposed study.  Both the health 
belief model and social cognitive theory have been used to evaluate the relationship of 
DTCA to health promotion (Duerksen et al., 2005; Mackert & Love, 2011; Young, 
Lipowski, & Cline, 2005).  These models are used to explain health behaviors.  
Motivating individual health behavior is a complex union of a person’s health beliefs, 
societal cues, and organizational influences that takes place within the context of an ever 
changing environment (Schommer & Hansen, 2005).  Although this dissertation seeks to 
determine the effects of the FDA report recommendations on DTCA, the importance of 
these effects is determined by the role that DTCA plays in motivating health behavior.  
Thus, it is important to understand these models and the ways in which they have been 
used in previous studies of DTCA. 
The health belief model, illustrated in Figure 2-5, was developed in the 1950s by 
the U.S. Public Health Service to explain why people did not participate in disease 
prevention and protection programs (Glantz, Rimer, & Lewis, 2002).  The model is based 
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Figure 2-5:  The health belief model 
on the individual’s perceived susceptibility to a disease, the perceived threat of the 
disease, and the perceived benefits to behavior change (Glantz et al., 2002).  As Glantz et 
al. (2002) explain: 
people will take action to prevent, to screen for, or to control ill-health 
conditions if they regard themselves as susceptible to the condition, if they 
believe it would have potentially serious consequences, if they believe that 
a course of action available to them would be beneficial in reducing either 
their susceptibility to or the severity of the condition, and if they believe 
that the anticipated barriers (or costs of) taking the action are outweighed 
by this benefits. (pp. 47–48) 
 
Mackert and Love (2011) compared the content of DTCA directly to the 
individual elements of the health belief model.  They identified four key constructs of the 
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theory:  “perceived susceptibility, perceived severity, perceived benefits, and perceived 
barriers” (Mackert & Love, 2011, p. 207).  An analysis of 82 pharmaceutical 
advertisements within this framework revealed that the vast majority of advertisements 
provided information about perceived benefits and perceived barriers (98.8 percent 
included statements about both the clinical benefits of the advertised drug and its possible 
side effects).  However, few (less than 20 percent) made statements associated with 
perceived susceptibility (e.g., population risk of a disease) or perceived severity (e.g., the 
consequences of the disease).  These researchers acknowledged that DTCA does provide 
some useful information, but felt that it omitted some valuable educational material, such 
as information about disease prevalence (Mackert & Love, 2011). 
The health belief model also recognizes that certain external cues, such as 
education, personal relationships, and the media, can motivate health behavior.  Repeated 
exposure to pharmaceutical advertising can be a cue to action, sparking individuals to 
seek additional information either from their doctor or another media source, such as a 
Web site or hotline (Duerksen et al., 2005).  Duerksen et al. (2005) noted that differences 
in knowledge about health risks, disease symptoms, and treatment options have been tied 
to racial disparities in health status.  Their study of health-related advertising in women’s 
magazines is based on the underlying premise of the health belief model that knowledge 
impacts “individual perceptions of health risk and the benefits of preventive action” 
(Duerksen et al., 2005, p. 2).   
Duerksen et al. (2005) found fewer advertisements promoting healthy behaviors 
in magazines read by African American and Hispanic women than in magazines oriented 
towards Caucasian women.  Advertisements promoting products with potentially 
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negative health consequences were more likely to feature African American models than 
Caucasian models.  These results led the researchers to conclude the following: 
To the extent that individual levels of health education and awareness can 
be influenced by advertising, variations in the quantity, quality, and 
content of health-related information among magazines read by different 
ethnic groups may contribute to disparities in health behaviors and health 
status (p. 7). 
 
 Social cognitive theory, as illustrated in Figure 2-6, contends that behavior is a 
dynamic concept, dependent on an individual’s environment and personal characteristics 
(Glantz et al., 2002).  The continual interaction among personal factors, environmental 
influences, and behavior is known as “reciprocal determinism.”  Glantz et al. (2002) 
elaborate further: 
Behavior is not simply the result of the environment and the person, just as 
the environment is not simply the result of the person and behavior.  
Instead, these three components are constantly influencing each other.  A 
change in one component has implications for the other. (p. 168). 
 
 
 
 
Figure 2-6:  Social cognitive theory 
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Observational learning and role modeling are important components of the theory 
because individuals learn not only from their direct experiences, but also through 
watching the behavior of others (Young & Cline, 2005).  Behavior change results when 
observed behaviors result in rewards that motivate actions (Cline & Young, 2004).  
However, behavior change is also based on an individual’s belief about whether he or she 
is able to perform the behavior (Young et al., 2005).  DTCA can be considered a channel 
through which “role modeling and reinforcement of behaviors are communicated to 
individuals” (Schommer & Hansen, 2005, p. 355).   
 In two separate studies, Young and Cline examined both the textual and visual 
cues contained within DTCA.  Using social cognitive theory as their framework, they 
explain,  
From the perspective of social cognitive theory, DTCA must facilitate a 
complex social influence process in order to be effective (Cline & Young, 
2004).  Ads must both sell the product to consumers and motivate them to 
engage in appropriate, credible, and persuasive interaction with health care 
professionals (Young & Cline, 2005, p. 363). 
 
These researchers looked at 225 unique pharmaceutical advertisements in 18 popular 
magazines.  In their study of visual cues, Young and Cline (2004) found that ads tended 
to reinforce gender-based stereotypes.  Half of the ads that featured women promoted 
drugs used to treat obstetric or gynecological problems or psychiatric disorders.  In 
contrast, two-thirds of ads for cardiovascular drugs featured men only, although 
cardiovascular disease is the leading cause of death for both men and women.  They also 
found that the race and ethnicity of the models used in the ads did not necessarily reflect 
the severity of the disease in minority populations.  For example, although cardiovascular 
disease and cancer are the leading causes of death for Caucasians, African Americans, 
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and Hispanics, all of the ads for drugs used to treat these conditions featured white 
models only.  However, African American models dominated ads for HIV/AIDs drugs, 
although less than 40 percent of AIDs patients in the United States are Black.  These 
findings led Cline and Young (2004) to conclude the following: 
…beyond promoting social stereotypes lies the potential for DTCA’s 
visual cues to reinforce already existing disparities in access to health 
information and, to the extent that ads promote visits to physicians, 
disparities in access to health care (p. 154). 
 
 Using the same database, Young and Cline (2005) also examined the textual cues 
contained in DTCA.  They found that ads tended to focus on the positive attributes of the 
products they promoted by repeatedly referring to medical rewards, such as effectiveness, 
symptom improvement, and product superiority.  They also found that the textual 
messages reinforced the relationship between the product advertised and positive identity 
characteristics, such as good health, normalcy, attractiveness, and self-empowerment.  
Textual cues often complement visual cues and together “paint an appealing picture of 
medications’ users and the medical consequences of product use (Young and Cline, 2005, 
p. 364).   
Kean and Prividera (2007) also used social cognitive theory as a framework in 
their examination of product ads placed in magazines with differing racial orientation.  
Although these researchers did not look specifically at pharmaceutical advertising, their 
work is relevant to the current study because they evaluated differences in the types of 
products advertised and the race of models used to advertise these products as a function 
of the racial orientation of the magazine in which the ads appeared.  They based their 
research on the following construct grounded in social cognitive theory: 
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African American women are likely to learn and execute behaviors from 
models with whom they identify and see as rewarded for particular 
behaviors.  Based on this premise, the types of products, claims made 
regarding these products, and the visual images involved in selling these 
products may all act as models for behavior (p. 295). 
 
 Kean and Prividera (2007) found differences in the 141 advertisements 
they examined based on race.  The black-oriented magazine (Essence) contained a 
far greater percentage of fast food advertisements (13 percent) than did the 
white-oriented magazine (Cosmopolitan).  (From a public health perspective, this 
is concerning since obesity is a greater problem among more African American 
women than among non-Hispanic white women (CDC, 2013)—but that is a topic 
for another dissertation!)  They also found fewer ads for weight loss products in 
the black-oriented magazine than in the white-oriented magazine.  While these 
findings are not directly relevant to the current study, the methods and theoretical 
constructs employed helped to frame the research questions investigated and the 
research design used.  In particular, the following observation underscores the 
importance that ad appearance and content can have to the educational and 
motivation value of DTCA: 
…an individual is more likely to imitate behaviors that are engaged in by 
models to whom the observer feels similar, who have qualities that the 
observer finds attractive, and/or who are rewarded for their behaviors.  
Therefore, print advertisements that included images of women the reader 
can relate or feel similar to, as well as print advertisements that make 
claims of reward or success due to product consumption, are more likely 
to be imitated through product liking and/or consumption (Kean & 
Prividera, 2007, p. 296). 
 
2.4  DTCA:  Education or Manipulation? 
Evaluating consumer response to DTCA within the context of the health belief 
model and social cognitive theory presumes that pharmaceutical advertising has a 
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positive impact on improving health outcomes.  Through this lens, DTCA is linked to 
changing expectations (the health belief model) and perceptions or personal factors 
(social cognitive theory) to motivate consumers to take actions that will enhance their 
health.  Consequently, this dissertation focuses on the positive aspects of DTCA.  
However, many critics of DTCA argue that pharmaceutical advertising actually 
manipulates people’s health beliefs causing consumers to seek unnecessary medical 
treatment (Finlayson & Mullner, 2005) and creating new disease categories (Conrad & 
Leiter, 2004).  The debate over the relative merits of DTCA continues even as 
pharmaceutical advertising becomes more and more a part of our daily life.  Three 
sources in particular offer a comprehensive, well-documented review of the literature.  A 
recent text, Advertising and Society:  An Introduction, edited by Carol J. Pardun, 
dedicates a chapter to direct-to-consumer pharmaceutical advertising (Barnes, Capella, 
Taylor, Treise, & Jung, 2014).  Three essays within that chapter offer an argument 
against DTCA and two counterarguments in favor of its continued presence.  Similarly, 
Auton (2004) and Ventola (2011) provide a critical review of existing research as each of 
these authors discuss the popular arguments for and against DTCA.   
Many of the concerns about DTCA stem from its intended purpose which, like all 
advertising, is to encourage consumers to buy products (Pardun, 2014).  Without a doubt, 
DTCA sells drugs.  That is its intent, first and foremost, and that is what it does.  
Although proponents tout its educational value, critics argue that the information 
presented is incomplete, incomprehensible, and misleading (Rubinella, Nakamoto, & 
Schulz, 2007; Ventola, 2011).  FDA regulations require a fair balance in an ad’s 
discussion of benefits and side effects, the goal of which is to “prevent advertisers from 
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minimizing or hiding drug-associated risks and from overemphasizing drug benefits” 
(Davis & Meader, 2009, p. 57).  The Pharmaceutical Research and Manufacturers of 
America (PhRMA) has adopted a set of voluntary guidelines consistent with the FDA 
regulations that call for DTCA to present accurate, balanced, and well-supported 
information about a drug’s intended risks and benefits (Arnold & Oakley, 2013).  
However, some studies have demonstrated that this is often not the case (Ventola, 2011; 
Macias, Pashupati, & Lewis, 2007), and FDA enforcement of its own regulations is 
inadequate (Government Accountability Office, 2006).  However, Arnold and Oakley 
(2013), in their study of television advertising for erectile dysfunction medications, found 
that most of the ads evaluated met the requirement that major risks be discussed.3   
The level of health literacy necessary to fully understand the information 
presented in DTCA is another major concern.  Several studies have evaluated literacy 
levels required by pharmaceutical advertising (Kaphingst, Rudd, DeJong, & Daltroy, 
2004; Kaphingst, DeJong, Rudd, & Daltroy, 2004; Mackert & Love, 2011; Arnold & 
Oakley, 2013).  The general consensus of these studies has been that information 
contained within DTCA is often written at a reading level above what is usually 
recommended for materials intended for the general public (Ventola, 2011).  In 
particular, information contained in the brief summary was found to require a reading 
ability at the college or graduate-school level (Kaphingst, Rudd, DeJong, & Daltroy, 
2004).   
                                                          
3 However, Arnold and Oakley (2013) found many areas of noncompliance with the industry’s guidelines 
resulting in children being “exposed to a total of over 100 billion erectile dysfunction impressions via 
television commercials during the period of study” (p. 532). 
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Concerns have also been expressed that DTCA implies that drugs alone are the 
key to improving one’s health, thereby discounting the value of health–promoting 
lifestyle changes (Auton, 2004; Ventola, 2011).4  Few ads suggest alternatives to 
medication and may lead consumers to reject recommendations about diet and exercise as 
unnecessary (Ventola, 2011).  Overprescribing is another oft-cited issue.  Doctors may 
feel pressured by their patients to prescribe a particular drug or risk losing them to 
another practitioner (Auton, 2004; Hollon, 2005; Ventola, 2011).  Or, they may be more 
likely to put a patient on a requested drug rather than encouraging alternative, nonmedical 
therapies that may be equally effective (Angell, 2005).  Rather than encouraging a 
meaningful dialog between a physician and patient, DTCA may strain that relationship by 
placing the two at odds over a prescription request (Ventola, 2011).   
The economic consequences of overprescribing as a result of DTCA have been 
explored by Hausman (2008), Block (2007), and Mintzes et al. (2003) among others.  
Advertising tends to be heaviest for newer, more expensive drugs for which 
pharmaceutical companies retain their patents regardless of whether they are more 
effective than older therapies (Avorn, 2003).  Singh and Smith (2005) cite a 2003 study 
by the Kaiser Family Foundation which demonstrated a 1 percent increase in 
pharmaceutical sales for every 10 percent increase in DTCA.  In an increasingly 
medicalized society, DTCA fuels the demand for “a pill for every ill” (Moynihan & 
Cassels, p. 103) and has led to accusations of disease mongering—creating an illness 
solely for the purpose of selling more drugs (Moynihan & Henry, 2006).  Some studies 
have concluded that DTCA leads to an increase in prescriptions for the advertised 
                                                          
4 See Stokes (2005) for an interesting discussion of the “pharmaceutically empowered consumer.” 
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medications, which in turn leads to increased societal costs (Mintzes et al., 2003; 
Wosinska, 2002).  Block (2007) cautions, however, that such costs must be evaluated 
against the benefits associated with addressing previously untreated or undertreated 
disease. 
The strongest arguments in favor of DTCA rest on the notion that DTCA does 
lead people to discuss advertised drugs with their physicians.  Research demonstrates that 
DTCA has empowered the patient to engage in conversations with their physicians about 
their health (Bell et al., 1999; Allison-Ottey, Ruffin, & Allison, 2002; Deshpande, 
Menon, Perri, & Zinkhan, 2004; White, Draves, Soong, & Moore, 2004; Porter, 2011).  
Weissman, Blumenthal, Silk, Zapert, Newman, and Leitman (2003) found that 35 percent 
of the 3,000 individuals they interviewed had been motivated by DTCA to discuss a drug 
or medical condition with their physician.  Advertisements for potentially embarrassing, 
but serious health problems, can encourage patients to overcome the stigma associated 
with such conditions and talk with their physician about their symptoms.  Auton (2004) 
provides two examples:  
The Merck campaign for Proscar—a treatment for benign prostatic 
hyperplasia—is widely regarded as having been successful in raising 
awareness about a medical condition that men were reluctant to discuss 
with their doctor.  In 1997 a drug campaign was run for treatment for 
genital herpes thought to be affecting up to 45 million people in the USA.  
In a survey of those responding to a toll-free number, 45% claimed to have 
visited their physician within three months of seeing the campaign (p. 32). 
 
And we all know the story of the little blue pill.  An aggressive marketing by 
Pfizer, the manufacturer of Viagra, led to 2.9 million prescriptions being written 
within its first three months on the market (Conrad & Leiter, 2004).   
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One advantage to patients being more active in their health care decisions is the 
greater likelihood that they will comply with their medication regimens (Deshpande et al. 
2004; White et al., 2004).  Ventola (2011) report the results of a 2004 FDA survey in 
which one-third of physicians stated that DTCA increased medication compliance among 
their patients.  A similar study by Harvard University, Massachusetts General Hospital, 
and Harris Interactive also reported that 46 percent of physicians credited DTCA with 
increasing patient compliance (Ventola, 2011).  A third study reported by Ventola (2011) 
found that patients who requested and received a prescription from their doctor after 
seeing DTCA were “the most compliant of any group tested” (Ventola, 2011, p. 673). 
DTCA may also reduce the underdiagnosis and undertreatment of medical 
conditions (Ventola, 2011).  For example, several studies have been done to determine 
the effect of DTCA on the diagnosis and treatment of depression.  Donohue, Berndt, 
Rosenthal, Epstein, and Frank (2004) examined the treatment patterns of over 30,000 
depressed individuals using insurance claims filed between 1997 and 2000.  They found 
that antidepressant DTCA may encourage a depressed individual to seek medication 
therapy but has no effect on medication adherence (Donohue et al., 2004).  Bell, Taylor, 
and Kravitz (2010) surveyed 148 members of a depression forum and found that, while 
DTCA increased awareness of antidepressants, most survey respondents expressed 
ambivalence toward the ads themselves.  However, almost 40 percent of respondents 
indicated that they had initiated “some form of conversation with their doctor due to an 
advertisement” (Bell et al., 2010, p. 248).   
A 2002 national survey of individuals exposed to DTCA found that, among those 
who sought out their physicians based on seeing a pharmaceutical ad, 25 percent were 
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diagnosed with a condition of which they were previously unaware (Weissman et al., 
2003).  New diagnoses included such serious conditions as hypertension, diabetes, and 
depression (Weissman et al., 2003).  Meade-D’Alisera, Merriweather, and Wentland 
(2001) noted the value of DTCA in raising awareness of urinary incontinence and 
encouraging individuals to seek treatment.  A study of women exposed to DTCA for 
drugs used to treat postmenopausal osteoporosis were significantly more likely to seek 
out and receive bone density tests (Hollon, Larson, Keopsell, & Downer, 2003).  Mastin 
et al. (2007) conclude that the “repetitive nature of DTCA may serve as a valuable tool to 
create awareness regarding underdiagnosed diseases” (p. 57), leading those who see such 
advertising to consult with their health care providers more often than those who do not.   
While patients are more empowered by DTCA, there is nothing to suggest that the 
professional prerogative of physicians has been compromised.  Using a nationally 
representative survey of 21,000 adults, White et al. (2004) concluded that DTCA has 
“little to no disruptive effect on the doctor-patient relationship” (p. 57).  While the 
relationship remains unchanged, the discussion may differ as better informed patients 
engage their physicians in conversations about their health (White et al., 2004).  
Ultimately, however, the physician remains the “final arbiter of patient care” (White et 
al., 2004, p. 58).  In addition, DTCA offers physicians some advantages.  Increased 
patient participation may result in more focused interactions and lessen the time 
constraints that many physicians feel (Deshpande et al., 2004).  Doctors may choose to 
prescribe advertised drugs because patients might be more adherent or more aware of the 
benefits of a particular drug (Hausman, 2008).  Similarly, a physician might prescribe an 
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advertised drug knowing that future exposure to DTCA could serve as a reminder to take 
the medication or refill a prescription (Hausman, 2008).   
 Despite legitimate concerns, DTCA is likely to remain a key way that individuals 
learn about medical conditions and potential therapies.  As Avery, Kenkel, Lillard, 
Mathios, and Wang (2008) point out, “[t]he public health implications of DTC 
advertising depend upon its ultimate impact on medical treatment, health behaviors, and 
health outcomes” (p. 15).  Its ability to reduce health disparities by increasing access to 
information among ethnic or racial minority populations has been recognized by the 
National Medical Association (NMA).  In a survey of its members, 90 percent of 
physicians responding reported that their patients were prompted to ask their medical 
opinion based on seeing a pharmaceutical advertisement (Allison-Ottey, Ruffin, & 
Allison, 2002).  Seventy-two percent were asked for a particular treatment based solely 
on an ad (Allison-Ottey, Ruffin, & Allison, 2002).  Most importantly, a majority of 
physicians felt that DTCA was a benefit to their patients, “particularly as it relates to 
education regarding disease states” (Allison-Ottey, Ruffin, & Allison, 2002, p. 201). 
 As mentioned earlier, the focus of this dissertation is on the positive aspects of 
DTCA.  However, it would be irresponsible not to acknowledge the potential negative 
consequences to an individual and to society as a whole if DTCA manipulates people into 
taking a drug that they do not need for a condition that they do not have.  Although 
physicians, as well as insurance companies, serve as moderators between the 
pharmaceutical company and consumers (presumably only prescribing and paying for 
medically necessary medications), research demonstrates that DTCA leads to increased 
prescription rates (Finlayson & Mullner, 2005).  In some cases, DTCA has led to an 
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expansion in prescribing patterns to encompass individuals whose need for the drug 
would once have been considered marginal (Avorn, 2003).  Consequently, concerns that 
DTCA inspires unnecessary and potentially dangerous uses of prescription medications 
should not be minimized (Singh & Smith, 2005). 
2.5  Previous Content Analyses of DTCA 
 
A number of previous content analyses have evaluated various aspects of DTCA 
to determine whether differences exist in the advertisements placed in magazines aimed 
at disparate audiences.  Because the current study is limited to print magazines, the most 
relevant research also focused on analyzing the content of print ads.  The results of 
content analyses of pharmaceutical advertising appearing in other forms of media, such 
as television and Internet, were considered less pertinent, but such studies were reviewed 
as a means of honing research questions and refining research methods.  
A comprehensive review of the literature revealed 12 content analyses of DTCA 
found in magazines tailored to a broad range of audiences.  One additional content 
analyses of advertisements for consumables (e.g., food, drink, vitamins, and supplements) 
was included because it focused on differences in advertising placed in magazines 
targeted to two racially diverse audiences (Blacks and Whites).  Thus, it was deemed 
relevant to the current study.  
Appendix B discusses in detail each of these studies.  This section provides an 
overview of previous research and highlights ways in which the current study builds upon 
and extends this earlier work.  Researchers varied the magazines evaluated, the time 
periods examined, and the methods used.  All of these studies found some difference in 
the advertising that appears in magazines targeted to a general audience and those 
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targeted to a specific population subset, such as African Americans, women, or the 
elderly.   
Taken together, these studies reveal the following: 
 All magazines evaluated contained DTCA (with the exception noted above).  
Nearly 1,600 magazine issues were reviewed, with the earliest issues being 
published in 1989 and the latest in 2007. 
 The amount of pharmaceutical advertising found in magazines grew dramatically 
during this time, with the greatest amount of growth reported in magazines 
targeted to African Americans (Mastin et al., 2007). 
 Women were more likely to be targeted than men (Abel, Lee, & Weeks, 2007; 
Woloshin, Schwartz, Tremmel, & Welch, 2001; Bell, Kravitz, & Wilkes, 2000) 
 Several studies found that magazines targeted to a black audience had 
significantly less health-promoting advertising (including DTCA) than magazines 
read by a predominately white audience (Omonuwa, 2001; Duerksen et al., 2005; 
Kean & Prividera, 2007).  One study (Crawley, Hisaw, & Iles, 2009) did not 
report a difference in ad volume based on magazine audiences. 
 White models were used more frequently than black (or other minority) models 
(Main, Argo, and Huhmann, 2004; Duerksen et al. 2005).  Mastin et al. (2007) 
found that ads in magazines targeted to African Americans were more likely to 
feature African American models than ads in magazines targeted to a Caucasian 
audience. 
 The type of drugs advertised varied as a function of the magazine’s target 
audience.  African American magazines were less likely to include advertisements 
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for drugs used to treat the most prevalent diseases within the African American 
community (Crawley, Hisaw, and Iles, 2009; Mastin et al., 2007; Duerksen et al., 
2005; Cline & Young, 2004; Omonuwa, 2001). 
 Common appeals included medication effectiveness, convenience, symptom 
control, and innovativeness (Bell, Kravitz, & Wilkes, 2000; Abel, Lee, & Weeks, 
2007).  Main, Argo, and Huhmann (2004) found that emotional appeals, which 
were more common, could be either positive or negative.  Pinto (2000) reported 
that the type of appeal did not vary with the type of drug advertised. 
The studies described above all point to differences in the appearance and content 
of pharmaceutical advertising based on a magazine’s intended audience.  Given the 
potential that DTCA has to narrow health disparities by improving information access, 
any differences should be biased towards increasing knowledge among racial and ethnic 
minority populations.  However, these results do not appear to suggest this.  Since the last 
DTCA reviewed in the literature was published in 2007, we cannot be sure what strides, 
if any, have been made to reach these underrepresented populations. 
2.6  Conclusion 
The study reported in this dissertation closes several key gaps in the existing 
literature.  First, the study updates the literature by examining DTCA published as 
recently as 2012 (the last DTCA looked at by previous researchers was published in 
2007).  The current study evaluates the impact on DTCA of the 2009 FDA report, which 
was issued in response to Section 901 of the FDAAA of 2007, with its focus on 
increasing access to health information and decreasing health disparities among racial 
and ethnic minority populations.  Using both qualitative and quantitative methods, the 
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study uncovers trends in the frequency of DTCA, as well as its appearance and content, 
as a function of a magazine’s racial orientation.  DTCA published before the 2009 FDA 
report is compared to DTCA published after the report to determine whether the 
pharmaceutical industry has made efforts to better tailor their advertising campaigns to 
enhance the educational and motivational value of DTCA, particularly among readers of 
black-oriented women’s magazines.   
 
 
 
CHAPTER 3:  THE FREQUENCY AND TYPE OF PHARMACEUTICAL 
ADVERTISING IN WOMEN’S MAGAZINES 
 
 
 The differences in health status between Blacks and Whites in the United States is 
well documented.  The Centers for Disease Control and Prevention (CDC) reported in 
2011 that African Americans fare more poorly than Caucasians on virtually all health 
outcome measures, with the exception of motor-vehicle-related deaths (CDC, 2011).  
African Americans, as well as other minorities, have less access to health care and 
preventive services, are more likely to live in unhealthy housing and breathe unhealthy 
air, and are at greater risk for developing a chronic disease than Caucasians (CDC, 2011).  
Consequently, the life expectancy for African Americans is 3.8 years less than for 
Caucasians based on 2010 data (Murphy, Xu, & Kochanek, 2013). 
 While direct-to-consumer pharmaceutical advertising remains a hotly debated 
topic, its potential to impact health disparities has been recognized by a number of 
researchers (Fry et al., 2007; Avery et al., 2008; Ball, Liang, & Lee, 2009; Crawley, 
Hisaw, & Illes, 2009; Young & Eckrick, 2013). Numerous studies have reported a high 
degree of awareness of pharmaceutical advertising among those surveyed (Bell, Kravitz, 
& Wilkes, 1999; Calfee, 2002; Weissman, et al., 2003; Aiken, Swasy, & Braman, 2004; 
Thomaselli, 2006; Lee & Begley, 2010), as well as a tendency to discuss advertised drugs 
with their doctors (Allison-Ottey, Ruffin, & Allison, 2003; Weissman et al., 2003; 
Thomaselli, 2006). 
 
41 
 
 
 Recognizing the potential of DTCA to increase access to health information and 
decrease health disparities within specific population subsets, including “racial and ethnic 
minority communities” (FDA, 2009, p. i), Congress directed the FDA to determine 
whether DTCA was reaching such populations in a sufficient manner.  In its report back 
to Congress, the FDA noted that “[r]esearch on DTC advertising of prescription 
medication has shown that this advertising can educate consumers about health issues” 
(FDA, 2009, p. iv).  However, the report did acknowledge that “research also shows that 
DTC advertising can have negative consequences and that improvements can be made to 
increase its effectiveness as a communication tool for population subgroups” (FDA, 
2009, p. iv).  The report provided a number of recommendations for enhancing the ability 
of DTCA to reach disadvantaged populations and called for further research into the 
potential impact of DTCA on “improving access to health information and reducing 
health disparities” (FDA, 2009, p. iv). 
 Pharmaceutical advertising is big business.  In 2010, the industry spent about 
$4.3 billion on advertising a variety of drugs to treat a myriad of diseases.  While 
television advertising claimed the largest percent of these expenditures (approximately 
55 percent), magazine advertising remained strong, with slightly more than 30 percent of 
the industry’s advertising budget devoted to this media outlet.  A recent study published 
by the Association of Magazine Media (MPA) found that 91 percent of adults surveyed 
had read at least one magazine during the previous six months (MPA, 2013).  African 
Americans read more magazine issues per month (14.6) than the average number of 
issues (10.0) read by all U.S. adults (MPA, 2013).  Critical to this study is the finding that 
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magazine readers are more likely to have discussed an ad seen in a magazine with their 
doctors than one seen on television (MPA, 2013). 
 This chapter examines differences in the amount of pharmaceutical advertising 
found in five popular women’s magazines as a function of the magazine’s racial 
orientation.  The types of drugs advertised are compared as well.  Particular emphasis is 
given to changes in the frequency of advertising and the type of drugs advertised in 
magazines published before and after the 2009 Food and Drug Administration’s (FDA’s) 
report to Congress.  By comparing differences in pharmaceutical advertising placed in 
magazines published before and after the FDA report, this chapter will provide the first 
insight into whether or not drug manufacturers have responded to the FDA’s 
recommendations.  The chapter begins with an overview of previous research in this area 
(Section 3.1).  Section 3.2 discusses the methods used to select the magazines surveyed 
and to identify the pharmaceutical advertising found within each issue.  Section 3.3 
describes the types of statistical analyses used, and Section 3.4 presents the results of 
these analyses.  Section 3.5 provides a detailed discussion of the observed differences in 
both the frequency of advertisement placement and the types of drugs advertised.  
Section 3.6 offers some final observations and draws conclusions as to the impact of the 
FDA report on the amount and type of pharmaceutical advertising placed in the five 
women’s magazines reviewed. 
3.1  Background 
 A number of content analyses have been conducted on pharmaceutical advertising 
appearing in print magazines.  Of the 13 discussed in Chapter 2 and summarized in 
Appendix B to this dissertation, one-third directly examined differences in DTCA based 
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on the racial orientation of the magazine (Crawley et al., 2009; Duerksen et al., 2005; 
Mastin et al., 2007; Omonuwa, 2001).  Of these, most found that white-oriented 
magazines contained a substantially larger proportion of DTCA than black-oriented 
magazines.  For example, Duerksen et al. (2005) found that 76 percent of the prescription 
drug ads identified in their sample were placed in the mainstream white-oriented 
magazines analyzed.  Similarly, Omonuwa (2001) found that white-oriented magazines 
had an average of 10.1 pharmaceutical ads for the three months included in his study, 
while the black-oriented magazines averaged only 1.6 during the same period.  Only 
Crawley et al. (2009) did not find a significant variation in the number of ads placed 
based on the racial orientation of the magazine. 
 However, Crawley et al. (2009) did find differences in the type of drugs 
advertised as a function of the magazine’s target audience.  Advertisements for drugs to 
treat life-threatening conditions and mental health conditions were more likely to appear 
in white-oriented magazines.  Advertisements for drugs to treat infectious disease and 
nonlife-threatening chronic diseases were more likely to appear in black-oriented 
magazines.  Omonuwa (2001) also found a difference in the types of drugs advertised as 
a function of the magazine’s target audience.  Unlike readers of white-oriented magazines 
during the study period, readers of black-oriented magazines were not exposed to ads for 
drugs used to treat Alzheimer’s disease, constipation, depression, dyspepsia, high 
cholesterol, joint pain or inflammation, menopause, osteoporosis, tobacco abuse, or 
weight reduction.  Readers of white-oriented magazines were not exposed to 
advertisements for drugs to treat human immunodeficiency virus (HIV) or contraceptive 
drugs. 
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 Recognizing the potential for DTCA to improve information access and reduce 
health disparities, the FDA report includes the following two recommendations relevant 
to the types of drugs advertised and the frequency with which these ads appear in 
magazines:   
(1) “Use communicators in the advertisements and channels to disseminate messages 
that the target populations rate as credible” (FDA, 2009, p. 26). 
(2) “Produce help-seeking or other ad campaigns concerning diseases and health 
issues that have particular relevance to the target community” (FDA, 2009, p. 26).  
 Based on these recommendations, pharmaceutical companies should shape their 
advertising campaigns to better inform those that see them by placing print ads in 
magazines that are commonly read by the targeted population, by running television ads 
during shows that are commonly watched by the targeted population, and by using the 
Internet and social media to reach the targeted population as appropriate.  Ads should 
feature models or celebrity spokespeople to which the target audience can relate, and the 
drugs advertised should treat diseases common to the target audience.  In this way, 
pharmaceutical companies can fulfill their commitment to “promote health and disease 
awareness as part of their DTC advertising” and “responsibly educate the consumer about 
that medicine and, where appropriate, the condition for which it may be prescribed.”  
(These excerpts were taken from Pharmaceutical Research and Manufacturers of 
America, “PhRMA Guiding Principles:  Direct to Consumer Advertisements about 
Prescription Medicines,” as quoted in Arnold and Oakley, 2013).  
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To evaluate the impact of these recommendations on DTCA appearing in 
women’s magazines published before and after the report, this chapter will address the 
following research questions identified in the first chapter of this dissertation: 
RQ1:  Does the frequency of pharmaceutical advertising vary based on the racial 
orientation of the magazine? 
RQ2:  Did the frequency of pharmaceutical advertising appearing in black-oriented 
women’s magazines increase following the 2009 FDA report? 
RQ3:  Do the types of drugs advertised vary by the racial orientation of the magazine? 
RQ4:  Have the types of drugs advertised become more concordant with the health risks 
of the race of the magazine’s readers following the 2009 FDA report? 
If pharmaceutical companies were to have adopted these recommendations, one 
would expect to see an increase in the amount of DTCA placed in magazines read by 
black women and a shift in the types of drugs advertised to better align them with the 
diseases of greatest concern to the black community.  
3.2  Data Collection 
Five women’s magazines were selected for the study based on previous research 
and current circulation figures.  The study focuses on women’s magazines because 
women tend to make the medical decisions for their families (Abel et al., 2007; Mastin et 
al., 2007).  In 2003, the Kaiser Family Foundation reported that mothers “play a key role 
in coordinating and ensuring access to health care for their children” (Kaiser Family 
Foundation, 2003, p. 4).  They also “assume an important role as caregivers of relatives 
who are sick, disable, or elderly” (Kaiser Family Foundation, p. 4)  A 2010 article that 
appeared in Time magazine noted that, in two-thirds of U.S. households, women are the 
46 
 
 
primary health care decision makers (Kluger, 2010).  Furthermore, earlier researchers 
found that women’s magazines contain more DTCA than other magazine genres and 
women, rather than men, are more likely to pay attention to these ads (Mastin et al., 
2007). 
Duerksen et al. (2005) identified Family Circle and Good Housekeeping as the 
top two women’s magazines read by a predominantly white audience and Ebony5and 
Essence as the top two magazines read by a predominantly black audience based on 
2002 circulation rates.  Current circulation figures (second half of 2013) indicate that 
Good Housekeeping and Family Circle are the second and third most widely circulated 
women’s magazines read by a predominantly white audience,6 and Ebony and Essence 
remain the top two magazines read by black women (Alliance for Audited Media, 2013).  
A fifth magazine, O, The Oprah Magazine, which is read by both black and white women 
was selected as an additional point of comparison.  Table 3-1 summarizes the relevant 
demographic information of the magazines selected for the study. 
  
                                                          
5 Although Ebony may not be considered a “women’s magazine,” many of its articles and the majority of 
its advertising is aimed at female readers.  For example, in the magazine issues reviewed for this study, 
non-DTCA advertising included numerous promotions for hair products, cosmetics, and women’s clothing.  
Recipes and parenting tips were often included in each issue.  Articles frequently focused on style trends, 
relationships, and other content characteristic of women’s magazines.  
6  The most widely circulated women’s magazine is Better Homes and Gardens with a circulation rate of 
7,615,581.  However, this magazine has a home-focused orientation and was therefore not considered 
appropriate for the purposes of this study. 
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Table 3-1:  Readership demographics 
 
 
 
Magazines 
 
Paid 
Circulation1 
 
 
%Female2 
 
 
%White2 
 
 
%Black2 
 
Median2 
Age 
Median 
Household 
Income2 
Ebony 1,280,350 65 10 90 42.5 54,240 
Essence 1,060,774 753 63 923 43.3 40,800 
Family 
Circle 
4,092,525 100 893 93 53.0 60,074 
Good 
Housekeeping 
4,348,641 90 74 11 55.4 63,300 
O, The Oprah 
Magazine 
2,386,601 87 64 30 49.9 66,900 
1 Circulation averages for the six months ended December 31, 2013.  Source:  Alliance for Audited Media, 
December 31, 2013. 
2 Except where noted otherwise, data were taken from the 2014 media kits for each magazine. 
3 Source:  Duerksen et al., 2005.  Data reported are for fall 2000.  Although these data could be considered 
outdated, there is no reason to suspect that these percentages would be significantly different today. 
 
 
 To determine whether the 2009 FDA report had an effect on the types of drugs 
advertised and the placement of DTCA in the selected magazine titles, issues dated 
January 2008 to December 2009 (i.e., the “before FDA report” period) were compared to 
issues dated January 2011 to December 2012 (i.e., the “after FDA report” period).  
Because the FDA report was published in September 2009, magazine issues published in 
2010 were excluded from the study sample.  It was assumed that pharmaceutical 
companies would need some period of time to implement the FDA report 
recommendations in their ongoing advertising campaigns. 
 Back issues of magazines were purchased either from individuals advertising on 
EBay or from oldmags.com, a commercial vendor located through the Internet.  The 
integrity of each magazine issue was verified, and magazines with missing pages were 
replaced.  For the most part, each magazine title was published 12 times a year.  
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However, in 2008 and 2009, Family Circle was published a total of 15 times with two 
issues published in April, October, and November.  For these years, the first issue 
published within a given month was included in the study population.  In the case of 
Ebony, only 11 issues were published in 2009, 2011, and 2012.  The study population 
consisted of a total of 237 individual magazine issues representing the primary monthly 
issue of each magazine title.7 
Data collection comprised a three-step process.  The first step consisted of 
manually counting each magazine page.8  The inside front cover, as well as the inside and 
outside back cover, was included in the count since these pages featured some form of 
advertising.  Next, the total number of advertising pages was counted.  Finally, the total 
number of DTCA pages was counted.  Full-page advertisements were counted as one 
page; if a portion of a page included an advertisement, no matter what the size, then the 
page was counted as a one-half page advertisement.  Advertisement inserts that were 
significantly smaller than the standard magazine page, such as coupon booklets, were 
excluded from all counts. 
                                                          
7 Recognizing that my study population is incomplete, I intend to collect data from the six magazine issues 
omitted from the current research. 
8 I discovered early on that the way in which a magazine is paginated does not reflect the actual number of 
pages in the issue.  For example, some magazines do not assign page numbers to multi-page advertising 
spreads.  For the purposes of this research, it was imperative that the magazine page counts were accurate.  
I achieved this by manually counting each page.  To ensure accuracy in page counts, all 48 issues of Family 
Circle were double counted.  When differences in page counts occurred, the issue was triple counted and 
the two matching pages counts were used.  Initially, nearly half the magazines had to be recounted because 
of slight differences (i.e., a single page or less) in either total page counts or total advertising page counts.  
No differences were observed in the DTCA page counts.  After adopting the use of a rubber fingertip and 
creating a code sheet on which I tallied the number of magazine pages, the number of advertising pages, 
and the number of DTCA pages, the number of issues needing to be triple counted went to zero.  
Consequently, issues of Ebony, Essence, Good Housekeeping, and O, The Oprah Magazine were counted 
only once.  However, given the sizeable number of magazine pages counted (nearly 49,000), any remaining 
error in page count would be randomly distributed and unlikely to affect the study results.  (The number of 
magazines pages counted was computed by multiplying the average number of pages per issue (205) by the 
number of issues examined (237)). 
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 The DTCA page count included both product claim ads and help-seeking ads.  In 
nearly all cases, product claim ads included the FDA-required product information (i.e., 
the “brief summary”) and were thus easily identifiable.  Mastin et al. (2007) also used the 
presence of this information to identify ads used in their study.  Help-seeking 
advertisements mentioned a particular medical condition, such as macular degeneration, 
but did not identify a particular drug.  Only those help-seeking ads sponsored by a 
pharmaceutical company were included in the DTCA count.  No reminder ads appeared 
in the study sample. 
 Each magazine issue was assigned a unique identification number, and the 
following information was recorded on individual code sheets: 
 ID # 
 magazine name 
 publication date 
 number of pages 
 number of advertising pages 
 number of DTCA pages 
 percent of advertising pages 
 percent of DTCA as a function of total magazine pages 
 percent of DTCA as a function of total advertising pages 
In addition, each pharmaceutical advertisement that appeared within a particular 
magazine issue was assigned a unique identification number, and the name and 
manufacturer of the drug, the page number on which the ad appeared, and the medical 
condition for which the drug is to be used was recorded.  These data were then entered 
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into a database for further analysis.  In addition, variables were included to identify the 
racial orientation of the magazine and whether the publication date fell before or after the 
FDA report date. 
3.3  Data Analysis 
 The unit of analysis for the data presented in this chapter is the individual 
magazine issue.  Version 22 of the Statistical Package for the Social Sciences (SPSS) was 
used for all statistical analyses.  Data were compiled by year for each magazine title, and 
descriptive statistics were used to ascertain the means for each magazine title and year for 
the following variables: 
 total number of magazine pages 
 total number of advertising pages 
 total number of advertising pages dedicated to DTCA 
 percent of advertising pages as a function of total magazine pages 
 percent of DTCA as a function of total magazine pages 
 percent of DTCA as a function of total advertising pages 
To account for the fewer number of issues of Ebony magazine published in 2009, 2011, 
and 2012, as well as the variability in the number of pages per magazine issue, a further 
calculation was performed.  In a method similar to that employed by Crawley et al. 
(2009), the density of DTCA was standardized by dividing the total number of 
pharmaceutical ads appearing in a given year by the total number of magazine pages for 
that year and multiplying by 100.  This calculation was repeated for every magazine title 
for each publication year.   
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Since the study focuses on the difference between black- and white-oriented 
magazines, rather than the difference between individual magazine titles, the data 
collected from Ebony and Essence magazines were collapsed into a single category, 
“Black-Oriented Magazines,” and the data for Family Circle and Good Housekeeping 
were collapsed into a single category, “White-Oriented Magazines.”  Data from O, The 
Oprah Magazine were categorized as “Crossover Magazine.”  Similarly, since the study’s 
goal is to discern whether a significant difference exists in the frequency of DTCA before 
and after the FDA report was issued, the data collected from issues published before the 
FDA report (i.e., 2008 and 2009) were collapsed into a single category, “Before FDA 
Report,” and the data collected from issues published after the FDA report (i.e., 2011 and 
2012) were collapsed into a single category, “After FDA Report.”   
To respond to RQ1, data were filtered by racial orientation to allow the frequency 
of pharmaceutical advertising to be compared based on the racial orientation of the 
magazine.  Means were calculated for each publication year.  To respond to RQ2, data 
were sorted by the relationship of the magazine’s publication date to the FDA report date 
(i.e., “before” or “after”).  This allowed data from magazines published before the FDA 
report to be compared to data from magazines published after the FDA report to 
determine whether the report recommendations had resulted in an increase in the amount 
of DTCA appearing in black-oriented women’s magazines.  Independent sample t-tests 
were used to evaluate the significance of differences in means. 
Descriptive statistics were also used to characterize all DTCA found in the 
237 magazine issues reviewed.  For the product claim ads, the name of each drug was 
identified, as well as the medical condition for which it was intended to treat.  Since 
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help-seeking ads do not mention a particular drug, these ads were characterized by 
medical condition only.  Medical conditions were then grouped into the following 
16 categories based on the work done by Bell et al. (2000): 
 Allergies 
 Cancer 
 Cardiovascular 
 Cosmetic 
 Dermatological 
 Diabetes 
 Gastrointestinal/Nutritional 
 Infections (Non-HIV) 
 Musculoskeletal 
 Obstetric/Gynecological 
 Ophthalmological 
 Psychiatric/Neurologic 
 Respiratory 
 Tobacco Addiction 
 Urological 
 Other 
Minor adjustments were made to the categories identified by these researchers.  
Specifically, the category entitled “Dermatologic” was split into two:  “Dermatologic” 
and “Cosmetic” to distinguish between those drugs used to treat serious dermatological 
conditions, such as psoriasis, and those used for cosmetic purposes, such as reducing fine 
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lines and wrinkles.  The category “HIV/AIDS” was omitted because no advertisements 
appeared for drugs used to treat this medical condition.  A new category, 
“Ophthalmological,” was created to capture drugs used to treat chronic dry eyes.  A final 
category “Other” comprises any medical condition not otherwise categorized.   
To address RQ3 and RQ4, which relate to the types of drugs being advertised, 
frequency distributions were obtained for the name of the drugs advertised and the 
medical conditions treated.  As described previously, data were collapsed to create three 
categories for racial orientation:  black-oriented magazines, white-oriented magazines, 
and crossover magazine.  Publication data were also collapsed to allow a comparison of 
drug types advertised before and after the issuance of the FDA report.  Because of the 
relatively small number of ads in many of the above categories, the mean of each 
category was not computed.  Instead, the trends in these data were identified, and these 
trends were then considered within the context of the FDA report recommendations. 
3.4  Results 
Every issue of the white-oriented magazines (n=96) contained at least one 
pharmaceutical advertisement.  Four issues of Ebony (n=45) and six issues of Essence 
(n=48) lacked DTCA.  Only one issue of the crossover magazine (n=48) did not include a 
single pharmaceutical ad.  A total of 1,163 pharmaceutical advertisements were 
identified; of these, 1,090 were product claim ads and 73 were help-seeking ads.  
Tables 3-2 and 3-3 present the number of ads of each type appearing in each magazine 
title by publication year.  Examining Table 3-2, we can see that the greatest number of 
product claim ads were placed in 2008, while the fewest were placed in 2012.  Note also 
that the number of ads varied only slightly between issues in the same magazine genre 
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(i.e., 88 ads in Ebony versus 83 in Essence; 378 in Family Circle versus 370 in Good 
Housekeeping). 
Table 3-2:  Product claim advertisements 
 
 
Year 
 
 
Ebony 
 
 
Essence 
 
Family 
Circle 
 
Good 
Housekeeping 
O, The 
Oprah 
Magazine 
 
 
Total 
2008 32 24 85 111 56 308 
2009 21 19 105 96 27 268 
2011 23 23 97 95 54 292 
2012 12 17 91 68 34 222 
Total 88 83 378 370 171 1,090 
 
 
By contrast, the number of help-seeking ads increased from 16 in 2008 and to 27 in 2012, 
as seen in Table 3-3. 
Table 3-3:  Help-seeking advertisements 
 
 
 
Year 
 
 
Ebony 
 
 
Essence 
 
Family 
Circle 
 
Good 
Housekeeping 
O, The 
Oprah 
Magazine 
 
 
Total 
2008 2 2 4 7 1 16 
2009 1 2 8 3 0 14 
2011 3 0 3 6 4 16 
2012 2 0 10 9 6 27 
Total 8 4 25 25 11 73 
 
 
 The number of magazine pages varied not only by magazine title, but also by 
year.  For example, the number of pages in the 2008 Family Circle issues ranged from as 
few as 131 to as many of 229.  For this same year, the number of pages in Ebony ranged 
from 151 to 217.  A similar variation can be seen across years.  In 2008, the number of 
pages of O, The Oprah Magazine ranged from 227 to 359, but in 2012 the number of 
pages ranged from 147 to 255. To adjust for these differences, an ad density value was 
calculated as described previously.  Table 3-4 presents the results of these calculations. 
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Table 3-4: Advertisement density 
 
 
 
Year 
 
 
Ebony 
 
 
Essence 
 
Family 
Circle 
 
Good 
Housekeeping 
O, The 
Oprah 
Magazine 
2008 1.5 1.1 3.9 4.2 1.7 
2009 1.6 1.0 4.6 3.7 1.0 
2011 1.7 1.0 4.6 3.9 2.2 
2012 0.8 0.9 4.9 3.3 1.7 
 
 
As we can see from Table 3-4, the density rates in Family Circle and Good 
Housekeeping were substantially greater than the rates found in Ebony, Essence, and 
O, The Oprah Magazine.  To enable the statistical significance of the identified 
differences in the frequency of DTCA to be determined, the mean values of the following 
key variables were calculated:  number of magazine pages, number of advertising pages, 
number of pharmaceutical advertising pages, percent of advertising pages, percent of 
DTCA as a function of all magazine pages, and percent of DTCA as a percent of all 
advertising pages.  Table 3-5 presents the means for each of these variables for each year 
by magazine title.   
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Table 3-5:  Descriptive statistics for key variables by year by magazine 
(2008, 2009, 2011, and 2012) 
 
 
 
 
 
 
 
Year 
 
# of 
Magazine 
Pages 
 
Mean 
(SD) 
(Min–Max) 
 
# of 
Advertising 
Pages 
 
Mean 
(SD) 
(Min–Max) 
 
# of DTCA 
Pages 
 
Mean 
(SD) 
(Min–Max) 
 
% of 
Advertising 
Pages 
 
Mean 
(SD) 
(Min–Max) 
% of DTCA as 
a Function of 
All Magazine 
Pages 
 
Mean 
(SD) 
(Min–Max) 
% of DTCA 
as a Function 
of All Ad 
Pages 
 
Mean 
(SD) 
(Min–Max) 
FAMILY CIRCLE 
2008 
n=12 
191.00 
(SD=34.67) 
(131–229) 
106.08 
(SD=21.58) 
(69–130) 
15.83 
(SD=5.52) 
(6–24) 
0.553 
(SD=0.021) 
(0.518–0.578) 
0.086 
(SD=0.038) 
(0.033–0.178) 
0.156 
(SD=0.072) 
(0.060-0.338) 
2009 
n=12 
205.33 
(SD=50.93) 
(131–309) 
115.71 
(SD=30.20) 
(70–173) 
20.67 
(SD=8.28) 
(10–36) 
0.562 
(SD=0.024) 
(0.530–0.601) 
0.099 
(SD=0.028) 
(0.057–0.161) 
0.176 
(SD=0.045) 
(0.107–0.269) 
2011 
n=12 
181.67 
(SD=33.57) 
(127–237) 
102.67 
(SD=23.07) 
(69–138) 
21.25 
(SD=5.75) 
(12.5-31.5) 
0.561 
(SD=0.029) 
(0.514-0.603) 
0.118 
(SD=0.030) 
(0.084-0.187) 
0.211 
(SD=0.060) 
(0.147-0.364) 
2012 
n=12 
173.50 
(SD=27.65) 
(107–219) 
99.38 
(SD=17.60) 
(58.5–126.5) 
20.00 
(SD=5.69) 
(8–27.5) 
0.571 
(SD=0.022) 
(0.540–0.600) 
0.114 
(SD=0.028) 
(0.075–0.165) 
0.200 
(SD=0.044) 
(0.137-0.275) 
GOOD HOUSEKEEPING 
2008 
n=12 
240.33 
(SD=22.75) 
(205–269) 
126.50 
(SD=15.64) 
(98.5–147) 
20.92 
(SD=7.00) 
(7–32) 
0.525 
(SD=0.022) 
(0.480–0.551) 
0.088 
(SD=0.031) 
(0.027–0.138) 
0.169 
(SD=0.063) 
(0.051–0.274) 
2009 
n=12 
223.83 
(SD=25.29) 
(189–269) 
113.92 
(SD=19.62) 
(85–146) 
18.75 
(SD=5.96) 
(12–29) 
0.506 
(SD=0.035) 
(0.450–0.568) 
0.084 
(SD=0.027) 
(0.045–0.134) 
0.166 
(SD=0.050) 
(0.089-0.278) 
2011 
n=12 
213.33 
(SD=20.05) 
(187–245) 
108.79 
(SD=17.71) 
(86.5–134.5) 
21.83 
(SD=7.26) 
(9–34.5) 
0.507 
(SD=0.035) 
(0.463–0.556) 
0.102 
(SD=0.032) 
(0.044–0.173) 
0.201 
(SD=0.066) 
(0.090–0.367) 
2012 
n=12 
198.17 
(SD=13.63) 
(179–233) 
95.17 
(SD=17.16) 
(61–127) 
14.38 
(SD=5.41) 
(4–25.5) 
0.478 
(SD=0.061) 
(0.323–0.547) 
0.073 
(SD=0.028) 
(0.020–0.134) 
0.154 
(SD=0.056) 
(0.039–0.267) 
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Table 3-5:  (continued) 
 
Year 
 
 
# of 
Magazine 
Pages 
 
Mean 
(SD) 
(Min–Max) 
 
# of 
Advertising 
Pages 
 
Mean 
(SD) 
(Min–Max) 
 
 
# of DTCA 
Pages 
 
Mean 
(SD) 
(Min–Max) 
 
 
% of 
Advertising 
Pages 
 
Mean 
(SD) 
(Min–Max) 
 
% of DTCA 
as a Function 
of All 
Magazine 
Pages 
 
Mean 
(SD) 
(Min–Max) 
 
% of DTCA as 
a Function of 
All Ad Pages 
 
Mean 
(SD) 
(Min–Max) 
EBONY 
2008 
n=12 
188.17 
(SD=17.59) 
(151–217) 
83.08 
(SD=13.27) 
(61.5–105.0) 
5.71 
(SD=2.78) 
(2.0–11.5) 
0.439 
(SD=0.041) 
(0.373–0.490) 
0.030 
(SD=0.014) 
(0.010–0.056) 
0.070 
(SD=0.033) 
(0.023–0.115) 
2009 
n=11 
126.82 
(SD=11.68) 
(115–147) 
54.32 
(SD=7.89) 
(41–66) 
4.05 
(SD=2.34) 
(0.0–7.5) 
0.428 
(SD=0.044) 
(0.357–0.508) 
0.032 
(SD=0.019) 
(0.000–0.059) 
0.073 
(SD=0.041) 
(0.000–0.126) 
2011 
n=11 
139.73 
(SD=10.09) 
(131–163) 
48.64 
(SD=8.76) 
(34.5–60.5) 
4.96 
(SD=2.39) 
(0.0–8.0) 
0.346 
(SD=0.044) 
(0.236–0.408) 
0.035 
(SD=0.016) 
(0.000–0.052) 
0.099 
(SD=0.039) 
(0.000–0.138) 
2012 
n=11 
153.36 
(SD=12.09) 
(139–183) 
59.50 
(SD=9.15) 
(48.5–82.5) 
2.91 
(SD=2.30) 
(0.0–6.0) 
0.387 
(SD=0.034) 
(0.349–0.451) 
0.020 
(SD=0.016) 
(0.000–0.043) 
0.052 
(SD=0.045) 
(0.000–0.124) 
ESSENCE 
2008 
n=12 
199.33 
(SD=34.03) 
(123–233) 
104.63 
(SD=20.32) 
(63.0–125.6) 
4.42 
(SD=2.46) 
(0.0–7.5) 
0.523 
(SD=0.027) 
(0.479-0.567) 
0.022 
(SD=0.012) 
(0.000–0.048) 
0.043 
(SD=0.024) 
(0.000–0.092) 
2009 
n=12 
174.67 
(SD=18.95) 
(153–211) 
95.29 
(SD=15.18) 
(76–126) 
3.88 
(SD=2.56) 
(0.0–8.5) 
0.544 
(SD=0.042) 
(0.491–0.609) 
0.022 
(SD=0.016) 
(0.000–0.048) 
0.041 
(SD=0.028) 
(0.000–0.085) 
2011 
n=12 
184.00 
(SD=28.33) 
(127–243) 
101.21 
(SD=18.15) 
(60.0–128.5) 
3.92 
(SD=2.22) 
(0.0–8.0) 
0.548 
(SD=0.034) 
(0.472–0.595) 
0.020 
(SD=0.010) 
0.000–0.033) 
0.037 
(SD=0.019) 
(0.000–0.062) 
2012 
n=12 
160.83 
(SD=18.36) 
(123–187) 
85.33 
(SD=16.86) 
(41.5–101.5) 
2.96 
(SD=2.13) 
(0.0–6.5) 
0.526 
(SD=0.065) 
(0.337–0.582) 
0.018 
(SD=0.012) 
(0.000–0.035) 
0.033 
(SD=0.023) 
(0.000–0.064) 
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Table 3-5:  (continued) 
 
Year 
 
# of 
Magazine 
Pages 
 
Mean 
(SD) 
(Min–Max) 
# of 
Advertising 
Pages 
 
Mean 
(SD) 
(Min–Max) 
 
# of 
DTCA 
Pages 
 
Mean 
(SD) 
(Min–
Max) 
 
% of 
Advertising 
Pages 
 
Mean 
(SD) 
(Min–Max) 
% of DTCA 
as a Function 
of All 
Magazine 
Pages 
 
Mean 
(SD) 
(Min–Max) 
% of DTCA as 
a Function of 
All Ad Pages 
 
Mean 
(SD) 
(Min–Max) 
O, THE OPRAH MAGAZINE 
2008 
n=12 
285.67 
(SD=47.01) 
(227–359) 
154.42 
(SD=33.97) 
(110.5–201.0) 
9.33 
(SD=3.81) 
(4–15) 
0.536 
(SD=0.036) 
(0.477–.588) 
0.034 
(SD=0.017) 
(0.012–0.066) 
0.064 
(SD=0.034) 
(0.021–0.136) 
2009 
n=12 
221.50 
(SD=35.23) 
(173–291) 
108.96 
(SD=28.04) 
(71.5–162.5) 
4.92 
(SD=2.46) 
(0.0–8.5) 
0.485 
(SD=0.049) 
(0.413–0.558) 
0.022 
(SD=0.011) 
(0.000–0.038) 
0.046 
(SD=0.025) 
(0.000–0.091) 
2011 
n=12 
220.75 
(SD=36.97) 
(165–276) 
112.58 
(SD=27.44) 
(70–159) 
11.33 
(SD=4.84) 
(6–23) 
0.503 
(SD=0.044) 
(0.419–0.576) 
0.053 
(SD=0.022) 
(0.024–0.087) 
0.106 
(SD=0.047) 
(0.042–0.186) 
2012 
n=12 
197.17 
(SD=30.11) 
(147–255) 
95.96 
(SD=22.21) 
(55.5–139.0) 
7.25 
(SD=5.22) 
(1.5–16.5) 
0.481 
(SD=0.048) 
(0.378–0.545) 
0.036 
(SD=0.232) 
(0.007–0.077) 
0.076 
(SD=0.047) 
(0.016–0.161) 
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We can see from Table 3-5 that advertising in general represented a large 
proportion of each magazine.  Family Circle had the largest percentage of advertising 
pages, ranging between 55 and 57 percent.  Ebony had the lowest percentage of 
advertising pages, ranging from a low of 35 percent to a high of 44 percent.  Focusing in 
on DTCA, we find that pharmaceutical advertising represented a small percentage of the 
total magazine pages in all five magazine titles (i.e., typically less than 10 percent).  
However, if we look at the percentage of DTCA as a function of just the number of 
advertising pages, we see that pharmaceutical advertising represented a relatively large 
proportion of the advertising appearing in Family Circle (16 to 21 percent), Good 
Housekeeping (15 to 20 percent), and Ebony (7 to 10 percent).  On the other hand, less 
than 5 percent of the ads found in Essence promoted pharmaceuticals.  The percent of 
DTCA as a function of all advertising pages found in O, The Oprah Magazine ranged 
from less than 5 percent in 2009 to just over 10 percent in 2011. 
3.4.1  Differences in Means 
To respond to RQ1 and RQ2, the frequency of DTCA appearing in black-oriented 
magazines was compared to the frequency of DTCA appearing in the white-oriented 
magazines.  Values were calculated for the following variables: 
 percent of DTCA as a function of all magazine pages 
 percent of DTCA as a function of all advertising pages 
These two variables serve to eliminate differences in the frequency of DTCA associated 
with differences in the size of the magazine (in terms of number of pages) and the amount 
of total advertising (in terms of number of advertising pages).  Using descriptive 
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statistics, the means for these variables were computed using the new categories for racial 
orientation and publication date.  Table 3-6 summarizes the results. 
Table 3-6:  Differences in DTCA before and after publication of FDA report  
 
TOTAL MAGAZINE PAGES 
 Before After 
Black-Oriented Magazines 
0.027 
(SD=0.015) 
(n=47) 
0.023 
(SD=0.015) 
(n=46) 
White-Oriented Magazines 
0.089 
(SD=0.031) 
(n=48) 
0.102 
(SD=0034) 
(n=48) 
Crossover Magazine 
0.028 
(SD=0.015) 
(n=24) 
0.044 
(SD=0.024) 
(n=24) 
TOTAL ADVERTISING PAGES 
 Before After 
Black-Oriented Magazines 
0.056 
(SD=0.034) 
(n=47) 
0.054 
(SD=0.041) 
(n=46) 
White-Oriented Magazines 
0.167 
(SD=0.057) 
(n=48) 
0.191 
(SD=0.059) 
(n=48) 
Crossover Magazine 
0.055 
(SD=0.031) 
(n=24) 
0.091 
(SD=0.049) 
(n=24) 
 
 
 From Table 3-6 we can see that the frequency of DTCA varies not only on the 
basis of a magazine’s racial orientation, but also on its issue date relative to publication of 
the FDA report.  For example, if we look at the mean of DTCA as a function of total 
advertising pages, we see that the mean for the black-oriented magazines and the 
crossover magazine was virtually identical (0.056 and 0.055, respectively) in the issues 
published in 2008 and 2009.  However, if we look at the means for the more recent issues 
(i.e., 2011 and 2012), we see a difference.  The mean for black-oriented magazines is 
relatively unchanged (0.054), while the mean for the crossover magazine increased from 
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0.055 to 0.091.  The mean amount of DTCA appearing in white-oriented magazines was 
greater than either the black-oriented or crossover magazines regardless of publication 
date.   
An independent samples t-test was used to determine the statistical significance of 
these observed differences.  In each case, the null hypothesis assumed that there would be 
no difference in the mean frequency of advertising based on the racial orientation of the 
magazine.  The alternative hypothesis suggested that more pharmaceutical advertising 
would be found in the white-oriented magazines and the crossover magazine than in the 
black-oriented magazines based on the results of previous research.  Means were 
analyzed both before and after publication of the FDA report.  Table 3-7 presents these 
results. 
Table 3-7:  Mean differences in DTCA frequency  
based on racial orientation of magazine 
 
 BEFORE AFTER 
 
% of All 
Magazine 
Pages 
% of All 
Advertising 
Pages 
% of All 
Magazine 
Pages 
% of All 
Advertising 
Pages 
White x Black 0.063 (p=.000) 0.111 (p=.000) 0.079 (p=.000) 0.137 (p=.000) 
Black x 
Crossover 
-0.002 (p=.704) 0.112 (p=.000) -0.021 (p=.006) -0.036 (p=.002) 
White x 
Crossover 
0.061 (p=.000) 0.112 (p=.000) 0.058 (p=.000) 0.100 (p=.000) 
 
 The results in Table 3-7 can be used to answer RQ1 which asks whether the 
frequency of pharmaceutical advertising varies based on the racial orientation of the 
magazine.  We can see that in virtually all cases, the difference in means is statistically 
significant.  As we hypothesized, the frequency of DTCA appearing in white-oriented 
magazines in statistically greater than in either the black-oriented magazines or the 
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crossover magazine (p < .001).  However, the difference in DTCA frequency between the 
black-oriented and crossover magazines is not significant when considered as a function 
of all magazines pages (p > 0.05), but becomes significant when examined as a function 
of just the advertising pages (p < .001).  The negative value found when comparing the 
mean of the black-oriented magazines to the crossover magazine reflects the fact that the 
black-oriented magazines has less DTCA than the crossover magazine as a function of 
total magazine pages in the period before the FDA report was published and as a function 
of both total magazine pages and total advertising pages in the period after publication of 
the FDA report. 
RQ2 explores the impact of the FDA report recommendations on the frequency of 
advertising appearing black-oriented magazines.  Independent samples t-tests were again 
used to evaluate the differences between the frequency of DTCA before and after the 
publication of the FDA report for each magazine genre.  In each of these cases, the null 
hypothesis assumed that there would be no difference in the mean frequencies of 
advertising based on the racial orientation of the magazine.  The alternative hypothesis 
assumed that the amount of DTCA placed in both the black-oriented magazines and the 
crossover magazine would increase as a result of the FDA recommendations.  Table 3-8 
presents these results. 
Table 3-8:  Mean differences in DTCA frequency before and after FDA report 
 
Magazine Genre % of All Magazine Pages % of All Advertising Pages 
Black-Oriented -0.004 (p=.263) -0.002 (p=.819) 
White-Oriented 0.012 (p=.065) 0.025 (p=.041) 
Crossover 0.016 (p=.007) 0.036 (p=.004) 
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 Table 3-8 suggests that the publication of the FDA recommendations had no 
impact on the amount of DTCA appearing in either the black-oriented or white-oriented 
magazines.  The difference between the means of these groups was not found to be 
significant (p>0.05).  However, in looking at the values for the crossover magazine, we 
do find that the difference in the mean amount of DTCA, as a percentage of advertising 
pages, represents a significant increase (p<.01).  Negative values in Table 3-8 reflect a 
relative decrease in DTCA pre- and post-FDA report. 
3.4.2  Differences in Drug Type 
 As discussed above, both product claim ads and help-seeking ads were identified 
in the study sample.  Product claim ads mention a specific drug and the medical condition 
for which it is used, while help-seeking ads only mention a particular medical condition.  
For the purposes of this study, these two types of ads were analyzed separately.  
However, product claim ads are most relevant to the research questions posed and will be 
the focus of much of the analysis. 
Ninety-five drugs were represented in the 1,090 product claim advertisements 
identified.  Table 3-9 provides an inventory of the drugs advertised for all years and all 
magazine titles included in the study sample.  Drugs were classified by the medical 
condition noted in the individual advertisement.  Some drugs were advertised for more 
than one purpose (e.g., Cymbalta is used to treat depression and fibromyalgia), but only 
three drugs (Enbrel, Humira, and Singulair) are used to treat conditions in different 
categories of medical conditions.  Consequently, Enbrel and Humira appear in both the 
“Dermatologic” (psoriasis) and “Musculoskeletal” (rheumatoid arthritis) categories, and 
Singulair appears in both the “Allergies” and “Respiratory” (asthma) categories. 
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The greatest number of drugs advertised (21) fall into the “Psychiatric/ 
Neurologic” category.  This is not surprising since the drugs in this category are used to 
treat the widest range of conditions, including Alzheimer’s disease, attention deficit and 
hyperactivity disorder (ADHD), chronic pain, depression, epilepsy, fibromyalgia, 
insomnia, migraines, and restless leg syndrome.  Ads in this category represented nearly 
31 percent of the total number of product claim ads identified.  Drugs to treat 
postmenopausal osteoporosis were the next most frequently advertised drugs over the 
study period, representing 17.2 percent of the product claim ads identified, followed by 
drugs to treat respiratory conditions, such as asthma and chronic obstructive pulmonary 
disorder (COPD), representing 11.3 percent of these ads.  The fewest number of ads 
promoted drugs to treat cancer, with a single ad for each of two cancer drugs (Arimidex 
and Femara) appearing only once in the four-year study period. 
Table 3-9:  Advertised drugs 
 
 
Medical Condition 
 
Brands 
No. of 
Ads 
 
Percent 
Allergies EpiPen, Singulair 4 0.4 
Cancer Arimidex, Femara 2 0.2 
Cardiovascular Caduet, Crestor, Lipitor, Livalo, 
Lovaza, Niaspan, Plavix, Pradaxa, 
TriCor, Vytorin, Xarelto, Zetia 
109 10.0 
Cosmetic ArteFill, Botox Cosmetic, Dysport, 
Latisse, Restylane, 
SculptraAesthetic, Vivite 
38 3.5 
Dermatologic Enbrel, Humira, Oracea 23 2.1 
Diabetes FlexPen, Januvia, Lantus, Victoza 53 4.9 
Gastrointestinal/Nutritional AcipHex, Amitiza, Transdermal 
Scop 
19 1.7 
Infectious (Non-HIV) FluMist, Fluzone, Gardasil, 
Incivek, Prevnar 13, Tamiflu, 
Valtrex, Zostavax 
68 6.2 
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Table 3-9:  (continued) 
 
 
Medical Condition 
 
Brands 
No. of 
Ads 
 
Percent 
Musculoskeletal Actonel, Boniva, Celebrex, Cimzia, 
Enbrel, Evista Humira, Orencia, 
Prolia, Reclast, Remicade, Simponi, 
Synvisc-One, Vimovo 
188 17.2 
Obstetric/Gynecological Estring, Mirena, NuvaRing, Plan B, 
Premarin Vaginal Cream, VagiFem, 
Yaz 
51 4.7 
Ophthalmological Restasis 14 1.3 
Psychiatric/Neurologic Abilify, AmbienCR, Aricept, 
Botox, Concerta, Cymbalta, Exelon 
Patch, Horizant, Keppra, Lunesta, 
Lyrica, Mirapex, Nuedexta, Pristiq, 
Provigil, Rozerem, Seroquel XR, 
Topamax, Treximet, Ultram ER, 
Vyvanse 
332 30.5 
Respiratory Advair Diskus, Dulera, Flovent 
Diskus, Pulmicort Respules, 
Singulair, Spiriva HandiHaler, 
Symbicort 
123 11.3 
Tobacco Addiction Chantix 7 0.6 
Urological Detrol LA, Enablex, Toviaz, 
VESIcare 
59 5.4 
 
 As anticipated, the types of drugs advertised varied by magazine title and by year.  
Table 3-10 compares the types of drugs advertised in each magazine title by year of 
publication.  Examining the data in Table 3-10 reveals some interesting trends. 
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While the number of ads placed in both Ebony and Essence decreased over the 
course of the study period, the reduction was far more dramatic in Ebony.  In 2008, 
Ebony included 32 pharmaceutical ads, while in 2012 only 12 appeared—a decline of 
nearly 60 percent.  In addition, the number of disease categories treated by the advertised 
drugs dropped from seven in 2008 to only three in 2012.  On the other hand, while the 
number of pharmaceutical ads found in Essence declined 30 percent, the number of 
disease categories only decreased by one.   
 We see a similar decline in pharmaceutical advertising appearing in Good 
Housekeeping.  The number of ads fell from 111 in 2008 to 68 in 2012—a decline of 
nearly 40 percent.  However, the number of disease categories only declined by one.  
Pharmaceutical advertising in Family Circle remained relatively constant over the study 
period, although the number of disease categories also fell by one.  O, The Oprah 
Magazine experienced a decline of about 40 percent in the number of pharmaceutical ads 
and a similar loss of a single disease category. 
 Although the number of disease categories did not change much (except in the 
case of Ebony), the actual categories represented varied by year and by magazine title.  
For example, drugs to treat postmenopausal osteoporosis were advertised in Essence in 
2008 but not in any subsequent year.  Drugs to treat tobacco addiction were advertised 
only in Family Circle and Good Housekeeping and only in 2008 and 2009.  No drug to 
treat overactive bladder symptoms was advertised in any issue of Ebony and Essence.  
Cardiovascular drugs were not advertised at all in Essence, although they were advertised 
in Ebony but not in 2011 or 2012. 
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To answer RQ3, which questions whether the types of drugs advertised vary by 
the racial orientation of the magazine, it was necessary to compare the types of drugs 
advertised in white-oriented magazines with those advertised in the black-oriented 
magazines and the crossover magazine.  Table 3-11 summarizes the percentage of drugs 
advertised in each disease category by the racial orientation of the magazine.  Data were 
further consolidated by publication year—either before publication of the FDA report 
(2008 and 2009) or after (2011 and 2012).   
Table 3-11:  Types of drugs advertised by racial orientation of magazine 
(percent of ad total) 
 
Disease Category BEFORE AFTER 
 Black White Crossover Black White Crossover 
Allergies --- 0.3 --- --- 0.9 --- 
Cancer 1.0 0.3 --- --- --- --- 
Cardiovascular 13.5 14.1 9.6 --- 8.5 2.3 
Cosmetic --- --- 20.5 --- 2.3 14.8 
Dermatologic --- 1.5 3.6 --- 0.9 12.5 
Diabetes 20.8 0.8 1.2 22.7 3.4 --- 
Gastrointestinal/ 
Nutritional 
--- 4.3 2.4 --- --- --- 
Infectious 
(Non-HIV) 
5.2 4.3 7.2 26.7 5.7 --- 
Musculoskeletal 8.3 19.1 15.7 6.7 22.5 8.0 
Obstetric/ 
Gynecological 
11.5 1.8 2.4 6.7 5.1 9.1 
Ophthalmological --- --- --- --- 2.3 6.8 
Psychiatric/ 
Neurologic 
22.9 31.5 30.1 24.0 31.1 37.5 
Respiratory 16.7 10.3 4.8 13.3 13.7 4.5 
Tobacco 
Addiction 
--- 1.8 --- --- --- --- 
Urological --- 10.1 2.4 --- 3.7 4.5 
 
 Table 3-11 further documents many of the previous observations.  The 
white-oriented magazines had a broader range of drugs advertised, with at least one 
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pharmaceutical ad appearing in each disease category sometime during the study period.  
The black-oriented magazines lacked advertising for drugs to treat allergies, 
gastrointestinal/nutritional conditions, ophthalmological concerns, tobacco addiction, and 
urological issues.  Readers of O, The Oprah Magazine were not exposed to any ads for 
drugs to treat allergies, cancer, and tobacco addiction in issues published during the study 
period.   
To shed further light on these differences, Appendix C tabulates data for each 
individual drug advertised.  Tables 3-12 and 3-13 summarize these data.  Table 3-12 
provides information on the three most prevalent drugs advertised in each magazine 
genre for the time period before and after publication of the FDA report 
recommendations.  Table 3-13 compares the most prevalent disease categories advertised 
in each magazine genre for the same time periods.  
Table 3-12:  Three most prevalent drugs advertised 
 
 BEFORE AFTER 
Black-Oriented (1) Januvia 
(2) Lyrica 
(3) Advair Diskus 
(1) Januvia 
(2) Gardasil 
(3) Lyrica, Pristiq 
White-Oriented (1) Vyvanse 
(2) Actonel 
(3) Cymbalta 
(1) Cymbalta 
(2) Advair Diskus 
(3) Premarin Vaginal Cream 
Crossover (1) Cymbalta 
(2) Abilify, Gardasil, Lyrica 
(3) Crestor, Evista, Plavix, 
Singulair 
(1) Abilify 
(2) Lyrica 
(3) Premarin Vaginal Cream 
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Table 3-13:  Three most prevalent disease categories advertised 
 BEFORE AFTER 
Black-Oriented (1) Psychiatric/Neurologic 
(2) Diabetes 
(3) Cardiovascular 
(1) Infectious (Non-HIV) 
(2) Psychiatric/Neurologic 
(3) Diabetes 
White-Oriented (1) Psychiatric/Neurologic 
(2) Musculoskeletal 
(3) Cardiovascular 
(1) Psychiatric/Neurologic 
(2) Musculoskeletal 
(3) Respiratory 
Crossover (1) Psychiatric/Neurologic 
(2) Cosmetic 
(3) Musculoskeletal 
(1) Psychiatric/Neurologic 
(2) Cosmetic 
(3) Dermatologic 
 
It is interesting to note the differences in the most popular drugs versus the most 
prevalent disease categories advertised.  While the most popular drug advertised in the 
black-oriented magazines was Januvia, the medical condition for which it is prescribed, 
diabetes, was not the most prevalent disease category.  Similarly, Premarin Vaginal 
Cream was the third most advertised drug in both the white-oriented and crossover 
magazines after the publication of the FDA report, but the “Obstetric/Gynecological” 
disease category was not among the top three advertised in any magazine genre during 
either the time period before or after the FDA report.  These tables highlight the 
importance of looking at not only the drug advertised, which can reflect a manufacturer’s 
desire to gain widespread exposure for a new product, but also the disease category, 
which tempers the influence of a single drug marketing campaign on overall DTCA 
trends.  
RQ4 probes the relationship of the drugs advertised to the health risks faced by 
the magazines’ targeted audiences.  Table 3-14 lists the leading causes of death for 
Blacks and Whites in the United States in 2010 (Heron, 2013).  Although the study 
reviewed only women’s magazines, it is appropriate to consider the leading causes of 
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death for both men and women in the United States since research shows that women are 
more likely to participate in the health care decisions for all family members, including 
children, grandchildren, spouses, and elderly parents (Abel et al., 2007; Kaiser Family 
Foundation, 2003; Kluger, 2010; Mastin et al., 2007).  Therefore, although a drug 
advertised might not be relevant to the health of the woman reading the magazine, it 
could be relevant to the health of one of her family members.   
For both Blacks and Whites, heart disease and cancer are the leading causes of 
death.  Table 3-14 documents the variation in the cause of death between Blacks and 
Whites in the United States.  Black Americans have a greater risk of dying from stroke or 
diabetes than do white Americans, but white Americans are more likely to die from 
chronic low respiratory disease and Alzheimer’s disease.  Homicide is the 8th leading 
cause of death for black Americans, although it is not in the top 10 for white Americans.  
On the other hand, suicide is the 10th leading cause of the death for white Americans but 
is not among the top 10 causes of death for black Americans.   
Table 3-14:  Leading causes of death in U.S. in 2010 
BLACK WHITE 
Heart Disease Heart Disease 
Cancer Cancer 
Stroke Chronic Low Respiratory Disease 
Diabetes Stroke 
Unintentional Injury Unintentional Injury 
Kidney Disease Alzheimer’s Disease 
Chronic Lower Respiratory Disease Diabetes 
Homicide Influenza and Pneumonia 
Septicemia Kidney Disease 
Alzheimer’s Disease Suicide 
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The FDA report recommendations dealt particularly with the relevance of DTCA 
to the health issues faced by the targeted community.  In other words, are the drugs 
advertised used to treat the serious medical conditions faced by those exposed to the ads?  
Tables 3-15 and 3-16 match the drugs advertised in the black-oriented magazines, both 
before and after the FDA report, to the leading causes of death in the black community. 
Tables 3-17 and 3-18 provide the same comparison for DTCA appearing in white-
oriented magazines.  Those causes of death for which there is no pharmaceutical remedy, 
such as unintentional injury, were omitted from the tables. 
From Table 3-15, we see that at least one drug was advertised in either Ebony or 
Essence or both during 2008 and 2009 that addressed 5 of the top 10 leading causes of 
death among black Americans in 2010.  However, in 2011 and 2012, these magazines no 
longer included ads for drugs used to treat heart disease, cancer, or stroke (see 
Table 3-16).  In addition, the number of drugs advertised to treat diabetes and chronic 
low respiratory disease declined during this period.  One possible explanation for this 
decline is that it is tied to the overall decrease in the amount of DTCA appearing in 
black-oriented magazines published in 2011 and 2012.  However, the difference in the 
means pre- and post-FDA report was not found to be statistically significant (see 
Table 3-9).  Therefore, we may assume that pharmaceutical manufacturers chose not to 
advertise drugs used to treat life-threatening diseases in favor of drugs prescribed for 
other conditions.  From Table 3-11, we can see that this is true.  Note the sizeable uptick 
in the percentage of ads that fall in the “Infectious (Non-HIV)” category—from 
5.2 percent in 2008 and 2009 to 26.7 percent in 2011 and 2012.  (This increase was 
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driven primarily by an aggressive ad campaign promoting Gardasil, a vaccination against 
human papillomavirus (HPV)). 
Table 3-15:  Drugs advertised in black-oriented magazines and  
associated cause of death 
(before FDA report publication) 
 
Cause of Death Drugs Advertised 
Heart Disease Caduet 
Cancer Femera 
Stroke Plavix 
Diabetes FlexPen, Januvia, Lantus 
Kidney Disease N/A 
Chronic Lower Respiratory Disease Advair Diskus, Pulmicort Respules, 
Spiriva HandiHaler 
Septicemia N/A 
Alzheimer’s Disease N/A 
 
 
Table 3-16:  Drugs advertised in black-oriented magazines and  
associated cause of death 
(after FDA report publication) 
 
Cause of Death Drugs Advertised 
Heart Disease N/A 
Cancer N/A 
Stroke N/A 
Diabetes Januvia, Victoza 
Kidney Disease N/A 
Chronic Lower Respiratory Disease Advair Diskus, Flovent Diskus, Symbicort 
Septicemia N/A 
Alzheimer’s Disease N/A 
 
 
In contrast, we continue to see advertising for a wide variety of drugs used to treat 
medical conditions of concern to white Americans.  With the exception of cancer and 
stroke, issues of Family Circle and Good Housekeeping published in 2008 and 2009 
advertised numerous drugs to treat heart disease, chronic low respiratory disease, stroke, 
diabetes, and suicide (see Table 3-17). 
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Table 3-17:  Drugs advertised in white-oriented magazines and  
associated cause of death 
(before FDA report publication) 
 
Cause of Death Drugs Advertised 
Heart Disease Caduet, Crestor, Lipitor, Lovaza, Niaspan, 
TriCor, Vytorin, Zetia 
Cancer Arimidex 
Chronic Low Respiratory Disease Advair Diskus, Pulmicort Respules, 
Singulair, Spiriva HandiHaler, Symbicort 
Stroke Plavix 
Alzheimer’s Disease N/A 
Diabetes Januvia, Lantus 
Influenza and Pneumonia N/A 
Kidney Disease N/A 
Suicide Abilify, Cymbalta, Pristiq 
 
 
Table 3-18:  Drugs advertised in white-oriented magazines and  
associated cause of death 
(after FDA report publication) 
 
Cause of Death Drugs Advertised 
Heart Disease Lipitor, Livalo, Lovaza, Niaspan, Xarelto, 
Zetia 
Cancer N/A 
Chronic Low Respiratory Disease Advair Diskus, Dulera, Flovent Diskus, 
Symbicort 
Stroke Pradaxa 
Alzheimer’s Disease Aricept, Exelon Patch 
Diabetes Lantus, Victoza 
Influenza and Pneumonia FluMist, FluZone, Tamiflu 
Kidney Disease N/A 
Suicide Abilify, Cymbalta, Pristiq, Seroquel XR 
 
 
As can be seen in Table 3-18, this trend continued after publication of the FDA 
report.  In fact, these later magazine issues included ads for drugs used to treat 
Alzheimer’s disease and influenza and pneumonia.  Taken together, these four tables 
suggest that pharmaceutical manufacturers are making less of an effort to place 
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advertisements for drugs to treat life-threatening diseases in black-oriented magazines 
than they are in placing such ads in white-oriented magazines. 
To some extent, pharmaceutical advertising in the crossover magazine mirrored 
that of the white-oriented magazines for the pre-FDA report time period (see 
Appendix C).  Drugs to treat heart disease, chronic low respiratory disease, stroke, 
diabetes, and suicide were found in issues published in 2008 and 2009.  However, in 
issues published in the time period following the FDA report, ads no longer appeared for 
drugs used to treat stroke and diabetes—two diseases of significant concern for both 
black and white readers. 
Although the focus of this study is on product claim ads, help-seeking 
advertisements can also be a valuable source of health information.  Because these types 
of ads do not mention a specific drug, but instead alert the reader to a medical condition, 
they may in fact be perceived more favorably.  The FDA report recognizes the value of 
such advertisements and recommends an increase in help-seeking campaigns targeted to 
medical conditions particularly relevant to minority communities.  (See report 
recommendation 4 highlighted in Chapter 1 of this dissertation.)  Table 3-19 
characterizes the 73 help-seeking advertisements found in terms of the racial orientation 
of the magazine and the disease category addressed.  An increase in the number of help-
seeking ads over time was observed in both the white-oriented and crossover magazines.  
The most significant increase in help-seeking ads appeared in O, The Oprah Magazine 
and was driven by a campaign by Allergan, Inc. related to chronic migraines.  Only 
black-oriented magazines saw a decrease in the number of help-seeking ads pre- and 
post-publication of the FDA report, although the number of ads related to diabetes 
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increased.  However, ads related to cancer and cardiovascular conditions were eliminated.  
Since the number of these ads is small compared to the number of product claim ads 
found, it would be inappropriate to assign too much weight to the variations observed.  
However, this is the first study to collect data on help-seeking ads and the results do 
suggest a need for further study. 
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3.5  Discussion 
 The above results update previous research and highlight continued differences in 
the frequency of DTCA and the types of drugs advertised based on a magazine’s racial 
orientation.  The impact of the FDA report recommendations on these aspects of 
pharmaceutical advertising was explored in depth and the results are discussed below. 
Section 3.5.1 addresses RQ1 and RQ2 as they relate to the frequency of pharmaceutical 
advertising.  Section 3.5.2 discusses RQ3 as it relates to the type of drugs advertised, and 
Section 3.5.3 addresses RQ4 as it relates to the relationship of the drugs advertised to the 
health risks faced by the readers of the three magazine genres studied.  Section 3.5.4 
notes the limitations of the current study. 
3.5.1  Frequency of Pharmaceutical Advertising 
 On all measures, the amount of pharmaceutical advertising appearing in 
white-oriented magazines was far greater than that appearing in either black-oriented 
magazines or the magazine read by both black and white women.  In terms of absolute 
numbers, the ratio of DTCA appearing in white-oriented women’s magazines versus that 
appearing in black-oriented women’s magazines was, on average, more than four to one 
based on the data provided in Tables 3-2 and 3-3.  The ratio between the crossover 
magazine and each of the two black-oriented magazines was nearly two to one, with O, 
The Oprah Magazine having twice the pharmaceutical advertising as either Ebony or 
Essence.  On the other hand, both Family Circle and Good Housekeeping had twice the 
DTCA as O, The Oprah Magazine.   
 In terms of advertisement density, Table 3-4 indicates that the white-oriented 
magazines had substantially more pharmaceutical advertising than either the 
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black-oriented magazines or the crossover magazine, although the relative amounts of 
advertising for each magazine were similar.  (From Table 3-5, we can see that Ebony had, 
on average, the least amount of advertising with 40.0 percent of its pages dedicated to 
ads, and Family Circle had the most amount of advertising with 56.2 percent of its pages 
dedicated to ads.)  Family Circle and Good Housekeeping averaged 4.5 and 
3.8 pharmaceutical ads per 100 magazine pages, respectively.  Ebony and Essence 
averaged 1.4 and 1.0 ads per 100 magazine pages, respectively.  O, The Oprah Magazine 
averaged 1.7 ads per 100 magazine pages.  These figures include both product claim ads 
and help-seeking ads. 
 Independent sample t-tests confirm these observations.  The difference in the 
amount of DTCA found in white-oriented magazines, both in terms of percent of all 
magazine pages and percent of all advertising pages, versus that found in black-oriented 
magazines, was found to be statistically significant, as shown in Tables 3-7 and 3-8.  
Similarly, the amount of DTCA found in white-oriented magazines versus the crossover 
magazine was also statistically significant.  However, the difference in DTCA between 
the black-oriented magazines and the crossover magazine was not statistically significant 
for magazines issued before the FDA report (i.e., 2008 and 2009).  
 A two-step process was next used to determine the impact of the FDA report 
recommendations on the frequency of DTCA.  First, the means of each magazine group 
(i.e., black-oriented, white-oriented, and crossover) were compared to one another for 
each of two time periods (i.e., before the report publication and after the report 
publication).  The results reported in Table 3-8 indicate that there was no statistical 
difference between the means for the black-oriented magazines and the white-oriented 
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magazines.  In other words, pharmaceutical manufacturers did not significantly increase 
the amount of advertising they placed in either of these magazine genres in the 2011/2012 
timeframe.  However, the difference in the means for the crossover magazine was 
statistically significant.  The advertisement density figures for O, The Oprah Magazine 
are consistent with this conclusion—the average number of ads per 100 magazine pages 
for issues published in 2008 and 2009 was 1.4; the average number of ads per 
100 magazine pages for issues published in 2011 and 2012 was 3.9, an increase of 
150 percent (see Table 3-4). 
 The next step was to compare the means of the issues published before the FDA 
report to the means of the issues published after the FDA report for each of the three 
groups using the data reported in Table 3-6.  In all but one case, the differences in the 
means before and after the FDA report was published were statistically significant.  In 
other words, the difference in the amount DTCA found in white-oriented magazines 
versus black-oriented magazines was statistically significant both before and after the 
FDA report recommendations were published.  The same is true for the differences 
between the amount of DTCA found in black-oriented magazines versus the crossover 
magazine and the white-oriented magazines versus the crossover magazine for the time 
period following the FDA report.  However, the difference in the mean amount of DTCA 
as a percentage of all magazine pages between the black-oriented magazine and the 
crossover magazine was not significant for the time period before publication of the FDA 
report. 
 These results reinforce the findings of previous researchers, such as Mastin et al. 
(2007) and Omonuwa (2001).  Magazines read predominantly by black women continue 
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to have significantly less pharmaceutical advertising than those read predominantly by 
white women.  The one magazine included in the study that is read by both white and 
black women also had less DTCA than magazines read predominantly by white women, 
although it did have more DTCA than the magazines read predominantly by black 
women.  More critical to the analysis however is that pharmaceutical advertising did not 
increase significantly in the black-oriented magazines after the publication of the FDA 
report recommendations.  Instead, the differences in mean DTCA pre- and post-FDA 
report were statistically insignificant.  As a percentage of total magazine pages, the mean 
DTCA in black-oriented magazines decreased from 0.027 to 0.023 (p=.263) pre- and 
post-FDA report.  As a percentage of total advertising pages, the mean DTCA decreased 
from 0.056 to 0.054 (p=.819).  On the other hand, O, The Oprah Magazine did show a 
statistically significant increase in the amount of DTCA found in issues published after 
the FDA report (0.055 to 0.091 (p=.004)), as did the white-oriented magazines (0.167 to 
0.191 (p=.004)) when DTCA is considered as a percentage of all advertising pages.   
 The fact that black-oriented magazines continue to have significantly less DTCA 
than white-oriented magazines suggests that differences in ad placement are intentional 
either on the part of pharmaceutical manufacturers or on the part of magazine publishers.  
If we revisit the advertisement density figures in Table 3-4, we see that, while the ad 
density fell in Ebony between 2008 (1.5 drug ads per 100 magazine pages) and 2012 
(0.8 drug ads per 100 magazine pages), it remained relatively constant in Essence over 
the same time period (1.1 drugs ads per 100 magazine pages in 2008 versus 0.9 drugs ads 
per 100 magazine pages in 2012).  These results suggest that drug manufacturers still 
value print advertisements in this magazine genre.  Again, looking at Table 3-4, we see 
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that the advertisement density in Ebony magazine remained virtually constant in 2008, 
2009, and 2011, dropping precipitously in 2012.  It is possible that Ebony’s publishers 
adopted a policy of limiting the amount of pharmaceutical advertising or the cost of 
advertising in Ebony became prohibitively expensive for certain pharmaceutical 
companies, but more research would be necessary to confirm such a conclusion. 
3.5.2  Type of Drugs Advertised 
 The type of drugs advertised varied not only by the racial orientation of the 
magazine, but also by the date of publication.  As reported in Table 3-12, the top three 
drugs advertised in black-oriented magazines in 2008 and 2009 were Januvia (used to 
treat diabetes), Lyrica (used to relieve nerve pain), and Advair Diskus (used to treat 
asthma and COPD).  In contrast, the top three drugs advertised in white-oriented 
magazines during the same period were Vyvanse (used to treat ADHD), Actonel (used to 
treat postmenopausal osteoporosis), and Cymbalta (used to treat either depression or 
nerve pain).  The top drug advertised in O, The Oprah Magazine in 2008 and 2009 was 
Cymbalta.  Tied for the second most popular drug advertised were Abilify (used to treat 
depression), Gardasil (a vaccine against HPV), and Lyrica.  Crestor (used to treat high 
cholesterol), Evista (used to treat postmenopausal osteoporosis), Plavix (used to reduce 
the risk of clots), and Singulair (used to treat asthma) were the third most prevalent drugs 
advertised. 
 Januvia remained the most popular drug advertised in the black-oriented 
magazines published in 2011 and 2012, followed by Gardasil.  Lyrica and Pristiq 
(another drug used to treat depression) were tied for the third most popular drugs 
advertised during this time period.  In the white-oriented magazines, Cymbalta was the 
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most popular drug advertised, followed by Advair Diskus and Premarin Vaginal Cream 
(used to treat vaginal dryness).  The most popular drugs advertised in O, The Oprah 
Magazine during 2011 and 2012 were Abilify, Lyrica, and Premarin Vaginal Cream. 
 These results are quite different than those reported by previous researchers.  
Omonuwa (2001) found that black-oriented magazines lacked advertisements for drugs to 
treat osteoporosis, Alzheimer’s disease, high cholesterol, and depression, although they 
did include ads for antiviral agents, oral contraceptives, vaginal antifungal agents, 
analgesics, impotence agents, and antihistamines.  Readers of white-oriented magazines 
would not be exposed to ads for drugs that treat HIV or provide contraception.  Mastin et 
al. (2007) found that black-oriented magazines were more likely to contain DTCA for 
drugs used to treat women’s health issues and sexually transmitted diseases.  Crawley et 
al. (2009) found that black-oriented magazines were more likely to include ads for 
products to treat colds and allergies and chronic, non-life-threatening diseases. 
 In contrast, the results of this study found that the drugs advertised most 
prevalently in the black-oriented magazines are used to treat significant health risks, 
including diabetes, depression, and asthma.  The most popular drugs advertised in the 
white-oriented magazines were used to treat ADHD, asthma, depression, postmenopausal 
osteoporosis, and vaginal dryness.  The most prevalent pharmaceuticals advertised in the 
crossover magazine included drugs to treat asthma, depression, postmenopausal 
osteoporosis, and vaginal dryness, as well as cardiovascular conditions.  These data 
suggest that magazine readers are more likely to be exposed to advertisements for drugs 
that treat serious medical conditions, regardless of the targeted audience, than was 
previously found.   
88 
 
 
 If we look at the most prevalent disease categories advertised (see Table 3-13), we 
find a similar pattern.  Although they did not specifically evaluate the relationship 
between a magazine’s racial orientation and the disease categories advertised, Bell et al. 
(2000) found that the most common disease categories advertised were dermatologic 
conditions, HIV/AIDS, and obstetrical/gynecological conditions.  Crawley et al. (2009) 
did contrast magazines targeted to black audiences (Essence, Jet, Black Enterprise) to 
those targeted to general audiences (Cosmopolitan, People, Forbes) and found that the 
general audience magazines were more likely to include DTCA for life-threatening 
conditions and mental health conditions. 
The results of this study indicate that the DTCA found in the magazines surveyed 
were also more likely to address serious medical conditions, regardless of the magazine’s 
genre, than previously found.  From Table 3-13, we see that the disease category 
comprising the most drug advertisements in 2008 and 2009 for all magazine genres was 
“Psychiatric/Neurologic.”  For black-oriented magazines, the second most popular 
category was “Diabetes,” and third most popular was “Cardiovascular.”  For 
white-oriented magazines, the second most popular category was “Musculoskeletal,” 
followed by “Cardiovascular.”  The second and third most popular disease categories in 
O, The Oprah Magazine were “Cosmetic” and “Musculoskeletal,” respectively.   
 The prevalence of disease categories changed slightly in the 2011 and 2012 time 
period.  In the black-oriented magazines, the three most popular disease categories were 
“Infectious (Non-HIV),” “Psychiatric/Neurologic,” and “Diabetes,” respectively.  The 
“Psychiatric/Neurologic” disease category remained the most prevalent in both the 
white-oriented magazines and the crossover magazine during this time period.  The 
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second and third most popular disease categories in the white-oriented magazines were 
“Musculoskeletal” and “Respiratory,” respectively.  “Cosmetic” and “Dermatologic” 
were the second and third most popular categories in O, The Oprah Magazine during this 
time period.   
 These results suggest that pharmaceutical companies are advertising drugs used to 
treat serious medical conditions more frequently in both black-oriented and 
white-oriented women’s magazine than previously found.  However, the category entitled 
“Psychiatric/Neurologic” is extremely broad and includes drugs used to treat not only 
depression and chronic pain, but also ADHD and insomnia.  Using the data reported in 
Appendix C to drill down into this category, we find that nearly two-thirds of the ads 
appearing in black-oriented magazines published before the FDA report were for drugs 
used to treat either depression or chronic pain.  After publication of the FDA report, all of 
the drugs advertised in this magazine genre were used to treat either depression or 
chronic pain.  In contrast, over 40 percent of the ads in this category that appeared in 
white-oriented magazines published before the FDA report were used to treat either 
ADHD or insomnia.  However, after the FDA report was published only three ads 
appeared for a sleep aid and no ads appeared for a drug to treat ADHD.  All other drugs 
advertised in the white-oriented magazines were used to treat serious psychiatric or 
neurologic conditions.  These detailed results also suggest a more concerted effort on the 
part of pharmaceutical manufacturers to advertise drugs used to treat serious medical 
conditions in black- and white-oriented women’s magazines published in 2011 and 2012 
than in earlier issues. 
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 Only the crossover magazine included drugs used to treat cosmetic conditions, 
such as wrinkles and frown lines, among the top three disease categories advertised.  This 
is likely to be less a function of its racial orientation since it is read by both white and 
black women and more a function of its median age (49.9) and median household income 
($66,900) (see Table 3-1).  Interestingly, no drugs used to treat cosmetic conditions were 
advertised in the black-oriented magazines either before or after the FDA report, and 
these types of drugs were only advertised in the white-oriented magazines after the report 
publication date.   
 Appendix C documents some other interesting patterns in the types of drugs 
advertised based magazine genre and publication date.  Advertising for allergy remedies 
only appeared in white-oriented magazines.  Drugs to treat cancer were not advertised in 
the crossover magazine, and only appeared in the black- and white-oriented magazines 
prior to the publication of the FDA report.  Advertisements for cardiovascular drugs did 
not appear in black-oriented magazines published after the FDA report recommendations.  
Similarly, advertising for drugs to treat diabetes did not appear in issues of the crossover 
magazine published in either 2011 or 2012.  Gastrointestinal/nutritional drugs were not 
advertised in any magazine genre in 2011 or 2012.  Advertising for drugs that fell into the 
“Infectious (Non-HIV)” categories did not appear in issues of the crossover magazine 
published in either 2011 or 2012.  Only one drug, Restasis, was advertised in the 
“Ophthalmological” category, and ads for this drug appeared only in the white-oriented 
and crossover magazines.  Drugs for tobacco addiction were not advertised in the 
post-FDA report time period, and no drug for urological conditions was advertised in any 
issue of the black-oriented magazines. 
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3.5.3  Concordance with Health Risks 
 As noted earlier, the types of drugs advertised in all magazine genres analyzed are 
more likely to treat serious medical conditions than previously reported.  Another 
important dimension of this discussion as it relates to narrowing health disparities is 
whether those drugs advertised in the black-oriented magazines treat conditions that pose 
the greatest health risks to the black community in the United States.  Since women tend 
to participate in the health care decisions for their families (Abel et al. 2007; Kaiser 
Family Foundation, 2003; Kluger, 2010; Mastin et al., 2007), it was important to consider 
the leading causes of death for both men and women.  Table 3-15 suggests a positive 
alignment between drug and disease in the black-oriented magazine issues published 
prior to the FDA report (i.e., 2008 and 2009).  The fact that drugs used to treat diabetes 
were the most prevalently advertised in black-oriented magazines is particularly 
promising since diabetes disproportionately affects blacks, especially black women who 
are nearly twice as likely to be diagnosed with diabetes as white, non-Hispanic women 
(CDC, 2014a). 
 However, only one drug (Caduet) used to treat heart disease was advertised in 
Ebony and Essence during this time period, while eight cardiovascular drugs were 
advertised in Family Circle and Good Housekeeping.  Only Crestor was advertised in 
O, The Oprah Magazine.  While heart disease is the number one cause of death for both 
blacks and whites, the CDC reports that, in 2009, black adults were 30 percent more 
likely to die from heart disease than non-Hispanic white men (CDC, 2014b).  Blacks are 
also more likely to suffer from key risk factors, such as high blood pressure and obesity.  
For example, the CDC reports that black adults are 40 percent more likely to suffer from 
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high blood pressure than non-Hispanic white adults, and black women are 1.6 times more 
likely than non-Hispanic white women to have high blood pressure (CDC, 2014b).  
Similarly, Blacks are 1.5 times more likely to be obese as non-Hispanic Whites, and 
black women were 80 percent more likely to be obese than non-Hispanic white women 
based on 2011 data (CDC, 2014c).   
Table 3-16, which looks at the types of drugs advertised after the publication of 
the FDA report (i.e., 2011 and 2012), paints a discouraging picture.  While drugs to treat 
diabetes remained the most heavily advertised in black-oriented magazines, the number 
of such drugs decreased from three to two.  More concerning, however, is that drugs used 
to treat heart disease, cancer, and stroke were not advertised at all in either Ebony or 
Essence during this time period.  Pharmaceutical companies continued to advertise 
cardiovascular drugs in the white-oriented and crossover magazines during the same time 
period.  These results suggest that, not only did the pharmaceutical industry ignore the 
FDA recommendations, but they also advertised far fewer drugs used to treat 
life-threatening conditions in black-oriented magazines after the report was published.   
Help-seeking advertisements can also provide health information.  Table 3-19 
does identify an increase in the number of help-seeking ads after publication of the FDA 
report, particular in the crossover magazine.  However, a closer examination shows a 
30 percent decrease in the number of help-seeking ads (from 7 to 5) that appeared in the 
issues of Ebony and Essence (i.e., the black-oriented magazines) published in 2011 and 
2012.  More significantly however is the decrease in the number of help-seeking ads 
related to cardiovascular disease that appeared before the report was published (5) versus 
after (0).  Ads related to diabetes did increase from one to three during this same time 
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period, however.  The largest increase in the help-seeking ads that appeared in the 
crossover magazine were associated with an ad campaign focused on chronic migraine 
headaches. 
3.5.4  Limitations 
This phase of analysis has several limitations.  Only five magazine titles and four 
years were selected for review.  A lag period of 15 months between the publication of the 
FDA report in September 2009 and the first magazine issue considered post-FDA report 
was considered adequate.  It is possible that pharmaceutical companies were adjusting 
their ongoing ad campaigns well into 2011 and that reviewing magazine issues published 
in 2013 would have yielded different results.   
The study focused on a single minority (Blacks) and evaluated only magazines 
read by women.  Therefore, the findings cannot be generalized to other minorities, such 
as Hispanics and Asians, or to other magazine genres, such as entertainment or news.  It 
is possible that pharmaceutical companies place much of their advertising directed to 
black readers in magazines other than Ebony and Essence, although circulation figures 
and previous research would not suggest this.  Furthermore, because this study only 
evaluated print ads, pharmaceutical companies may have increased their advertising to 
minority populations after publication of the FDA report using other media outlets, such 
as television or the Internet. 
Another limitation unique to this phase of the analysis was the possibility of 
human error in the manual counting of magazine pages and pharmaceutical ads.  The 
study sample consisted of 237 magazines with an average page count of 205 for a total of 
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nearly 49,000 pages.  It is possible some magazine issues were miscounted, although 
such error would be randomly distributed.   
While the analysis discusses results in the context of pre- and post-FDA report 
publication, causality between the report and any decrease in advertising frequency is not 
presumed.  Companies make advertising decisions for a variety of reasons.  To some 
extent the data collected represent the natural ebb and flow of advertising—advertising 
focus shifts away from older drugs as new drugs enter the market.  For example, Januvia 
was introduced in October 2006 (FDA, 2014) and was advertised in all three magazine 
genres in 2008 and 2009.  Victoza, another medication to treat diabetes, was introduced 
in January 2010 (FDA, 2014).  Ads for this drug appear in 2011 and 2012.  The data also 
reflect the changing popularity of certain drugs, such as Yaz, a birth control pill that was 
also advertised to treat acne and premenstrual syndrome.  Introduced in 2006, Yaz 
quickly became a best seller claiming an 18-percent market share in 2008 (Singer, 2009).  
However, evidence of a higher risk of potentially fatal blood clots among users of Yaz 
and other birth control pills containing drospirenone led to numerous lawsuits and 
regulatory action (Wilson, 2011).  Consequently, although Yaz was heavily advertised in 
the black-oriented magazines in 2008, no advertisements for Yaz appeared in 2009, 2011, 
or 2012.  Therefore, while an increase in the frequency of advertising appearing in 
black-oriented magazines could indicate that pharmaceutical companies had chosen to 
implement the FDA report recommendations, any decrease in advertising should not be 
construed as an intentional rejection of the report’s recommendations. 
A final threat to the internal validity of this phase of the analysis is the possible 
impact that both the recession of 2008 and the reported 20-percent decrease in 
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pharmaceutical advertising dollars between 2006 and 2010 (see Figure 2-1) had on the 
observed frequency of DTCA.  Although the number of advertisements decreased from 
308 in 2008 to 222 in 2012 (a 28-percent decline), the relative percentage of DTCA as 
both a function of total magazine pages and total advertising pages increased significantly 
in both the white-oriented and crossover magazines.  The decline in advertising placed in 
black-oriented magazines was not found to be statistically significant.  However, future 
research in this area should control for this limitation. 
3.6  Conclusions 
 Both the health belief model and social cognitive theory rely on knowledge to 
provide the necessary impetus for behavior change.  DTCA is one source of information 
that may contribute to changing people’s perceptions regarding susceptibility to disease 
and their ability to take action to treat it.  Mastin et al. (2007) and Duerksen et al. (2005) 
suggest that the repetitiveness of DTCA can inform individuals and prompt them to 
preventive action.  However, if pharmaceutical advertising is to positively impact the 
health of those it seeks to influence, then it is important that drugs used to treat 
significant health risks comprise the majority of such advertising.  Furthermore, if 
pharmaceutical advertising is to be an effective tool in combating the disparities in health 
between Blacks and Whites in the United States, then it must promote drugs that treat the 
diseases that are of greatest concern to the black community.  Congress noted its concern 
that pharmaceutical advertising was not reaching certain populations, including “racial 
and ethnic minority communities” (FDA, 2009, p. i), when it directed the FDA to study 
DTCA as it “relates to increase access to health information and decreased health 
96 
 
 
disparities for these populations” (FDA, 2009, p. i).  FDA reported the results of its 
review to the Congress in September 2009. 
 This phase of the dissertation analysis looked specifically at the frequency of 
pharmaceutical advertising both before and after publication of the FDA report.  Results 
indicate that differences in advertising frequency between black- and white-oriented 
magazines continue.  The study also looked at the type of drugs advertised both before 
and after the FDA report was published.  Again, the types of drugs advertised and the 
medical conditions they treat varied based on the racial orientation of the magazine.  
However, in all cases, the drugs advertised were more likely to treat serious medical 
conditions than previously reported. 
The most disappointing results from a policy perspective were found when 
comparing the drugs advertised to the causes of death.  Only a small percentage of drugs 
advertised are used to treat life-threatening conditions.  While the most prevalent drug 
advertised in the black-oriented magazines is used to treat diabetes (a disease that 
disproportionately affects black Americans), far fewer ads for cardiovascular drugs 
(another disease of particular concern for the black community) appeared in 
black-oriented magazines than in white-oriented magazines.   
The question was raised at the beginning of this chapter whether the FDA report 
had any impact on the frequency of pharmaceutical advertising or the types of drugs 
advertised.  Based on the results presented, we would have to conclude that it did not.  
The disparities between white-oriented and black-oriented magazines in the frequency of 
advertising noted by previous researchers remains unchanged.  Nor did the report have 
any impact on the frequency of advertising placed in black-oriented magazines—that 
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amount remained relatively constant over the study period.  The types of drugs advertised 
did address serious medical conditions in the black community, particularly diabetes.  
However, the most prevalent disease category advertised after publication of the FDA 
report was “Infectious (Non-HIV),” driven by advertisements for Gardasil, the vaccine 
administered to young adults to prevent HPV.  This category was followed by 
“Psychiatric/Neurologic,” which encompasses conditions not listed in the leading causes 
of death for Blacks in the United States.  “Diabetes” fell from the second most prevalent 
disease category advertised in black-oriented magazines prior to the FDA report to the 
third most prevalent after publication of the FDA report.  Most significantly, the disease 
category, “Cardiovascular,” which had been the third most advertised category pre-FDA 
report publication, was not included in the top three disease categories advertised 
post-FDA report. 
Pharmaceutical companies also did not use their help-seeking advertisement 
campaigns as a vehicle for conveying important health information to black readers.  
Although there was a significant increase in the number of help-seeking ads after 
publication of the FDA report, these ad campaigns were not attached to life-threatening 
diseases.  Instead, campaigns that appeared prior to the FDA report that did highlight 
heart disease and stroke were dropped from all three magazine genres in the issues 
published after 2009. 
Based on these results, we must conclude that the FDA report had no impact on 
the advertising decisions made by pharmaceutical companies in terms of either the 
frequency with which they place ads in magazines read by black women or the types of 
drugs advertised.  The next chapter of this dissertation examines the appearance and 
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content of DTCA.  Differences in the advertisements found among the five magazines 
included in the study sample are identified and discussed. 
 
 
 
CHAPTER 4:  THE APPEARANCE AND CONTENT OF PHARMACEUTICAL 
ADVERTISING IN WOMEN’S MAGAZINES 
 
 
 The previous chapter examined the frequency and type of pharmaceutical 
advertising placed in five women’s magazines published January 2008 through 
December 2009 and January 2011 through December 2012.  This chapter takes that 
analysis one step further and looks at the individual characteristics of a subset of the 
advertisements identified.  Specifically, each ad was evaluated in terms of its appearance 
(visual elements) and content (text elements).  The differences in ads were then compared 
as a function of the racial orientation of the magazine in which they appeared and the 
time period in which the magazine was published (i.e., before or after the 2009 FDA 
report).  By comparing the appearance and content of pharmaceutical advertising 
published before and after the FDA report, this chapter will provide further insight into 
whether or not the pharmaceutical industry has responded to the FDA’s 
recommendations. 
 The chapter begins with an overview of the theoretical constructs underpinning 
the possible value of DTCA as a health promotion tool (Section 4.1).  Section 4.2 
discusses the methods used to select the advertisements evaluated and the way in which 
individual advertising elements were coded.  Section 4.3 describes the quantitative and 
qualitative analyses conducted, and Section 4.4 presents the results of these analyses.  
Section 4.5 discusses the differences observed in both the appearance and content of 
advertising placed in different magazine genres during the study period, including a 
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comparison of ads for two drugs that were placed in different magazine genres during the 
same month and year.  Section 4.6 offers some final observations and draws conclusions 
as to the impact of the FDA report recommendations on the appearance and content of 
pharmaceutical advertising placed in the five women’s magazines reviewed. 
4.1  Background 
 Researchers from several disciplines have examined DTCA using the organizing 
frameworks common to their fields.  In a review of the health policy literature, two 
models stand out as being particularly applicable to the proposed study.  Both the health 
belief model and social cognitive theory have been used to evaluate the relationship of 
DTCA to health promotion (Duerksen et al., 2005; Schommer & Hansen, 2005; Young, 
Lipowski, & Cline, 2005).  The health belief model (see Figure 2-5) was developed in the 
1950s by the U.S. Public Health Service to explain why people did not participate in 
disease prevention and protection programs (Glantz, Rimer, & Lewis, 2002).  The model 
is based on the individual’s perceived susceptibility to a disease, the perceived threat of 
the disease, and the perceived benefits to behavior change (Glantz et al, 2002.).  As 
Glantz et al (2002) explain: 
…people will take action to prevent, to screen for, or to control ill-health 
conditions if they regard themselves as susceptible to the condition, if they 
believe it would have potentially serious consequences, if they believe that 
a course of action available to them would be beneficial in reducing either 
their susceptibility to or the severity of the condition, and if they believe 
that the anticipated barriers (or costs of) taking the action are outweighed 
by the benefits (pp. 47–48). 
 
In his discussion of the relevance of the health belief model to pharmaceutical 
advertising, Roth (2003) identifies a two-step process in which consumers become 
engaged in positive health behaviors.  In the first step, an individual becomes convinced 
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that he or she is susceptible to a disease or serious illness.  In the second step, an 
individual identifies an appropriate solution that he or she can implement.  Hence, drug 
advertisements often provide information about a disease and its symptoms, as well as the 
benefits of using the advertised product to provide relief (Roth, 2003).  The health belief 
model also recognizes that certain external cues, such as education, personal 
relationships, and the media, can motivate health behaviors.  Repeated exposure to 
pharmaceutical advertising can be a cue to action, sparking individuals to seek additional 
information either from their doctor or another media source, such as a Website or hotline 
(Duerksen et al., 2005).   
 Social cognitive theory (see Figure 2-6) contends that behavior is a dynamic 
concept, dependent on an individual’s environment and personal characteristics (Glantz 
et al., 2002).  The continual interaction among personal factors, environmental 
influences, and behavior is known as reciprocal determinism.  Glantz et al. (2002) 
elaborate further: 
Behavior is not simply the result of the environment and the person, just as 
the environment is not simply the result of the person and behavior.  
Instead, these three components are constantly influencing each other.  A 
change in one component has implications for the other (p. 168). 
 
Consequently, behaviors are learned through “observation, role models, and responses 
from others” (Kean & Prividera, 2007, p. 289).  An individual is more likely to “model 
the behaviors of people with whom they identify or feel similar to” (Kean & Prividera, 
2007, pp. 289–290).  Hence, visual cues in advertising, such as race, gender, and age, can 
help gain the attention of the targeted audience (Mastin et al., 2007). 
As discussed previously, a number of content analyses have been conducted on 
pharmaceutical advertising appearing in print magazines (see Appendix B).  Several of 
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these studies found a positive correlation between the race of the models that were used 
in an advertisement and the race of the readers of the magazine in which it appeared.  
Mastin et al. (2007) and Kean and Prividera (2007) found that pharmaceutical 
advertisements that appeared in black-oriented magazines were more likely to feature 
black models.  Similarly, advertisements that appeared in white-oriented magazines were 
more likely to feature white models.  Researchers also found that the race of the models 
used in an advertisement varied by product type.  Main et al. (2004) found that 
prescription drug advertisements featured more white models than nonpharmaceutical 
advertising.  Mackert and Love (2011) also found that a relatively smaller proportion of 
the pharmaceutical ads they evaluated featured black models as compared to white 
models (nearly 50 percent of ads featured white models while less than 20 percent 
featured black models).  Duerksen et al. (2005) observed that white models were more 
likely to be used than black models to advertise health-promoting products, while black 
models were more likely to be used than white models to advertise health-diminishing 
products, such as fast food and alcohol.  Cline and Young (2004) found a difference in 
the type of drugs advertised as a function of model race.  Black models were not used in 
ads for cardiovascular- or cancer-related medications, but dominated ads for HIV/AIDS 
drugs.  These researchers noted the potential for DTCA to perpetuate health disparities: 
Consider the potential disparity-promoting function of DTCA with regard 
to ethnicity for cardiovascular disease and cancer….  The principle of 
homophily suggests that consumers are more likely to attend to and be 
persuaded by sources perceived as similar to themselves.  However, in our 
samples, ads for cancer- and cardiovascular-related products feature White 
people only….Ethnic minorities are ignored and thus likely fail to gain 
any educational value that DTCA offers regarding the leading causes of 
death (Cline & Young, 2004, p. 153). 
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 Researchers also evaluated the type of appeals used in pharmaceutical advertising.  
Through the use of both visual and textual cues, advertisers may appeal to either an 
individual’s emotions or intellect or both (Macias, Pashupati, & Lewis, 2007).  
Shaughnessy, Slawson, and Bennett (1994) noted that pharmaceutical advertising 
“provides information intricately combined with logical and emotional appeals, slogans, 
wishful thinking, behavior modification techniques, and gimmicks” (p. 563).  The results 
of previous content analyses confirm this observation.  In their evaluation of over 
300 pharmaceutical ads, Bell et al. (2000) found the most common appeals to be 
innovativeness, effectiveness, symptom control, and convenience.  In contrast, Main et al. 
(2004) found that emotional rather than rational appeals dominated the promotional part 
of the advertisements that they assessed.  Woloshin et al. (2001) found a mix of both 
emotional and rational appeals in the 67 advertisements they analyzed.  Most of the ads 
(87 percent) included some sort of benefit statements, while virtually all (98 percent) 
explicitly identified side effects.  Over half (67 percent) of the ads used an emotional 
appeal, particularly the desire to “get back to normal” (p. 1144).  However, no previous 
study has explored the relationship between the type of appeal used in a particular 
advertisement and the racial orientation of the magazine in which it was placed.   
 The 2009 FDA report included several recommendations relevant to the 
appearance and content of pharmaceutical advertising.  Specifically, the following 
recommendations are applicable to this phase of the analysis (FDA, 2009, p. 26): 
(1) “Use communicators in the advertisements and channels to disseminate messages 
that the target populations rate as credible.” 
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(2) “Produce help-seeking or other ad campaigns concerning diseases and health 
issues that have particular relevance to the target community.” 
(3) “Provide information and relevant nondrug interventions (e.g., diet and exercise) 
that patients should consider.” 
(4) “Provide information on any available discounts or patient assistance programs 
that can help low income individuals obtain medications.” 
Based on these recommendations, pharmaceutical companies should create 
advertising campaigns tailored to the readers of magazines in which they intend to place 
ads.  Models used in these ads should reflect the predominant race of the magazine’s 
readers; messages should be clear and easy to understand.  Ads should include 
information on alternative, nonpharmaceutical therapies, as well as information about 
financial assistance.  Ads that embrace these recommendations should enhance their 
educational value and further empower consumers in their health care decision making.   
To evaluate the impact of these recommendations on DTCA appearing in 
women’s magazines published before and after the report, this chapter will address the 
following objectives and research questions identified in the first chapter of this 
dissertation: 
RQ5:  Does the race of the models used in DTCA vary based on the racial orientation of 
the magazine? 
RQ6:  Did the percentage of advertisements featuring black models increase following 
the 2009 FDA report? 
RQ7:  Does the provision of information about nondrug interventions vary based on the 
racial orientation of the magazine? 
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RQ8:  Did the percentage of advertisements that include information about nondrug 
interventions increase following the 2009 FDA report?  
RQ9:  Does the provision of information about available discounts or patient assistance 
programs vary based on the racial orientation of the magazine? 
RQ10:  Did the percentage of advertisements that include information about available 
discounts or patient assistance programs increase following the 2009 FDA report?  
 If pharmaceutical companies were to have adopted these recommendations, one 
would expect to see an increase in the number of advertisements that feature black 
models, particularly in ads placed in black-oriented magazines, and an increase in the 
number of ads that suggest nondrug interventions and that provide information on 
financial assistance.  
4.2  Data Collection 
 The first phase of the analysis identified 1,090 product claim advertisements.  
This type of ad mentions a specific drug and the medical condition for which it is used.  
These 1,090 ads promoted 95 different drugs falling into 15 categories of medical 
conditions (see Table 3-9).  Because the focus of this dissertation is on the potential 
impact of DTCA on health disparities, only those drugs used to treat life-threatening 
conditions were considered in the second phase of analysis.  Consequently, out of the 
initial 1,090 ads, 439 were identified for further analysis.  Within this group, 
158 represented unique versions of an ad.  An ad version was considered to be unique if it 
differed in any of its graphic or written elements or if it included a postcard or other tear 
out that the reader could use to obtain additional information.  The 158 ads identified 
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promoted 31 individual drugs used to treat the following conditions:  Alzheimer’s9 
disease, cancer, cardiovascular disease, depression,9 diabetes, and respiratory illness.  
Table 4-1 provides the total number of ads and the total number of unique ads within 
each disease category. 
Table 4-1:  Frequency of pharmaceutical advertisements by disease category 
 
Disease Category 
# of Drugs 
Advertised 
# of Advertisements 
# of Unique 
Advertisements 
Alzheimer’s 
Disease 
2 17 3 
Cancer 2 2 2 
Cardiovascular 12 108 46 
Depression 4 137 43 
Diabetes 4 53 17 
Respiratory 7 122 47 
TOTAL 31 439 158 
 
 
4.2.1  Code Sheet Development 
 A code sheet was developed (see Appendix A) to evaluate and document several 
elements of each advertisement.  For each of the 158 unique ad versions identified above, 
the name of the coder and the advertisement identification number were recorded.  Next, 
the type of drug, the medical condition it is used to treat, and the manufacturer were 
documented.  Finally, the size of both the promotional part of the ad and the brief 
summary (in terms of magazine pages) was noted.   
The visual and written content of the promotional part of each ad was then coded.  
The ad was coded for the use of human models or likenesses, cartoon characters, or 
inanimate objects, such as diagrams or illustrations.  If an ad featured human models, 
                                                          
9 Drugs used to treat Alzheimer’s disease and depression were originally coded as “Psychiatric/ 
Neurologic” (see Chapter 3).  For the purposes of the Phase 2 analysis, these ads were recoded as either 
“Alzheimer’s” or “Depression.” 
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their race, gender, and age were recorded.  If the ad included more than one human 
model, the race of the primary model was also noted.  Race was coded as either Black, 
White, Other, or Unknown.  Gender was coded as either male, female, or unknown, and 
age was coded as either child, adult, or senior.  An ad was considered to use a human 
 
Figure 4-1:  Advertisement for Zetia (Family Circle, September 2011) 
 
 
likeness if the race of the person depicted could be discerned.  For example, Figure 4-1 is 
an ad for Zetia.  Note the cutaway of a person’s digestive tract.  Because the race of the 
torso illustrated is discernable, this ad was coded as using a human model whose race is 
White.  The ad also included additional graphic images to convey how Zetia works.  
Therefore, the ad was coded as using inanimate objects. 
Given that the advertisements evaluated in this phase of the analysis promote 
drugs used to treat potentially life-threatening diseases, few ads featured a cartoon 
character.  However, a series of ads for the antidepressant drug, Abilify, did use a cartoon 
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character to depict depression (see Figure 4-2).  This ad was coded as using a white 
female adult model and a cartoon character. 
 
Figure 4-2:  Advertisement for Abilify (Good Housekeeping, November 2011) 
 
 
Next, the type of appeal used in the ad was considered.  Appeals can be either 
rational or emotional.  Many of the ads examined included both rational and emotional 
appeals.  Rational appeals tend to motivate individuals through the use of logical and 
informational arguments (Main et al., 2004).  Pharmaceutical ads may provide 
information related to the drug’s effectiveness, social or psychological benefits, ease of 
use, and safety.  Emotional appeals can be either positive or negative.  Positive emotional 
appeals try to evoke a favorable consumer response by conveying a sense of warmth, 
happiness, or relief (Main et al., 2004).  Such appeals may also be humorous, nostalgic, 
fanciful, or sexual (Main et al., 2004).  Negative emotional appeals can inspire feelings of 
anger, fear, or sadness (Main et al., 2004).  Tables 4-2 and 4-3 provide the coding scheme 
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used for recording appeal type.  This scheme is based on the work of Main et al. (2004) 
and Bell et al. (2000).   
The work of Bell et al. (2000) focused on the product claims made in the 
advertisement.  These researchers identified four key attributes—effectiveness, 
social-psychological enhancements, ease of use, and safety—as well as a number of 
descriptors for each.  Building on Bell et al. (2000), Main et al. (2004) coded their ads for 
both rational and emotional appeals.  Unlike Bell et al. (2000), they did not identify 
individual attributes associated with rational appeals, coding instead for the mere 
presence of such an appeal.  In terms of emotional appeals, Main et al. (2004) coded for 
both positive and negative appeals, noting whether the positive appeals used humor, 
nostalgia, fantasy, or sex appeal.   
Table 4-2 is taken from Bell et al. (2000) and modified to capture the attributes 
and descriptive phases found in the advertisements included in the current study.   
Table 4-2:  Coding of rational appeals 
Claimed Attribute Description of Drug 
Effectiveness 
Effective “lowers,” “helps,” “proven,” “more 
effective,” “works to,” “showed 
improvement,” “improve,” “reduce” 
Innovative “the first,” “only,” “different,” “works 
differently” 
Powerful “highest approved dose,” “concentrated,” 
“combines two proven medicines,” “one 
pill that does two things,” “treats both” 
Prevention “reduce the risk,” “help stay protected,” 
“prevent symptoms” 
Reduced Mortality “help save lives” 
Symptom Control “treat the symptoms,” “treats many 
symptoms,” “symptom improvement,” 
“helps control the symptoms” 
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Table 4-2:  (continued) 
 
Social-Psychological Enhancements 
Lifestyle “may help me lose some weight,” “fits 
into my busy life,” “breathe better” 
Psychological  “help reduce your risk,” “can reduce your 
risk” 
Ease of Use 
Convenience “once-daily,” “once a day,” “easy to use,” 
“daily,” “no regular blood tests”   
Quick Acting “as soon as two weeks,” “in as early as 
1–2 weeks”  
Safety 
Safe “over 8 years of safety and efficacy data,” 
“approved,” “FDA approved,” 
“extensively studied,” “steroid-free,” “#1 
prescribed” 
Natural “a prescription made from nature,” “made 
from a natural ingredient” 
 
 
 Coding emotional appeals was more nuanced in some cases.  Emotions can be 
conveyed both visually and textually.  In addition, some ads relied on both positive and 
negative emotional appeals.  Table 4-3 presents a selection of visual and textual cues 
associated with the types of emotional appeals coded by Main et al. (2004).  Again, the 
images and text were found in the advertisements included in the study sample.  Because 
of the purpose of the drugs advertised, no fantasy or sex appeals were found.   
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Table 4-3:  Coding of emotional appeals 
 
Emotion Images Text 
Positive Emotional Appeals 
Warmth, Happiness. 
Empowerment 
Grandmother and 
granddaughter blowing 
bubbles, child blowing 
pinwheel, photo of woman 
with boxing gloves 
“My asthma…under 
control with the help of 
SYMBICORT”; “take 
center stage in your own 
life”; “I am a strong 
woman”; “Doctors 
removed my lump, not my 
spirit”; “Today, I took 
steps to balance my Type 2 
Diabetes” 
Humor 
A cutway of $1 bill with 
George Washington seen 
blowing bubbles; elephant 
sitting on woman in a 
recliner; illustration of 
animated bathrobe 
following woman 
 
Nostalgia 
Pictures of previous events 
in the featured model’s life; 
daughter hugging her 
elderly mother 
“Throughout my life, mom 
has been there for me.  
Now it’s my turn”; “I want 
to give to the man who 
gave me a sense of 
harmony” 
Negative Emotional Appeals 
Fear 
Word “Emergency” printed 
across page; photo of 
person on gurney being 
rushed through hospital 
corridor 
“Is your asthma really 
under control, or do you 
just think it is?”; “I never 
thought it could happen to 
me.   A heart attack at 53”; 
“Are you kidding 
yourself?”   
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Table 4-3:  (continued) 
 
Emotion Images Text 
Sadness 
Photo of emotionally 
distraught young woman; 
illustration of woman 
looking in a mirror seeing 
what she could be doing if 
she were not depressed; 
dog holding ball looking 
longingly at its master who 
looks back vacantly 
“Depression hurts”; “hello 
hurts”; “With depression, 
simple pleasures can 
simply hurt”; “Depression 
can make you feel like you 
have to wind yourself up to 
get through the day” 
Guilt 
Mother holding daughter 
who is obviously having 
trouble breathing 
“If she needs a rescue 
medicine more than twice a 
week, this could be your 
wake up call”; “Is your 
child’s asthma really under 
control, or do you just 
think it is?”; “a kid who’s 
got what your kid’s got is 
out doing what your kid’s 
not” 
 
 
 When coding for the type of appeal, both the text and the images used in the ad 
were considered.  Figure 4-1 is an example of an ad that uses only a rational appeal.  The 
illustrations used are informative rather than provocative, explaining to the reader how 
Zetia works and why it differs from other cholesterol lowering drugs.  In contrast, the 
Abilify ad (Figure 4-2) relies primarily on an emotional appeal, combining the elements 
of humor, in the form of a bathrobe (the embodiment of depression) chasing after a 
woman, and fear as the expression on the woman’s face conveys to the reader her distress 
that she has been unable to shake her depression.  The text provides the rational appeal, 
explaining that Abilify “may help with unresolved symptoms in as early as 1–2 weeks.”  
This ad was coded as having both a rational (effective; quick-acting) and emotional 
appeal (humor; fear).   
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An ad for Cymbalta (Figure 4-3), another antidepressant, has an extremely strong 
emotional appeal, both in its visual and textual cues.  The young woman featured in the 
ad appears to be emotionally distraught, which is confirmed by the first half of the tag 
line, “Depression hurts.”  The second half of the tag line, “Cymbalta can help,” suggests 
that Cymbalta may offer relief.  The text lets the reader know that Cymbalta “treats many 
symptoms of depression.”  Like the Abilify ad, this ad was coded as having both a 
rational (effective) and emotional (sadness) appeal.  However, the emotional appeals used 
to promote Abilify and Cymbalta are quite different.  The Abilify ad uses both humor (a 
positive emotion) and fear (a negative emotion) to convey its message.  The Cymbalta ad 
relies on a negative emotion (sadness) alone.  The coding sheet included subcategories to 
capture the more subtle differences between positive and negative emotional appeals.   
 
 
 
Figure 4-3:  Advertisement for Cymbalta (Ebony, June 2008) 
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 Pharmaceutical ads may also include other information, such as an offer to help in 
finding patient support services or a Web site address and telephone number from which 
the reader can gain additional information.  The 2009 FDA report recommended that ads 
provide information about nonpharmaceutical interventions (e.g., diet and exercise), as 
well as information about discounts or other programs to assist patients in obtaining 
medications (FDA, 2009).  Ads should also encourage readers to talk with their doctor or 
healthcare provider about the product.  Finally, the FDAAA of 2007 requires that print 
ads include the statement, “You are encouraged to report negative side effects of 
prescription drugs to the FDA.  Visit MedWatch, or call 1-800-FDA-1088” (FDA, 
2012b).    
 The code sheet included the following series of yes/no questions to document 
whether or not each ad included such information: 
 Is the reader offered help in finding patient support services? 
 Is the reader referred to a Web site for additional information? 
 Is the reader given a telephone contact for additional information? 
 Is the reader encouraged to talk with a doctor or another individual? 
 Is the reader offered monetary incentives or other financial support? 
 Is the reader informed of nondrug interventions, such as diet and exercise, which 
might be helpful? 
 Is the reader encouraged to report negative side effects of prescription drugs to the 
FDA? 
Any offer of patient support services was coded affirmatively.  Such offers might 
include a postcard to send off for an informational brochure or CD-ROM, a Web site 
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offering supportive tips for making positive lifestyle changes, or a Web site detailing 
patient and caregiver resources.  Similarly, any offer of financial assistance, whether it be 
a free 30-day trial or a referral to the Partnership for Prescription Assistance or a similar 
manufacturer-sponsored program, was coded affirmatively.  However, such information 
had to have appeared within the promotional part of the ad, where it is most likely to be 
seen, rather than within the brief summary.   
The inclusion of Web site addresses and telephone numbers was fairly obvious, 
although some were associated with monetary incentives rather than additional disease 
and treatment information.  However, after visiting a few of these Web sites, it was 
determined that regardless of the stated purpose in the ad, all provided additional 
substantive information about the drug and its purpose.  Therefore, if the ad referred the 
reader to either a Web site or telephone number or both it was coded affirmatively.   
While no ad suggested that an alternative therapy, such as dietary changes, would 
be as effective as a pharmaceutical intervention, several did suggest that improved diet 
and increased exercise could be used in conjunction with the drug.  Others suggested the 
use of a drug when exercise and diet were not enough (this sentiment was found in many 
of the ads for cholesterol lowering medications).  If the ad mentioned any lifestyle 
change, no matter the context, this question was coded in the affirmative. 
Each ad was also coded for the appearance of the statement required by the 
FDAAA encouraging consumers to report negative side effects.  This is a regulatory 
requirement resulting from the same statute in which Congress directed the FDA to study 
DTCA as it “relates to increased access to health information and decreased health 
disparities for these populations” (FDA, 2009, p. i).  This variable was included as a basis 
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for comparing the response of pharmaceutical companies to a regulatory requirement 
found in the FDAAA versus the voluntary recommendations contained in the 2009 FDA 
report.   
4.2.2  Procedure and Reliability 
 Once the code sheet was initially developed, both the author and an independent 
colleague pretested it on five pharmaceutical ads that appeared in magazines outside the 
sample universe.  After comparing the pretest results, minor revisions were made to the 
code sheet to aid in interpretation of graphic images.  The author reviewed the coding 
procedures with a second coder, and five ads outside of the sample universe were jointly 
coded to enhance reliability.  The author coded all of the 158 ads in the sample; the 
second coder coded a random subsample of 10 percent of the ads (n=16).   
Average percent agreement for the 20 variables used in this phase of the analysis 
was 90.3 percent, and average kappa for 17 of the 20 variables was 0.81 (range 0.05–1.0).  
Interrater reliabilities reported as Cohen’s kappas were:  use of human models (1.0), use 
of cartoon characters (1.0), use of inanimate objects (0.59), race of primary model (.82), 
social/psychological enhancement (.48), ease of use (.50), safety (0.05), positive appeal 
(.74), humor appeal (.64), negative appeal (.87), patient support services (1.0), Web 
address (1.0), telephone number (1.0), referral to health care provider (1.0), offer of 
financial assistance (1.0), mention of nondrug interventions (1.0), and statement 
regarding the reporting of negative side effects to the FDA.  Kappas could not be 
calculated for 3 of the 20 variables because the value assigned by one of the two raters 
remained constant, thereby creating an error in SPSS.  However, the percent agreement 
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for these three variables was greater than 50 percent—rational appeal (93.8 percent), 
effectiveness (62.5 percent), and nostalgic appeal (93.8 percent). 
Agreement between the two raters was weakest among the variables associated 
with the types of claims made in the ads (effectiveness, social/psychological 
enhancement, ease of use, and safety).  However, in all cases, the percent of agreement 
was at least 50 percent.  In addition, these variables are not central to the study’s research 
questions.  Therefore, the results of the primary researcher were used in the final analysis.  
An independent third party will resolve the observed differences prior to future analysis. 
4.3  Data Analysis 
 This level of analysis focused on the individual advertisement.  SPSS Version 22 
was used for all statistical analyses.  A total of 158 unique ads were coded; however, the 
ID numbers for identical ads were noted on the coding sheet.  Data were then entered for 
the entire subset of 439 advertisements.   
 Using the same methods described in Chapter 3, the data collected from Ebony 
and Essence magazines were collapsed into a single category, “Black-Oriented 
Magazines,” and the data for Family Circle and Good Housekeeping were collapsed into 
a single category, “White-Oriented Magazines.”  Data from O, The Oprah Magazine 
were categorized as “Crossover Magazine.”  Similarly, data collected from magazine 
issues published before the FDA report (i.e., 2008 and 2009) were collapsed into a single 
category, “Before FDA Report,” and data collected from issues published after the FDA 
report (i.e., 2011 and 2012) were collapsed into a single category, “After FDA Report.”  
In this way, advertisements placed in different magazine genres could be compared, and 
differences in ad appearance and content across time could be identified. 
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Qualitative techniques were used to evaluate each advertisement.  Qualitative 
observations were then translated into quantitative, categorical variables to facilitate 
statistical analyses.  Descriptive statistics (i.e., frequency distributions and 
cross-tabulations) were used to ascertain quantitative differences in the appearance and 
content of the ads as a function of the racial orientation of the magazine in which they 
appeared and their publication date relative to the 2009 FDA report.  A Chi-square test 
for independence was used to explore the associations among the categorical variables.  
In some cases, a difference in proportions test was also used to determine the statistical 
significance of percentage differences pre- and post-FDA report publication (such as a 
change in the percentage of black models used in advertisements found in black-oriented 
magazines). 
4.4  Results 
 Of the 439 pharmaceutical ads included in this phase of the analysis, a total of 
206 ads appeared in magazines published before the FDA report, and 233 appeared in 
magazines published after the report.  The following results pertain only to this subset of 
439 advertisements.  All observations made refer only to this subset of ads and not to the 
universe of DTCA discussed in Chapter 3. 
Within the 206 ads published before the FDA report, 22 drugs were advertised.  
The 233 ads published after the report promoted 21 different medications.  Drugs used to 
treat cancer, cardiovascular disease, diabetes, depression, and respiratory illness were 
advertised in magazines published before the 2009 FDA report.  Drugs used to treat 
Alzheimer’s disease, cardiovascular disease, diabetes, depression, and respiratory illness 
were advertised in magazines published after the 2009 FDA report.  Table 4-4 presents 
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the distribution of ads by disease category before and after publication of the FDA report, 
and Figure 4-4 illustrates these data.   
Table 4-4:  Types of drugs advertised by disease category  
before and after publication of FDA report 
 
Disease Category Before After Total 
Alzheimer’s 
N 
% 
 
0 
0.0 
 
17 
100.0 
 
17 
100.0 
Cancer 
N 
% 
 
2 
100.0 
 
0 
0.0 
 
2 
100.0 
Cardiovascular 
N 
% 
 
76 
70.4 
 
32 
29.6 
 
108 
100.0 
Depression 
N 
% 
 
44 
32.1 
 
93 
67.9 
 
137 
100.0 
Diabetes 
N 
% 
 
24 
45.3 
 
29 
54.7 
 
53 
100.0 
Respiratory 
N 
% 
 
60 
49.2 
 
62 
50.8 
 
122 
100.00 
Total 
% 
206 
46.9 
233 
53.1 
439 
100.0 
χ2 (5, n=439) = 53.50, p < .001 
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Figure 4-4:  Distribution of DTCA by disease category  
before and after publication of FDA report 
 
 
From Table 4-4 and Figure 4-4, we can see variation in the frequency of the 
various types of drugs advertised pre- and post-FDA report.  The most notable 
differences occurred in the number of ads for cardiovascular drugs, which declined from 
76 (36.9 percent) to 32 (13.7 percent).  In contrast, antidepressants increased from 44 
(21.4 percent) to 93 (39.9 percent).  Both of these differences are statistically significant 
at the 95 percent confidence level.  A Chi-square test for independence indicated a 
positive association (p < .001) between the type of drug advertised (by disease category) 
and the year in which the ad was published (either pre- or post-FDA report). 
The three drugs most advertised before the FDA report was published were 
Advair Diskus, used to treat asthma or COPD (12.6 percent of all ads); Plavix, used to 
reduce the risk of blood clots (11.7 percent); and Abilify, used to treat depression and 
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bipolar disorder (11.2 percent).  In contrast, all three of the drugs (Cymbalta 
(12.4 percent), Abilify (10.7 percent), and Pristiq (10.7 percent)) most advertised in 2011 
and 2012 (the period after publication of the FDA report) are used to treat depression.   
 The number of pages devoted to the promotional part of the advertisement was 
greater in ads published after the FDA report than before.  The promotional part of the 
vast majority of ads (84.0 percent) published in 2008 and 2009 was a single page; less 
than 5 percent of the ads included a two-page promotional spread and less than 1 percent 
included a three-page promotional spread.  By contrast, one-third of the ads published in 
2011 and 2012 featured a two-page promotional spread, although none featured a 
three-page promotional spread.  Many of these longer ads were associated with the drug 
Cymbalta.  Nearly all of the ads examined, regardless of publication date, dedicated a 
single page to the brief summary material.  
The majority of DTCA evaluated in this phase of the analysis featured at least one 
human model or likeness.  In 2008 and 2009, 156 ads (75.7 percent) included a human 
model.  In 2011 and 2012, this number increased to 216 (92.7 percent).  Again, this 
difference was driven by the overall increase in ads for medications used to treat 
Alzheimer’s disease or depression, all of which featured human models.  It was possible 
to identify the race of the models used in all but six of the ads.   
Nearly 60 percent of ads published in 2008 and 2009 included an inanimate object 
of some sort, whether it be a chart, diagram, or an image of the actual medical device, 
such as an inhaler or injection pen.  That proportion declined to 43 percent for ads 
published in 2011 and 2012.  Few ads in any year studied included cartoon characters. 
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To respond to the research objectives posed at the beginning of this chapter, it 
was necessary to examine differences in appearance and content of ads as a function of 
the racial orientation of the magazines in which they appeared.  The following sections 
provide further analysis. 
4.4.1  Differences in Appearance 
RQs 5 and 6 relate to differences in the race of models used in DTCA placed in 
black-oriented women’s magazines versus white-oriented women’s magazines before and 
after the 2009 FDA report.  RQ5 asks whether the race of the models used in DTCA 
varies based on the racial orientation of the magazine, and RQ6 questions whether the 
number of advertisements featuring black models increased after publication of the FDA 
report in 2009.  To answer these questions, data were first filtered by whether the 
advertisement included a human model or likeness.  Those ads that did feature a human 
model or likeness were then filtered by magazine genre and publication date.   
To address RQ5, Table 4-5 looks at the race of the primary model used in DTCA 
placed in different magazine genres.  The number of ads in which the primary model is 
either Black or White is reported.  From this table we can see that the race of the models 
used in pharmaceutical advertising is positively associated with the racial orientation of 
the magazine in which it appears (χ2 (2, n=348) = 103.8, p < .001).  Over 70 percent of 
the ads appearing in black-oriented magazines featured black models.  Similarly, over 
80 percent of the ads appearing in white-oriented magazines featured white models. 
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Table 4-5:  Race of primary model by magazine genre 
Magazine Genre Primary Model Race Total 
 Black White  
White-Oriented 
N 
% 
 
33 
13.8 
 
207 
86.3 
 
240 
100.0 
Black-Oriented 
N 
% 
 
52 
76.5 
 
16 
23.5 
 
68 
100.0 
Crossover 
N 
% 
 
 
12 
30.0 
 
28 
70.0 
 
40 
100.0 
Total 
% 
97 
27.9 
251 
72.1 
348 
100.0 
χ2 (2, n=348) = 103.8, p < .001 
 
This trend was present regardless of when the ad was published.  Tables 4-6 and 
4-7 compare the frequency with which model race aligned with magazine genre in DTCA 
published before and after the 2009 FDA report.  The number of ads in which the primary 
model is either Black, White, or another identifiable race or ethnicity (e.g., Hispanic, 
Asian, or Indian) is reported.  A Chi-square test confirms the statistical significance of 
this trend for both time periods examined (pre-FDA report publication:  χ2 (4, n=150) = 
56.47, p < .001; post-FDA report publication: χ2 (4, n=216) = 60.41, p < .001).   
The results for the crossover magazine are interesting.  In the time period before 
publication of the FDA report, DTCA placed in the crossover magazine, O, The Oprah 
Magazine, included a similar number of ads featuring either a black or white model 
(7 and 10, respectively).  However, in the time period following publication of the FDA 
report, this proportion shifted dramatically.  Twenty-one ads published between 2011 and 
2012 featured white models, while only two ads featured black models.  Statistical testing 
for significant difference between two proportions revealed that the decrease in the 
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number of ads featuring black models found in O, The Oprah Magazine over time was 
statistically significant at the 95 percent confidence level.  
Table 4-6:  Race of models appearing in DTCA by magazine genre 
before FDA report 
 
 Race of Primary Model  
Magazine 
Genre 
White Black Other 
Total 
White 
N 
% 
 
84 
89.4 
 
9 
9.6 
 
1 
1.1 
 
94 
100.0 
Black 
N 
% 
 
11 
28.2 
 
28 
71.8 
 
0 
0.0 
 
39 
100.0 
Crossover 
N 
% 
 
7 
41.2 
 
10 
58.8 
 
0 
0.0 
 
17 
100.0 
Total 
% 
102 
68.0 
47 
31.3 
1 
0.7 
156 
100.0 
χ2 (4, n=150) = 56.47, p < .001 
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Table 4-7:  Race of models appearing in DTCA by magazine genre 
after FDA report 
 
 Race of Primary Model  
Magazine 
Genre 
White Black Other 
Total 
White 
N 
% 
 
123 
77.8 
 
24 
15.2 
 
11 
7.0 
 
158 
100.0 
Black 
N 
% 
 
5 
15.6 
 
24 
75.0 
 
3 
9.4 
 
32 
100.0 
Crossover 
N 
% 
 
21 
80.8 
 
2 
7.7 
 
3 
11.5 
 
26 
100.0 
Total 
% 
149 
69.0 
50 
23.1 
17 
7.9 
216 
100.0 
χ2 (4, n=216) = 60.41, p < .001 
 
Figure 4-5 and Table 4-8 help us to answer RQ6, which asks whether the 
percentage of advertisements featuring black models increased following the 2009 FDA 
report.  Figure 4-5 illustrates the distribution of model race by time period.  
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Figure 4-5:  Frequency of model race appearing in DTCA published before 
and after FDA report 
 
 
As one can see, the race of the majority of the models used was White, followed by 
Black.  The number of ads featuring black models remained relatively unchanged over 
time (47 versus 50), while the number of ads featuring white models and models that 
were neither Black nor White increased.  From Table 4-8, which presents the results of a 
Chi-square test for independence, we can see that the association between the race of the 
primary model used in advertisements and the racial orientation of the magazine in which 
they appear remains significant over time (χ2 (3, n=372) = 19.96, p < .001). 
  
4
7
1
0
2
1
5
0
1
4
9
1
7
B L A C K W H I T E O T H E R
Before After
127 
 
 
Table 4-8:  Race of primary model appearing in DTCA published 
before and after FDA report 
  
Primary Model Race Before After Total 
White 
N 
% 
 
102 
40.6 
 
149 
59.4 
 
251 
100.0 
Black 
N 
% 
 
47 
48.5 
 
50 
51.5 
 
97 
100.0 
Other 
N 
% 
 
1 
5.6 
 
17 
94.4 
 
18 
100.0 
Total 
% 
150 
41.9 
216 
58.1 
366 
100.0 
χ2 (2, n=366) = 11.59, p=.003 
 
 
 In terms of whether the percentage of advertisements featuring black models 
increased following the FDA report, it appears that the percentage decreased from 
31.3 percent (see Table 4-6) in the 2008/2009 timeframe to 23.1 percent (see Table 4-7) 
in the 2011/2012 timeframe.  However, if we look only at the difference in the percentage 
of ads featuring black models that appeared in black-oriented magazines, we find a slight 
increase from 71.8 percent (see Table 4-6) of ads published in the 2008/2009 timeframe 
to 75.0 (see Table 4-7) of ads published in the 2011/2012 timeframe.  Neither of these 
percentage differences are statistically significant at the 95 percent confidence level.  
The relationship between the type of drug advertised, model race, and magazine 
genre was also explored.  Tables 4-9 and 4-10 examine the association between the race 
of the primary model used in an advertisement and the disease category in which the 
advertised medication falls.  Table 4-9 provides these data for ads published in the 
2008/2009 timeframe, and Table 4-10 provides these data for ads published in the 
2011/2012 timeframe.  As can be seen, the majority of ads in all disease categories but 
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one feature white models.  Diabetes is the only disease category in which a 
preponderance of ads for medications to treat this disease feature black models.  In the 
2008/2009 timeframe, 19 of the 24 ads (79.2 percent) for diabetes medications featured a 
black model.  In the 2011/2012 timeframe, 21 of the 29 ads (72.4 percent) for this drug 
type feature a black model.  A Chi-square test for independence indicates that the 
association between the race of the primary model featured in an ad and the medication 
that is advertised is statistically significant for both time periods studied:  (pre-FDA 
report:  χ2 (8, n=150) = 39.78, p < .001; post-FDA report:  χ2 (8, n=216) = 53.65,  
p < .001).   
Table 4-9:  Race of primary model in DTCA published before the FDA report 
by disease category 
 
 
Race of Primary Model 
 
Disease  
Category 
White Black Other 
Total 
Alzheimer’s 
N 
% 
 
0 
0.0 
 
0 
0.0 
 
0 
0.0 
 
0 
100.0 
Cancer 
N 
% 
 
1 
50.0 
 
1 
50.0 
 
0 
0.0 
 
2 
100.0 
Cardiovascular 
N 
% 
 
46 
88.5 
 
5 
9.6 
 
1 
1.9 
 
52 
100.0 
Depression 
N 
% 
 
25 
64.1 
 
14 
35.9 
 
0 
0.0 
 
39 
100.0 
Diabetes 
N 
% 
 
5 
20.8 
 
19 
79.2 
 
0 
0.0 
 
24 
100.0 
Respiratory 
N 
% 
 
25 
75.8 
 
8 
24.2 
 
0 
0.0 
 
33 
100.0 
Total 
% 
102 
68.0 
47 
31.3 
1 
0.7 
150 
100.0 
χ2 (8, n=150) = 39.78, p < .001 
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Table 4-10:  Race of primary model in DTCA published after the FDA report 
by disease category 
 
 
Race of Primary Model 
 
Disease  
Category 
White Black Other 
Total 
Alzheimer’s 
N 
% 
 
11 
64.7 
 
6 
35.3 
 
0 
0.0 
 
17 
100.0 
Cancer 
N 
% 
 
0 
0.0 
 
0 
0.0 
 
0 
0.0 
 
0 
100.0 
Cardiovascular 
N 
% 
 
25 
80.6 
 
2 
6.5 
 
4 
12.9 
 
31 
100.0 
Depression 
N 
% 
 
69 
74.2 
 
16 
17.2 
 
8 
8.6 
 
93 
100.0 
Diabetes 
N 
% 
 
8 
27.6 
 
21 
72.4 
 
0 
0.0 
 
29 
100.0 
Respiratory 
N 
% 
 
36 
78.3 
 
5 
10.9 
 
5 
10.9 
 
46 
100.0 
Total 
% 
149 
69.0 
50 
23.1 
17 
7.9 
216 
100.0 
χ2 (8, n=216) = 53.65, p < .001 
 As discussed in the previous chapter, the types of drugs advertised varied by the 
racial orientation of the magazine.  Chapter 3 provided information for drugs advertised 
in all disease categories.  Since the focus of this chapter is on drugs used to treat 
life-threatening conditions, the data presented in the following figures and table represent 
only the six disease categories of interest in the second phase of analysis.  Figures 4-6 
and 4-7 illustrate the distribution of advertisements by disease category as a function of 
magazine genre.  Figure 4-6 provides this information for ads published before the 2009 
FDA report; Figure 4-7 provides this information for ads published after the report.  As 
noted previously, drugs used to treat diabetes were most likely to be found in magazines 
130 
 
 
read by a predominantly black audience, regardless of publication date.  Cardiovascular 
drugs were advertised in all magazine genres studied with publication dates in either 
2008 or 2009; however, no cardiovascular drugs were advertised in either Ebony or 
Essence in 2011 or 2012.  Antidepressant drugs were more likely to be advertised in 
magazines read by a predominantly white audience in both time periods studied, although 
the number of ads for these types of drugs that appeared in O, The Oprah Magazine (i.e., 
the crossover magazine) more than doubled between 2008 and 2012 (from 10 to 22).   
 
Figure 4-6:  Frequency of DTCA published before FDA report by disease category 
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Figure 4-7:  Frequency of DTCA published after FDA report by disease category 
 
 
Looking solely at the number of ads published may be misleading given the 
disparity in the amount of DTCA appearing in Family Circle and Good Housekeeping 
relative to the other magazine titles studied.  Table 4-11 presents the percentage of ads 
published both before and after the FDA report by the six disease categories of interest as 
a function of magazine genre.  The greatest percentage of ads within these six disease 
categories published in Family Circle and Good Housekeeping prior to the FDA report 
promoted drugs to treat cardiovascular disease (42.3 percent) and respiratory illness 
(30.8 percent).  After the report, the majority of ads promoted drugs to treat depression 
(46.0 percent) and respiratory illness (28.4 percent).  Regardless of publication date, the 
greatest percentage of ads within the six disease categories of interest that were published 
in Ebony and Essence during the time period studied promoted drugs used to treat 
diabetes (37.7 percent and 47.0 percent, respectively) and respiratory illness (30.2 percent 
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and 27.8 percent, respectively).  Similarly, the greatest percentage of ads within the six 
disease categories of interest published in O, The Oprah Magazine promoted drugs used 
to treat depression (43.5 percent and 79.6 percent, respectively). 
Table 4-11:  Percent of DTCA published before and after FDA report 
by disease category as a function of magazine genre 
 
 BEFORE AFTER 
Disease 
Category 
Magazine Genre Magazine Genre 
 White Black Crossover White Black Crossover 
Alzheimer’s  N/A N/A N/A 10.1 
(n=17) 
N/A 
 
N/A 
Cancer 0.8 
(n=1) 
1.9 
(n=1) 
N/A N/A N/A N/A 
Cardiovascular 42.3 
(n=55) 
24.5 
(n=13) 
34.8 
(n=8) 
17.8 
(n=30) 
N/A 
 
7.1 
(n=2) 
Depression 23.8 
(n=31) 
5.7 
(n=3) 
43.5 
(n=10) 
46.0 
(n=68) 
25.0 
(n=9) 
79.6 
(n=22) 
Diabetes 2.3 
(n=3) 
37.7 
(n=20) 
4.5 
(n=1) 
7.1 
(n=12) 
47.0 
(n=17) 
N/A 
Respiratory 30.8 
(n=40) 
30.2 
(n=16) 
17.4 
(n=4) 
28.4 
(n=48) 
27.8 
(n=10) 
14.3 
(n=4) 
N/A indicates that no ads for drugs in this disease category appeared during the time period studied. 
 
 
4.3.2  Differences in Content 
 The second phase of analysis examined the differences in the content of DTCA 
found in black-oriented women’s magazines versus white-oriented women’s magazines 
before and after the 2009 FDA report.  For the purposes of this study, content refers to 
the type of appeal used in an advertisement, as well as the type of information provided, 
particularly information about financial assistance and nondrug interventions.  The 2009 
FDA report specifically recommends that DTCA include such information.   
The first step of this analysis looked at whether the type of appeal varied as a 
function of the racial orientation of the magazine.  A Chi-square test for independence 
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found that ads using a rational appeal were just as likely to be found in a white-oriented 
magazine as in the black-oriented or crossover magazines (χ2 (2, n=439) = 1.41,  
p=.493).  This was also true of DTCA using an emotional appeal (χ2 (2, n=439) = .777, 
p=.678) (see Tables D-1 and D-2).  However, as Tables 4-12 and 4-13 demonstrate, the 
type of appeal used in an advertisement is associated with the disease category of the 
advertised drug.   
Table 4-12:  DTCA using a rational appeal by disease category 
 Rational Appeal? 
Disease Category No Yes Total 
Alzheimer’s 
N 
% 
 
0 
0.0 
 
17 
100.0 
 
17 
100.0 
Cancer 
N 
% 
 
0 
0.0 
 
2 
100.0 
 
2 
100.0 
Cardiovascular 
N 
% 
 
0 
0.0 
 
108 
100.0 
 
108 
100.0 
Depression 
N 
% 
 
0 
0.0 
 
137 
100.0 
 
137 
100.0 
Diabetes 
N 
% 
 
3 
5.7 
 
50 
94.3 
 
53 
100.0 
Respiratory 
N 
% 
 
0 
0.0 
 
122 
100.0 
 
122 
100.0 
Total 
% 
3 
0.7 
439 
99.3 
439 
100.0 
χ2 (5, n=439) = 22.00, p=.001 
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Table 4-13:  DTCA using an emotional appeal by disease category 
 Emotional Appeal? 
Disease Category No Yes Total 
Alzheimer’s 
N 
% 
 
0 
0.0 
 
17 
100.0 
 
17 
100.0 
Cancer 
N 
% 
 
0 
0.0 
 
2 
100.0 
 
2 
100.0 
Cardiovascular 
N 
% 
 
21 
19.4 
 
87 
80.6 
 
108 
100.0 
Depression 
N 
% 
 
12 
8.6 
 
125 
91.3 
 
137 
100.0 
Diabetes 
N 
% 
 
0 
0.0 
 
53 
100.0 
 
53 
100.0 
Respiratory 
N 
% 
 
27 
22.1 
 
95 
77.9 
 
122 
100.0 
Total 
% 
60 
13.7 
379 
86.3 
439 
100.0 
χ2 (5, n=439) = 24.66, p < .001 
 
 
Virtually all advertisements (99.3 percent) made some sort of rational appeal.  
Only three ads for a diabetic drug did not.  These ads were for the diabetes drug, Victoza, 
and focused on a patient support program that the manufacturer, novo nordisk, had 
initiated with celebrity spokesperson, Paula Deen.  
A majority of ads (86.3 percent) also included some type of emotional appeal.  
Some ads for cardiovascular and respiratory drugs provided only a rational appeal, 
preferring to state facts and figures about the drugs’ effectiveness and the extent of its 
use.  For example, the advertisement for Zetia (see Figure 4-1), states, “If you diet and 
take a statin, ZETIA can help lower LDL (bad) cholesterol even more.”  This is followed 
by a series of statements explaining how Zetia works and why it is unique.  An ad for 
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Advair Diskus, used to treat asthma and COPD, simply directs the reader to talk to his or 
her doctor about Advair.  Table 4-13 also indicates that about 9 percent of the ads for 
drugs used to treat depression did not include an emotional appeal.  A version of an ad for 
Abilify published in 2009 features a series of medicine bottles labeled with the names of 
common antidepressants, such as Lexapro, Zoloft, and Prozac.  The tag line reads, “Talk 
to your doctor.  Adding Abilify to an antidepressant such as one of these can help treat 
unresolved symptoms of depression.”  As noted earlier, many ads contained both a 
rational and an emotional appeal. 
Because the type of appeal used is positively associated with the drug advertised, 
rather than with the magazine genre in which the advertisement appeared, several 
research questions probing the general differences in ad content used over time were 
reconsidered.  These original research questions were replaced with RQs 7–10, which 
focus on whether an ad provided information on nondrug interventions and financial 
assistance, as recommended in the 2009 FDA report.  While no longer central to the 
primary purpose of this study, Appendix D does report the frequency of ads using various 
types of rational and emotional appeals as a function of time and magazine genre.  
Advertisements were also coded for their inclusion of more general information, 
Table 4-14 summarizes these data.  Most of the content remained the same between the 
two study periods.  For example, all advertisements, regardless of their publication date 
referred the reader to a Web site where he or she could obtain additional information.  
Nearly all encouraged readers to talk to their doctor or healthcare provider about the 
advertised medication.  The percentage of ads offering patient support services and 
financial assistance remained relatively unchanged between the two study periods, with 
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few (14–15 percent) offering patient support services and most (87–88 percent) offering 
financial assistance.  The percentage of ads providing a telephone number declined over 
the two periods studied, although over three-quarters of the DTCA reviewed did offer 
one.  The most noticeable differences were in the percentage of ads recommending 
alternative therapies, such as diet and exercise, and the percentage of ads that encouraged 
consumers to report negative side effects of prescription drugs to the FDA.  In the first 
case, the percentage declined from 44.4 percent to 38.1 percent; in the second case, the 
percentage increased from 82.4 percent to 99.6 percent (see Table 4-14).  The increase in 
the number of ads encouraging consumers to report negative side effects would be 
expected given the regulatory requirement to do so promulgated as a result of the 
FDAAA.  However, a difference in proportion test suggests that none of the differences 
are statistically significant at the 95 percent confidence level.10 
Table 4-14:  Other content included in DTCA published 
before and after FDA report 
 
 BEFORE AFTER 
Content Frequency Percent Frequency Percent 
Support Services 31 15.0 34 14.6 
Web Site 206 100.0 233 100.0 
Telephone Number 171 83.0 180 77.3 
Healthcare Provider 204 99.0 229 98.3 
Financial Assistance 180 87.4 206 88.4 
Nondrug 
Interventions 
91 44.2 88 37.8 
Side Effects to FDA 170 82.5 232 99.6 
 
 
                                                          
10 A difference in proportions test could not be conducted for the variable, “Side Effects to FDA,” because 
the values violated the requirements of the test.  However, the fact that nearly 100 percent of ads now 
include this requirement is noteworthy, if not statistically significant. 
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 Table 4-15 looks at these data by magazine genre.  A lower percentage of ads 
published before the FDA report that appeared in black-oriented magazines included 
information about patient support services (7.5 percent versus 18.5 percent of ads 
appearing in white-oriented magazines and 13.0 percent of ads appearing in the crossover 
magazine).  This difference reversed itself in ads published after the FDA report, with a 
greater percentage of ads appearing in black-oriented magazines containing such 
information (27.8 percent versus 12.4 percent of ads appearing in white-oriented 
magazines and 10.7 percent of ads appearing in the crossover magazine).  A difference in 
proportions test reveals that the change in the percent of ads offering patient support 
services that appeared in black-oriented magazines over time is statistically significant at 
the 95 percent confidence level.   
Table 4-15:  Percent of DTCA published before and after FDA report that 
includes other content 
 
 BEFORE AFTER 
Content Magazine Genre Magazine Genre 
White Black Crossover White Black Crossover 
Support 
Services 
18.5 
(n=24) 
7.5 
(n=4) 
13.0 
(n=3) 
12.4 
(n=21) 
27.8 
(n=10) 
10.7 
(n=3) 
Web Site 100.0 
(n=130) 
100.0 
(n=53) 
100.0 
(n=23) 
100.0 
(n=169) 
100.0 
(n=36) 
100.0 
(n=28) 
Telephone 
Number 
83.1 
(n=108) 
86.8 
(n=46) 
73.9 
(n=17) 
84.0 
(n=142) 
44.4 
(n=16) 
78.6 
(n=22) 
Healthcare 
Provider 
98.5 
(n=128) 
100.0 
(n=53) 
100.0 
(n=23) 
97.6 
(n=165) 
100.0 
(n=36) 
100.0 
(n=28) 
Financial 
Assistance 
87.7 
(n=114) 
83.0 
(n=44) 
95.7 
(n=22) 
87.6 
(n=148) 
97.2 
(n=35) 
82.1 
(n=23) 
Nondrug 
Interventions 
42.3 
(n=55) 
49.1 
(n=26) 
43.5 
(n=10) 
35.5 
(n=60) 
52.8 
(n=19) 
32.1 
(n=9) 
Side Effects to 
FDA 
83.8 
(n=109) 
79.2 
(n=42) 
82.6 
(n=19) 
99.4 
(n=168) 
100.0 
(n=36) 
100.0 
(n=28) 
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While all ads included a Web site address, the number offering a telephone 
number ranged from about 74 to 87 percent in ads published in the 2008/2009 timeframe, 
depending on magazine genre.  In the timeframe after the FDA report was published (i.e., 
2011/2012), the percentage ranged from about 44 to 84 percent.  The greatest decrease 
occurred in ads published in black-oriented magazines.  The decline from 86.8 percent of 
ads published in 2008/2009 to 44.4 percent of ads published in 2011/2012 was found to 
be statistically significant at the 95 percent confidence level using a difference in 
proportions test.   
The number of ads referring readers to their health care provider remained at or 
close to 100 percent over time for all magazine genres.  In terms of offers for financial 
assistance, the number of ads providing such offers placed in black-oriented magazines 
increased over time (83.0 percent to 97.2 percent), while the number of such ads placed 
in the crossover magazine decreased over time (95.7 percent to 82.1 percent).  The 
observed differences are statistically significant at the 95 percent confidence level.   
The percentage of ads that included information about nondrug interventions 
declined in the period following the FDA report for the white-oriented and crossover 
magazines (42.3 percent versus 35.5 percent and 43.5 percent versus 32.1 percent, 
respectively).  However, the percentage of ads that included this information increased 
slightly (49.1 percent versus 52.8 percent) in black-oriented magazines.  The decline in 
ads placed in the crossover magazine that provided information on nondrug interventions 
was statistically significant at the 95 percent confidence level.   
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4.5  Discussion 
 The results reported in this chapter provide additional insight into the potential for 
DTCA to narrow health disparities by educating and motivating consumers, particularly 
black consumers, to seek additional information from their physicians.  Recall that both 
the health belief model and social cognitive theory identify information as a key 
motivator in changing behavior.  The study updates previous research regarding the 
appearance and content of DTCA and identifies interesting trends in terms of the race of 
human models used, the types of appeals made, and the information provided in 
pharmaceutical advertising.  The impact of the FDA report recommendations on each of 
these aspects of DTCA was explored in depth and the results are discussed in the 
following sections.  Section 4.5.1 addresses RQ5 and RQ6 as they relate to the use of 
black models in DTCA.  Section 4.5.2 addresses RQs 7–10 as they relate to the type of 
information provided in the promotional content of DTCA.  To delve deeper into 
potential differences between DTCA place in white-oriented versus black-oriented 
magazines, Section 4.5.3 qualitatively explores differences in advertisements for the 
same drug published in the same month and year in magazines of differing racial 
orientation.  Section 4.5.4 notes the limitations of the current study. 
4.5.1  Model Race 
 The study results confirm the work of earlier researchers.  Both Mastin et al. 
(2007) and Kean and Prividera (2007) found that black models were more likely to 
appear in advertisements placed in magazines read by predominantly black audiences.  
From Table 4-6, we see that over 70 percent of advertisements appearing in 
black-oriented magazines published prior to the FDA report featured black models; this 
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percentage rose slightly to 75 percent in ads published after the FDA report (see 
Table 4-7).  Nearly 89 percent of the ads appearing in white-oriented magazines 
published before the FDA report featured white models; after publication of the FDA 
report, this percentage fell to 77.8 (see Tables 4-6 and 4-7).  As noted earlier, the 
decrease over time in the percentage of ads featuring black models placed in O, The 
Oprah Magazine (from 58.8 percent to 7.7 percent), a magazine read by both black and 
white women, was statistically significant at the 95 percent confidence level. 
Tables 4-6 and 4-7 also reveal that the percentage of ads featuring black models 
that appeared in white-oriented magazines increased over time.  In white-oriented 
magazines published before the FDA report, only 10 percent of the ads featured black 
models.  After the report, this percentage increased to 15.2 percent.  The difference 
between these two values is statistically significant at the 95 percent confidence level.  
While this change is certainly a positive trend, it may have little value with regard to the 
larger question of health disparities because only a small percentage of black women read 
Family Circle or Good Housekeeping (9 percent and 11 percent, respectively (see 
Table 3-1)).   
Another potentially positive trend is the increase in DTCA that features models 
that are neither Black nor White.  Looking at Figure 4-5, we see that, of the 206 ads 
published before the FDA report, only one featured a model that could be identified as 
either Hispanic, Asian, or Indian.  After the FDA report, that number rose to 17 of the 
233 ads published, an increase of nearly 1,500 percent.  Increasing the use of a broader 
range of nonwhite models may have important policy implications, especially if women 
of color identify with any nonwhite model. 
141 
 
 
These results confirm that the race of models used in DTCA does vary based on 
the racial orientation of the magazine (RQ5) and that the race of models used in DTCA is 
positively associated (χ2 (6, n=348) = 103.8, p < .001).  In other words, white models are 
more likely to be used in DTCA appearing in white-oriented magazines and black models 
are more likely to be used in DTCA appearing in black-oriented magazines.  However, 
before we can conclude that the racial orientation of a magazine drives the race of models 
used in its advertising, we must consider the possibility that the product advertised might 
drive the race of models used to promote it.   
Cline and Young (2004) found differences in the race of models used to advertise 
certain drugs.  Black models did not appear in advertisements for drugs used to treat 
cardiovascular disease or cancer, although they were featured prominently in ads 
promoting HIV/AIDs drugs.  Unlike those of Cline and Young (2004), the results of this 
study show that black models were used to promote medications in all disease categories 
(see Tables 4-9 and 4-10).  However, fewer ads, as well as a smaller percentage of ads, 
featured black models versus white models in all disease categories but one (diabetes).  
Figures 4-6 and 4-7 illustrate the frequency of DTCA published before and after the FDA 
report by disease category.  From Figure 4-6, we see that the greatest number of ads 
placed in black-oriented magazines promoted drugs used to treat diabetes.  Figure 4-7 
shows this same trend.  From Table 4-10, we see that ads for diabetes drugs are more 
likely to feature a black model than a white model.  This is a notable finding, given that 
African Americans have twice the risk of non-Hispanic Whites of being diagnosed with 
diabetes (CDC, 2012).  Based on social cognitive theory, black readers are more likely to 
self-identify with ads featuring a black model than a white model.  Consequently, a 
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diabetes ad featuring a black model may be more likely to encourage a black reader to 
take a more proactive role in his or her health care than an ad featuring a white model. 
Ads for diabetes ads were the only ads that consistently featured black models.  
Drugs to treat cardiovascular disease, another illness to which Blacks are more 
susceptible than Whites (CDC, 2011), were more likely to feature white models (see 
Table 4-6).  In fact, ads used to treat all other disease categories were more likely to 
feature white models than black models. 
RQ6 asks whether there has been an increase in the number of advertisements 
featuring black models following publication of the 2009 FDA report.  Figure 4-5 reveals 
that the number of ads featuring black models rose slightly, from 47 to 50, after 
publication of the FDA report.  However, on a percentage basis, the amount of 
advertising in the six disease categories of interest actually declined, from 23 percent to 
21.5 percent (although this decline was not statistically significant).  Looking more 
closely at the results for the individual disease categories reported in Tables 4-9 and 4-10, 
we find that both the number and percentage of ads featuring black models declined over 
time in three categories:  cardiovascular disease, cancer, and respiratory illness.  The 
number and percentage of ads increased in three categories over time:  Alzheimer’s 
disease, depression, and diabetes.  Interestingly, although 6 of the 17 ads for drugs used 
to treat Alzheimer’s disease featured black models, none of these ads appeared in a 
black-oriented magazine (see Table 4-11).  Thus the use of black models in these ads may 
be of dubious educational value to the target population if they are not seen by black 
readers. 
143 
 
 
These results do not suggest that pharmaceutical manufacturers have heeded the 
FDA recommendations and increased their outreach to black consumers.  While the 
number of ads for drugs used to treat life-threatening conditions increased over time, the 
number of those ads that appeared in black-oriented magazines decreased from 53 to 36 
(see Figures 4-6 and 4-7).  Particularly troubling is the decline in advertising for 
conditions of great concern to the African American community, such as cardiovascular 
disease and asthma.  The one disease category in which the ads consistently featured 
black models was diabetes.  However, of the 40 ads that featured black models, 30 were 
for a single drug, Januvia, which is used to treat diabetes (see Table C-1).  The other ads 
included in this category used both white and black models in relatively equal 
proportions. 
Furthermore, not all ads that featured black models were found in black-oriented 
magazines (see Tables 4-9 and 4-10).  Ads for drugs to treat Alzheimer’s disease, which 
were introduced after the FDA report was published did feature black models, but the ads 
did not appear in black-oriented magazines.  This is also true of ads for antidepressant 
drugs.  Of the 132 ads for antidepressants identified, 30 featured a black model.  
However, only 6 of those 30 ads were placed in black-oriented magazines (17 were 
placed in white-oriented magazines and 7 were placed in the crossover magazine).  Three 
were placed in black-oriented magazines published prior to the FDA report and three 
were placed in black-oriented magazines published after the report.   
4.5.2  Advertising Appeals and Information Provided 
 As could be expected, appeals used in the DTCA evaluated were positively 
associated with the type of drug advertised (see Tables 4-12 and 4-13).  Nearly every ad 
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included some type of rational appeal—most often claims about the drug’s effectiveness 
(see Tables D-3 and D-4).  The majority of ads (see Table D-5) also included emotional 
appeals (over 80 percent in ads published before the FDA report and 91 percent of ads 
published after the report).  Because the type of appeal used in an advertisement is 
dependent on the drug being advertised, further analysis of appeal type as a function of 
magazine genre and publication date is less important than originally thought.  Thus, the 
results of these analysis can be found in Appendix D.  However, a brief discussion of the 
trends in these data follows. 
Positive appeals were found in nearly 50 percent of the ads published before the 
FDA report and in nearly 63 percent of the ads published after the report (see Table D-6).  
Negative appeals were used in 60 percent of ads published before the report and 
65 percent of ads published after the report (see Table D-6).  The increase in positive and 
negative appeals can likely be explained by the more than doubling in the number of ads 
for antidepressant drugs that occurred over the time period studied.  These ads often used 
both a positive and negative appeal.  Relatively few ads featured either a humorous or 
nostalgic appeal, perhaps because of the seriousness of disease categories included in the 
subset of ads used in this phase of the analysis. 
 Ads placed in white-oriented magazines used a broader range of emotional 
appeals (see Table D-7).  At least one ad used either a humorous or nostalgic appeal, in 
addition to a positive and/or negative appeal.  Ads that appeared in black-oriented 
magazines used either a positive or negative appeal or both.  Ads that appeared in the 
crossover magazine included positive, negative, and humorous appeals, but not nostalgic 
appeals.  However, the vast majority of all ads (at least 95 percent) appearing in O, The 
145 
 
 
Oprah Magazine included a negative appeal.  As discussed earlier, this observation can 
be explained by the types of drugs advertised.  Most of the drugs advertised in O, The 
Oprah Magazine during the time period studied are used to treat cardiovascular disease 
or depression.  Advertisements for these types of drug tend to use negative appeals more 
frequently than drugs used to treat other diseases.   
 Few changes were observed in the type of information provided in the DTCA 
evaluated over time.  As reported in Table 4-14, the majority of ads, both pre- and 
post-publication of the FDA report, included a Web site address and telephone number.  
Virtually all ads recommended talking with a doctor or other healthcare provider.  A 
minority of ads provided information about patient support services, and the proportion 
of those doing so did not change over time (15.0 and 14.6 percent pre- and post-FDA 
report).   
 RQs 7–10 address the FDA recommendations concerning the provision of 
information about nondrug interventions and financial assistance.  The PhRMA DTC 
Guiding Principles also recommend that its members include this information in their 
advertisements (as quoted in Arnold & Oakley, 2013).  Therefore, we would expect that a 
significant proportion of ads would comply with these recommendations.  RQs 7 and 8 
ask whether the provision of information about nondrug interventions varies with 
magazine genre and whether the percentage of ads offering such information increased 
following the 2009 FDA report.  From Table 4-14 we can see that less than half the ads 
published during the study period discussed nondrug interventions.  From Table 4-15, we 
see that the provision of this information did not vary as a function of the racial 
orientation of the magazine and that differences between the two study periods were not 
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statistically significant.  A Chi-square test for independence suggests that the provision of 
information about nondrug interventions was positively associated with the type of drug 
advertised (χ2 (5, n=439) = 150.79, p < .001) rather than the genre of the magazine in 
which the drug appeared (χ2 (2, n=439) = 4.45, p=.0108).  
 RQs 9 and 10 relate to the provision of information about available discounts or 
patient assistance programs.  Table 4-14 reports that nearly 90 percent of the ads 
evaluated offered some sort of financial assistance, such as a free trial or a discounted 
prescription rate.  RQ 9 asks whether offers of financial assistance varied by the racial 
orientation of the magazine.  From Table 4-15, we see that a high percentage of ads, 
regardless of when and where they were published, included this information.  
Differences in the percentage of ads placed among the three magazine genres were not 
statistically significant.  RQ 10 asks whether the percentage of ads that offered some sort 
of financial assistance increased following the 2009 FDA report.  Looking again at 
Table 4-15, we see that the percentage of ads offering financial assistance placed in 
black-oriented magazines increased from 83.0 percent to 97.2 percent over time.  Ads 
appearing in the white-oriented or crossover magazines did not experience comparable 
increases.  A difference in proportions test indicated that this increase was statistically 
significant.  To confirm that the provision of financial assistance was not dependent on 
the drug advertised, a Chi-square test for independence was conducted.  A positive 
association was not found between the offer of financial assistance and the drug 
advertised (χ2 (5, n=439) = 11.04, p=.051), although future research should explore the 
relationship between offers of financial assistance and the length of time the advertised 
drug has been on the market. 
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 Table 4-15 reports some additional results worth noting.  If we focus on changes 
in the information provided in ads placed in black-oriented magazines before and after 
publication of the FDA report, we can see some statistically significant trends.  The 
percentage of ads offering patient support services increased from 7.5 percent to 
27.8 percent.  This change was statistically significant at the 95 percent confidence level.  
However, the percentage of ads appearing in black-oriented magazines that provided a 
telephone number by which the consumer could gain additional information declined 
from 86.8 to 44.4 percent.  This change was statistically significant at the 95 percent 
confidence level.  This could be a problematic trend if it were to continue.  Consumers 
without access to a computer would have a limited ability to gain further information 
about an advertised drug.  This is more likely to be a barrier for ethnic and minority 
households than for non-Hispanic white households (U.S. Census Bureau, 2013).   
The most notable difference in ad content was in the percentage of ads advising 
consumers to report adverse side effects to the FDA.  About 80 percent of ads published 
in 2008/2009 included this advice; by 2011/2012, nearly 100 percent contained language 
to this effect.  The reason for this change is clear.  The FDAAA of 2007 mandated that 
print ads include the statement, “You are encouraged to report negative side effects of 
prescription drugs to the FDA.  Visit MedWatch, or call 1-800-FDA-1088” (FDA, 
2012b).   
 Overall, the DTCA evaluated did a good job in providing consumers with access 
to additional information via a Web site or telephone number (with the exception noted 
above) and encouraging them to discuss their symptoms with a healthcare provider.  The 
vast majority of ads offered consumers a means of obtaining financial assistance in 
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acquiring their prescription drugs.  Information about support services and nondrug 
interventions was dependent on the drug advertised.  For example, an advertisement for 
the Exelon Patch lets consumers know that, “[t]he makers of Exelon Patch also offer 
tools to help you handle the challenges of caregiving,” and encourages them “to explore 
all the patient and caregiver resources on exelonpatch.com.”  An ad for Victoza, a 
diabetes drug, features Paula Deen encouraging readers to exercise every day and eat 
smaller portions.  This ad also refers consumers to a Web site to learn more about making 
positive lifestyle changes.  However, there was no real discernable in the number of ads 
offering such information pre- and post-publication of the FDA report, despite the 
report’s express recommendation to do so. 
 On the other hand, pharmaceutical manufacturers did respond to the regulatory 
requirement to advise patients to report negative side effects to the FDA.  The percentage 
of ads that included the required statement increased from just over 80 percent in 
2008/2009 to nearly 100 percent by 2012.  This finding suggests that regulatory action 
may be necessary if FDA is interested in leveraging DTCA as a means of improving 
health information access and reducing health disparities. 
4.5.3  Same Drug—Different Magazine Genre 
 
 A final step in the analysis was to qualitatively review advertisements for the 
same drug placed in different magazine genres during the same month and year.  While 
not a formal research question, it was thought that such a comparison might reveal 
differences in the approach used to advertise a drug in magazines with different target 
audiences.  Particular attention was paid to the race of the featured models used in the ad 
as differences in this variable might suggest a more focused attempt on the part of the 
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pharmaceutical companies to appeal to the magazine’s targeted audience.  Four of the six 
disease categories (Cardiovascular, Diabetes, Depression, and Respiratory) included 
advertisements that met the criteria.  A total of 10 drugs were advertised in both 
black-oriented and white-oriented magazines during the same month and year.  (Drug ads 
that appeared in the crossover magazine were omitted from this phase of the analysis 
since its target audience is less defined.)  Twenty-seven ad versions were evaluated. 
 Only 2 of the 10 drugs advertised to treat cardiovascular disease met the selection 
criteria (i.e., advertisements for these drugs appeared during the same month and year in 
magazines of differing racial orientation).  Identical versions of ads for Caduet were 
placed in the July and September 2009 issues of Ebony and Family Circle.  Identical 
versions of ads for Plavix were published in the May 2008 issues of Ebony and Family 
Circle and the February 2008 issues of Ebony and Good Housekeeping.  Different ads for 
Plavix were found in the May 2009 issues of Ebony and Family Circle and in the 
February 2009 issues of Good Housekeeping and Ebony.  The February 2009 Plavix ad 
published in Good Housekeeping did not include a human model or likeness and focused 
on the life-saving advantages for those who have had a heart attack of used Plavix to 
prevent clots.  The February 2009 Plavix ad that appeared in Ebony featured two white 
models and promoted Plavix as a treatment for peripheral artery disease.  This same ad 
version was published in the May 2009 issue of Family Circle.  That same month (i.e., 
May 2009), another version of a Plavix ad appeared in Ebony magazine.  It too featured 
white models but targeted those who had experienced a heart attack rather than those with 
peripheral artery disease.   
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 A total of four drugs used to treat depression or bipolar disorder were advertised 
during the study period.  Advertisements for two of these drugs, Cymbalta and Pristiq, 
were placed in the same month and year in both black-oriented and white-oriented 
magazines.  Identical versions of a Pristiq ad were found in the November 2011 issues of 
Essence and Family Circle; the December 2011 issues of Ebony and Family Circle; the 
October 2011 issues of Essence and Family Circle, and the February 2012 issues of 
Essence and Good Housekeeping.  Different versions of an ad for Cymbalta were placed 
in the June 2008 issues of Ebony and Family Circle.  The ad that appeared in Ebony 
featured a black model, while the ad that appeared in Family Circle featured a white 
model. 
 Advertisements for two of the four drugs used to treat diabetes met the selection 
criteria.  Identical ads for Victoza appeared in the February 2011 issues of Family Circle 
and Ebony.  Different ad versions for Januvia appeared in the June 2008 issues of 
Ebony/Essence11 and Good Housekeeping.  In the version of the ad that appeared in 
Ebony and Essence, the featured model was Black.  In the version that appeared in Good 
Housekeeping, the featured model was White. 
 In the Respiratory category, four drugs were advertised in the same month and 
year in both white-oriented and black-oriented magazines.  Identical ads for Symbicort 
were found in the April 2012 issues of Ebony and Good Housekeeping.  Somewhat 
different ads for Symbicort appeared in the October 2012 issues of Ebony and Good 
Housekeeping.  Both included a human model whose race was neither Black nor White.  
The difference in the ad versions was associated with the placement of an offer for a free 
                                                          
11 The same ad version appeared in both Ebony and Essence in June 2008. 
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month’s prescription—in one version, the offer was placed on the opposing page; in the 
other version, it was placed on the same page. 
 Identical ads for Advair Diskus were found in the October 2008 issues of Good 
Housekeeping and Essence and the May 2009 issues of Ebony, Essence, and Family 
Circle.  Differing versions of Advair ads appeared in the July 2008 issues of Ebony and 
Good Housekeeping; the December 2009 issues of Ebony/Essence12 and Family Circle; 
and the May 2011 issues of Essence and Good Housekeeping.  Neither the July 2008 nor 
the December 2009 ads for Advair featured a human model of likeness.  The Advair ad 
published in the May 2011 issue of Good Housekeeping featured two human models, 
both of whom were White.  The version of the Advair ad that appeared in Essence that 
same month did not include a human model or likeness.   
 In only two cases (the June 2008 ads for Cymbalta and the June 2008 ads for 
Januvia) did ads for the same drug published in the same month and year appear to target 
the race of a magazine’s primary audience through their choice of human models.  
(Although these ads happened be published in the same month and year, we have to 
assume a coincidence since the drugs advertised have different manufacturers and 
different purposes.)  A closer examination of these ads, found in Figures 4-8 and 4-9 at 
the end of this chapter, reveals more subtle differences.  Figure 4-8 presents two 
advertisements for the diabetes drug, Januvia:  Figure 4-8a appeared in the June 2008 
issue of Ebony magazine, and Figure 4-8b appeared in the June 2008 issue of Good 
Housekeeping.  The most prominent difference in these two ads is the race of the models 
                                                          
12 The Advair ads that appeared in the December 2009 issues of Ebony and Essence differed in appearance, 
but neither featured a human model of likeness.  The version of the ad that appeared in Ebony also 
appeared in Family Circle. 
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used.  In the ad appearing in Ebony, the race of the primary model is Black.  
Interestingly, his two lunch companions are White.  They are all male and they all appear 
to be middle-aged.  In the ad that appeared in Good Housekeeping, the primary model is a 
White, middle-aged woman.  She is joined at lunch by two adult female companions, one 
of whom is White and one of whom is Black.  The ages of these women is less 
identifiable.   
 The layout of the ads is identical, as well as the majority of the text.  The key 
difference in text is the type of meal chosen.  In the ad that appeared in Ebony, the 
primary is eating a salad, and the tag line states, “Today, I chose salad and talked to my 
doctor.”  In the ad that appeared in Good Housekeeping, the primary model is eating fish, 
and the tag line states, “Today, I chose salmon and talked to my doctor.”  Note that in 
both ads, the lunch companions are eating high fat, high calorie meals thereby 
highlighting the primary models’ determination to eat more healthfully. 
 Figures 4-9a and 4-9b are advertisements for the antidepressant drug, Cymbalta.  
The ads are virtually identical, with the exception of the age and race of the model used.  
In the ad that appeared in the June 2008 issue of Family Circle, the model is an older 
white woman.  A younger, black woman is used in the ad version that appeared in the 
June 2008 issue of Ebony.  Most of the text is the same, although the ad appearing in 
Family Circle directs people to inform their doctors if they use nonsteroidal 
anti-inflammatory drugs (NSAID) pain relievers, aspirin, or blood thinners as they may 
lead to an increase in bleeding risk.  It is beyond the scope of this study to evaluate why 
this caution is included in one ad and not the other, but exploring such differences could 
be the focus of future research.  
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 This phase of the analysis was strictly exploratory.  Since no previous researcher 
had evaluated ads for the same drug placed in magazines of differing racial orientation, 
the methodology used was developed solely for this study.  Although limited to just a few 
advertisements, the results do suggest that drug companies tailor certain ads for their 
intended audience.  Future research will look at a larger variety of drug ads as well as 
expand the comparison period beyond a month.   
4.5.4  Limitations 
 Many of the limitations of this phase of the analysis are the same as those 
described in Chapter 3.  The study was limited to five magazine titles and four 
publication years.  The final publication year reviewed was 2012; it is possible that 
reviewing magazine issues published more recently would yield different results.   
 The study only looked at women’s magazines and focused on a single minority 
(Blacks).  Therefore, the findings cannot be generalized to other minorities or other 
magazine genres.  The study also only evaluated print advertisements.  No attempt was 
made to evaluate the appearance or content of DTCA that appeared on television or the 
World Wide Web.  Pharmaceutical advertising using these media outlets could be more 
targeted to the anticipated audience than that appearing in the magazine titles selected for 
review. 
 Establishing causality between the advertisements reviewed and the magazines in 
which they appeared was impossible.  While many of the ads that appeared in the 
black-oriented magazines featured black models, a number of ads that featured black 
models appeared only in white-oriented magazines and a number of ads that appeared in 
black-oriented magazines featured white models.  Although certain advertising 
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campaigns appeared to be targeted to black consumers, many did not.  Hence, it is 
possible, and perhaps even likely, that the appearance and content of a particular 
advertisement appearing in a specific magazine has more to do with the medication 
advertised than with the demographics of the magazine’s readership.  Thus, differences in 
ad appearance and content pre- and post-publication of the FDA may have more to do 
with the introduction of new drugs than with any other factor. 
 A limitation unique to this phase of the study is the use of subjective judgments 
inherent to any content analysis.  Although each unique ad was coded using an explicit 
code sheet and coding differences were settled by a third party, it is possible that some 
bias occurred.  However, the code sheet used was extremely detailed and provided 
specific examples of text that should be coded in a certain way to limit potential bias.   
 Finally, the number of unique ads coded (158) was relatively small compared to 
the entire universe of ads identified (1,090) (about 15 percent).  An ad was considered 
unique if it differed in any of its visual or textual elements or if it included a post card of 
other tear out that the reader could use to obtain additional information.  Limiting the 
number of ads to those promoting medications used to treat life-threatening conditions 
could skew the results in one direction or another.  On the other hand, the focus of this 
study is on the possible impact of DTCA on health disparities so it is less important that 
advertisements promoting contraceptives feature black models than advertisements 
promoting drugs used to treat cardiovascular disease.  In addition, certain ad versions 
appeared only once during the timeframe studied, while others appeared numerous times.  
Thus, a single ad version could bias a particular variable.  A larger number of ads would 
reduce the effect of an individual ad version on the overall results. 
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Figure 4-8a:  Advertisement for Januvia (Ebony, June 2008) 
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Figure 4-8b:  Advertisement for Januvia (Good Housekeeping, June 2008) 
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Figure 4-9a:  Advertisement for Cymbalta (Ebony, June 2008) 
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Figure 4-9b:  Advertisement for Cymbalta (Family Circle, June, 2008) 
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4.6  Conclusions 
 This chapter opened with a discussion of the theory that frames DTCA as a 
potential health promotion tool.  Social cognitive theory suggests that models used in 
advertising should reflect the appearance of those who the advertiser wishes to persuade.  
The results of this study indicate that pharmaceutical companies are continuing to do a 
good job aligning model race with the racial orientation of the magazines in which their 
ads are placed.  As found in previous research, black models are more likely to be 
featured in ads placed in black-oriented magazines, and white models are more likely to 
be used in ads placed in white-oriented magazines.  However, drug companies are 
missing an opportunity to positively impact the health of black Americans by limiting the 
amount of advertising for drugs to treat life-threatening conditions that they place in 
black-oriented magazines.  Although this study, unlike previous research, found that 
black models were used to advertise drugs in all disease categories of interest, ads for 
certain types of drugs, such as cardiovascular disease, did not appear in black-oriented 
magazines published in 2011 or 2012 (i.e., after publication of the FDA report).   
The health belief model tells us that people will take action if they believe that 
they are susceptible to a condition and that ignoring the condition will lead to serious 
consequences.  DTCA commonly identifies symptoms that the advertised drug is 
intended to treat and often indicates relief from these symptoms once the drug is taken.  
This information can serve to educate consumers and motivate them to seek out their 
health care professional (Mackert & Love, 2011).  Therefore, it is important that ads for 
drugs used to treat serious medication conditions be seen by those at risk. 
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 The health belief model also tells us that people will pursue a course of action if 
they believe “that the anticipated barriers (or cost of) taking action are outweighed by the 
benefits” (Glantz et al., 2002, p. 48).  Thus information about nondrug interventions and 
financial assistance may facilitate behavior change.  Ads that omit this information are 
less likely to fulfill their health promotion potential.   
The results of this study indicate that, in most cases, the content of the ad did not 
vary as a function of magazine genre or publication date.  Virtually all ads used a rational 
appeal, claiming the drug’s effectiveness in particular.  Most ads also made some sort of 
emotional appeal, either positive or negative or both.  The type of appeal used in an ad 
was found to be positively associated with the drug advertised rather than with either 
magazine genre or publication date. 
Almost all ads provided a telephone or Web site address, encouraged readers to 
talk to their healthcare providers about their symptoms, and offered financial assistance.  
Offers of patient support services and recommendations of alternative therapies were 
dependent on the drug advertised.  For example, the ad for the Exelon Patch, which is 
used to treat Alzheimer’s disease offered a Web site address to obtain additional 
caregiver resources; the ad for Aricept, another drug used to treat Alzheimer’s disease, 
did not.  Similarly, advertisements for Pristiq, a drug used to treat depression, were the 
only ones in this disease category to offer patient support services.  Nondrug 
interventions were mentioned in the majority of advertisements for drugs used to treat 
diabetes and cardiovascular disease, especially those used to treat high cholesterol, but in 
relatively few ads for drugs used to treat other medical conditions. 
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 The most noteworthy conclusion that can be drawn from this phase of the analysis 
relates to the impact of a regulatory requirement on ad content.  Although most ads 
published in 2008 and 2009 encouraged consumers to report negative side effects to the 
FDA, it was not until the FDA required pharmaceutical manufacturers to do so did a 
statement to this effect appear in nearly 100 percent of the ads evaluated.  This finding 
has important policy implications if DTCA is ever to be used effectively as a means to 
increase access to health information and reduce health disparities among minority and 
disadvantaged populations.   
 To further highlight the difference in responsiveness of pharmaceutical companies 
to a regulatory requirement versus a voluntary recommendation, let us contrast the 
number of ads that included a statement regarding the reporting of negative side effects to 
those suggesting alternative therapies.  The former was a requirement of the FDAAA of 
2007; the latter a recommendation in the 2009 report issued as a result of the FDAAA.  
As mentioned above, virtually 100 percent of the ads published in 2011 and 2012 
included the negative side effects statement.  In contrast, the number of ads placed in the 
white-oriented and crossover magazines that recommended alternative therapies actually 
declined over time, and the number of ads placed in black-magazines that included this 
information rose only slightly.  In any case, the percentage of ads that recommended 
alternative therapies was never greater than 55 percent, despite the fact that the PhRMA 
DTC Guiding Principles encourage pharmaceutical manufacturers to “include 
information about the availability of other options such as diet and lifestyle changes 
where appropriate for the advertised condition” (as quoted in Arnold & Oakley, 2013, p. 
510). 
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 Based on these results, we must conclude that the FDA report had no impact on 
the advertising decisions made by pharmaceutical companies in terms of the appearance 
or content of the ads placed in magazine read by black women, with one notable 
exception as discussed above.  Enhancing the educational and motivational value of 
DTCA, while a laudable goal, will require more than a set of recommendations in a 
report submitted to Congress.  Regulatory action may be the only way possible to assure 
that pharmaceutical manufacturers develop advertising campaigns that not only promote 
their product, but also positively impact the health outcomes of those who read their ads.   
 
 
 
 
CHAPTER 5:  CONCLUSIONS 
 
 
Disparities in health outcomes among various racial and ethnic groups persist in 
the United States.  While a myriad of reasons have been advanced to explain these 
differences, this dissertation focused on one—differences in access to health information 
delivered via DTCA placed in popular women’s magazines.  Pharmaceutical advertising 
offers a “vehicle that can provide important information in a pithy and purposive way to 
patients” (Kontos & Viswanath, 2011, p. 142).  Along with a high degree of awareness 
(Bell, Kravitz, & Wilkes, 1999; Weissman et al., 2003) comes the potential for DTCA to 
have a tremendous effect on its target audience (Kontos & Viswanath, 2011).  
Recognizing the health promotion possibilities of DTCA, the FDA issued a series of 
recommendations in a 2009 report to Congress aimed at enhancing the ability of these ads 
to reach disadvantaged populations.  This dissertation examined differences in 
pharmaceutical advertising published before and after these recommendations in terms of 
its frequency, appearance, and content.   
Within the constructs of the health belief model and social cognitive theory, 
well-designed pharmaceutical advertising can serve a health promotion function.  Typical 
ads include information designed to change individual perceptions about their 
susceptibility to a particular disease and the consequences of inaction.  Through various 
cues to action embedded within the ad (such as a tag line from a 2008 ad for Singulair 
which reads, “Is your asthma really under control or do you just think it is?”), as well as
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the repetitive nature of DTCA, consumers be compelled to seek out their health care 
providers.  Pharmaceutical companies further reinforce their messages by aligning the 
race of models used in their ads with the race of their intended audience.  Thus, ads 
appearing in magazines read predominantly by black women are more likely to feature 
black models than magazines read by white women (Mastin et al., 2007).  Advocates of 
DTCA highlight its potential to reduce the underdiagnosis and undertreatment of serious 
medical conditions (Ventola, 2011), while critics claim that, at a minimum, it manipulates 
consumers into seeking treatment for diseases they do not have (Finlayson & Mullner, 
2005).  At its worst, DTCA creates illnesses solely for the purpose of selling more pills 
(Moynihan & Henry, 2006).  While such concerns cannot be dismissed, this dissertation 
focuses on the potential of DTCA to improve health outcomes. 
The results of my research indicate that the pharmaceutical industry has yet to 
embrace the FDA recommendations.  Differences in advertising frequency between 
black- and white-oriented magazines persist.  Far more DTCA was placed in 
white-oriented magazines than in black-oriented magazines.  The amount of DTCA 
placed in O, The Oprah Magazine was more than in the black-oriented magazines, but 
less than in the white-oriented magazines.  Furthermore, there was little difference in the 
amount of advertising placed in black-oriented magazines published before the FDA 
report than after the report.   
 The types of drugs advertised and the medical conditions they treat were found to 
vary based on the racial orientation of the magazine.  Drugs that were advertised in both 
white-oriented and black-oriented magazines were more likely to treat serious medical 
conditions than previously reported.  However, only a small percentage of drugs 
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advertised are used to treat life-threatening conditions.  While the most prevalent drug 
advertised in the black-oriented magazines is used to treat diabetes (a disease that 
disproportionately affects black Americans), far fewer ads for cardiovascular drugs 
(another disease of particular concern for the black community) appeared in 
black-oriented magazines than in white-oriented magazines.  More troubling was the fact 
that no cardiovascular drug was advertised in black-oriented magazines in either 2011 or 
2012. 
 Pharmaceutical companies are continuing to do a good job aligning the race of 
models used in their ads with the race of a magazine’s primary audience.  Black models 
were more likely to be featured in ads placed in black-oriented magazines and white 
models were more likely to be used in ads placed in white-oriented magazines.  However, 
a number of ads that featured black models did not appear in black-oriented magazines.  
On the other hand, there was an increase in the number of ads that featured models that 
were either Hispanic, Asian, or Indian.  This is a positive trend, particularly if women of 
color identify with any nonwhite model.   
 Advertising appeals were dependent on the type of drug advertised rather than 
where the ad was place or the year in which it was published.  Virtually all ads included a 
rational appeal, most often touting the drug’s effectiveness.  The use of emotional appeals 
increased pre- and post-FDA report, but a closer examination of the data tied that 
increase to a rise in the number of antidepressant drugs advertised.  Ads for such drugs 
always included some sort of emotional appeal.   
 Few differences were observed in the other information contained within the 
pharmaceutical advertisements evaluated, regardless of magazine genre or publication 
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date.  The majority of ads included a Web site address, telephone number, and 
information concerning patient discounts or other financial assistance.  Virtually all ads 
recommended talking with a doctor or other healthcare provider, but only 40 percent 
suggested nondrug interventions.  A minority of ads provided information about patient 
support services.  Information about nondrug therapies and patient support services were 
dependent on the type of drug advertised. 
 The most significant difference in ad content was in the percentage of ads 
advising consumers to report adverse side effects to the FDA.  About 80 percent of ads 
published in 2008/2009 included this advice; by 2011/2012, nearly 100 percent contained 
language to this effect.  The reason for this change is clear.  The FDAAA of 2007 
mandated that print ads include the statement, “You are encouraged to report negative 
side effects of prescription drugs to the FDA.  Visit MedWatch, or call 1-800-FDA-1088” 
(FDA, 2012b). 
 Table 5-1, which appears at the end of this chapter, summarizes the research 
findings.  From a health policy perspective, the results are disappointing.  The FDA 
report recommendations had no impact on the advertising decisions made by 
pharmaceutical companies in terms of the frequency or content of DTCA.  While the 
industry does tend to use black models to advertise in black-oriented magazines, it has 
not increased the amount of advertising it does in these magazines and, in fact, has cut 
back on the number of ads it places that promote drugs used to treat the health issues of 
most concern to the black community.  Enhancing the educational and motivational value 
of DTCA, while a laudable goal, will require more than a set of recommendations in a 
report submitted to Congress.  The following section presents a series of policy remedies 
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that the FDA should consider if it is serious in its intent to shape DTCA in such a way 
that it can increase access to health information and decrease health disparities among 
racial and ethnic minority groups.   
5.1  Policy Recommendations 
 To date, the FDA has combined the typical command and control regulatory 
approach with “soft” regulations in the form of various guidance documents as a means 
of monitoring pharmaceutical advertising in this country.  The intent of these regulations 
is to ensure that pharmaceutical companies, in their efforts to promote their products, do 
not cause harm (Handlin, Mosca, Forgione, & Pitta, 2003).  Thus, the FDA requires that 
ads present both the benefits and risks of a drug in a balanced manner.  Ads may only 
state the FDA-approved use for the drug and may only make claims that are substantiated 
by scientific evidence or clinical experience.  And, as a result of the FDAAA of 2007, 
print ads must also include a statement encouraging consumers to report negative side 
effects to the FDA (FDA, 2012b). 
 The pharmaceutical industry has adopted a strategy of self-regulation when it 
comes to DTCA.  The Pharmaceutical Research and Manufacturers of America has 
adopted a series of guiding principles for DTCA consistent with FDA requirements.  
PhRMA member companies not only pledge to adhere to these principles, but also must 
certify their compliance (Arnold & Oakley, 2013).  Like the FDA regulations, the 
PhRMA guiding principles also require that DTCA clearly state the intended use of the 
medication, include a balanced presentation of its risks and benefits, and make only 
claims that are supported by a significant amount of evidence (Arnold & Oakley, 2013).  
Ads should also include information “about the availability of other options such as diet 
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and lifestyle changes where appropriate for the advertised condition”, and “include 
information…about help for the uninsured and underinsured” (as quoted in Arnold & 
Oakley, 2013, pp. 510–511).   
 Critics claim that the current regulatory approach, which relies in large part on the 
industry’s willingness to police itself, is not working (Government Accountability Office 
(GAO), 2006; Arnold & Oakley, 2013).  Despite evidence of regulatory violations, FDA 
issues few enforcement letters.  Those that are issued are often the result of months of 
internal agency deliberations.  In the meantime, the offending advertisement continues to 
run (GAO, 2006).  Similarly, Arnold and Oakley (2013) found numerous violations of the 
PhRMA guiding principles in their 4-year study of advertising for erectile dysfunction 
drugs.  Thus, neither formal agency regulations nor voluntary industry guidelines appear 
to exact responsible pharmaceutical advertising on a consistent basis.   
The results of the current study shed additional light on the industry’s compliance 
with both hard and soft regulations.  Information that is not required by regulation, such 
as information about nondrug interventions, appeared in less than 50 percent of the ads 
evaluated.  Arnold and Oakley (2013) found that no ad in their study provided 
information about nondrug options for erectile dysfunction.  The number of ads that 
included a telephone number also declined significantly over time.  On the other hand, 
the number of ads compliant with the FDA’s requirement to include a statement 
encouraging consumers to report negative side effect increased to nearly 100 percent in 
ads published in 2011 and 2012.  This result suggests that regulatory action may be 
necessary to ensure that pharmaceutical manufacturers develop advertising campaigns 
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that not only promote their product, but also positively impact the health outcomes of 
those who read their ads. 
Rather than recommending a strict command and control regulatory approach, I 
believe that the FDA should establish a program of voluntary agreements with 
pharmaceutical companies to increase their use of help-seeking advertising campaigns 
and to enhance the educational value of their product claim advertising.  These 
collaborative agreements between regulatory agencies and private companies have been 
used by the U.S. Environmental Protection Agency (EPA) to reduce the release of toxic 
chemicals and greenhouse gas emissions (Delmas & Terlaak, 2001).  Participating 
companies submit plans to their state regulators and the EPA based on their own 
pollution reduction targets; regulators offer these firms financial support and technical 
assistance.  The advantage to the private sector of these agreements is less regulatory 
burden; the advantage to public sector is a less confrontational and less costly way of 
achieving its goals (Delmas & Terlaak, 2001). 
While certain enhancements to DTCA could and should be achieved through 
regulation (such as the provision of a telephone number, information about nondrug 
interventions, and offers of financial assistance), mandating too many specifics may not 
be practical given the dependence of ad content on the unique attributes of the drug being 
advertised.  In addition, the FDA cannot insert itself into the advertising practices of a 
pharmaceutical company lest it be accused of endorsing one drug over another.  A key 
role of the FDA is to ensure the drug safety; it cannot be seen as colluding with industry 
to promote their products.  However, the FDA could work actively and collaboratively 
with drug companies to improve the health literacy aspects of DTCA rather than relying 
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on the industry to voluntarily adopt agency guidelines and recommendations into their 
advertising campaigns.  To better reach disadvantaged populations, the FDA could assist 
companies in developing help-seeking advertisements that provide valuable information 
about medical conditions of particular importance to the targeted community.  The 
industry could commit to targeting a certain percentage of both their help-seeking and 
product claim ads to at-risk populations, which would likely result in less criticism of 
their motives and advertising practices.  Rather than using its self-regulation strategy as a 
means of blocking more stringent regulatory action (Arnold & Oakley, 2013), the 
industry should demand more of its members and aggressively promote high-quality, 
responsible advertising that provides valuable health information to consumers.   
5.2  Study Limitations 
 The current study has several limitations.  Only five magazine titles and four 
years were selected for review.  A lag period of 15 months between the publication of the 
FDA report in September 2009 and the first magazine issue considered post-publication 
of the FDA report was considered adequate.  It is possible that pharmaceutical companies 
were adjusting their ongoing ad campaigns well into 2011 and that reviewing magazine 
issues published in 2013 would have yielded different results. 
 The study focused on a single minority (Blacks) and evaluated only magazines 
read by women.  Therefore, the findings cannot be generalized to other minorities, such 
as Hispanics and Asians, or to other magazine genres, such as entertainment or news.  It 
is possible that pharmaceutical companies place much of their advertising directed to 
black readers in magazines other than Ebony and Essence, although circulation figures 
and previous research would not suggest this.  Furthermore, because this study only 
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evaluated print ads, pharmaceutical companies may have increased their advertising to 
minority populations after publication of the FDA report using other media outlets, such 
as television or the Internet.   
 While the analysis discusses results in the context of pre- and post-FDA report 
publication, causality between the report and any decrease in advertising frequency or 
seemingly negative changes in advertising content (e.g., the lack of cardiovascular ads in 
black-oriented magazines published in 2011 and 2012) is not presumed.  Companies 
make advertising decisions for a variety of reasons.  To some extent, the data collected 
represent the natural ebb and flow of advertising—advertising shifts away from older 
drugs as new drugs enter the market.  Therefore, it is important not to construe the lack of 
change in DTCA frequency, appearance, and content as an intentional rejection of the 
report’s recommendations. 
 Finally, the focus of the study is on the appearance and content of the 
advertisement, rather than on its effects.  No attempt was made to evaluate the 
effectiveness of the advertisement in motivating consumer behavior, the appropriateness 
of the information conveyed in the advertisement, or how that information is understood 
by the consumer.   
5.3  Next Steps 
 This study represents the most recent compilation of data on the frequency and 
content of pharmaceutical advertising.  The data set developed is larger than most used 
by previous researchers, both in terms of the number of magazine issues reviewed and the 
amount of advertisements identified.  Furthermore, it is the only data set that compiles 
data on not only ad placement, but also on the visual and written characteristics of the 
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individual ads.  Thus, it is a rich data set that can be used to examine multiple dimensions 
of the DTCA included.   
In doing my analysis, I noticed a number of interesting trends in the data that are 
worthy of further research.  For example, no advertisements for drugs to treat overactive 
bladder appeared in any of the 96 issues of Ebony or Essence reviewed, although ads for 
these types of drugs appeared frequently in Family Circle and Good Housekeeping. 
Given that overactive bladder may be considered a medicalized condition, it would be 
interesting to determine whether advertising for other medicalized conditions vary based 
on the racial orientation of the magazine in which it appears.  And if it does, what are the 
policy implications of such a finding? 
 Two models underpin this and previous studies of DTCA.  The health belief 
model and social cognitive theory each have elements that can be used to explain the 
health promotion potential of DTCA.  While working on this dissertation, I began to 
develop a new model that synthesized various aspects of these two models into a single, 
innovative framework to better explain the interaction of DTCA and consumer behavior.  
Further research would look at ways to test and refine this model with the goal of one day 
creating a model that could be used as a basis for future studies. 
 I also intended to look at the health literacy aspects of DTCA.  As I conducted my 
literature review, I found numerous studies that had evaluated the health literacy demands 
of DTCA, all of which concluded that much of the information provided in these ads is 
well beyond the ability of most consumers to understand.  I quickly realized that I would 
not be able to contribute to the literature in this area within the scope of the current study.  
However, I envision a future study using the same database that focuses exclusively on 
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health literacy and evaluates the use of visual cues, such as inanimate objects, font size, 
and color selection, and written cues in the form of tag lines and slogans, to communicate 
information in a more user-friendly manner. 
 DTCA is embedded in our culture.  Further research should focus more on ways 
to improve its value as a health promotion tool and less on its shortcomings in an effort to 
curtail its use.  The potential is there—one only has to determine ways to marry the 
financial interests of the pharmaceutical industry with the broader healthcare goals of the 
policymakers. 
Table 5-1:  Summary of Research Findings 
 
Research Question Findings Policy Recommendations 
RQ1:  Does the frequency 
of pharmaceutical 
advertising vary based on 
the racial orientation of the 
magazine? 
The amount of DTCA in 
white-oriented magazines 
is significantly greater than 
in black-oriented 
magazines. 
Despite the FDA 
recommendations, the 
pharmaceutical industry 
has not increased its 
outreach to readers of 
black-oriented magazines.   
The lack of DTCA in 
black-oriented magazines 
perpetuates disparities in 
access to health 
information.   
 
The FDA should enter into 
voluntary agreements with 
pharmaceutical companies 
to increase the number of 
help-seeking ads placed in 
black-oriented magazines. 
RQ2:  Did the frequency of 
pharmaceutical advertising 
appearing in black-oriented 
women’s magazine 
increase following the 
2009 FDA report? 
The amount of DTCA in 
black-oriented women’s 
magazines did not increase 
significantly following the 
2009 FDA report. 
  
174 
 
 
Table 5-1: (continued) 
 
Research Question Findings Policy Recommendations 
RQ3:  Do the types of 
drugs advertised vary by 
the racial orientation of the 
magazine? 
The types of drugs 
advertised varied by the 
racial orientation of the 
magazine.  The drugs 
advertised most prevalently 
in black-oriented 
magazines are used to treat 
diabetes, depression, and 
asthma.  The most popular 
drugs advertised in white-
oriented magazines are 
used to treat ADHD, 
asthma, depression, 
postmenopausal 
osteoporosis, and vaginal 
dryness. 
The most frequently 
advertised drugs in black-
oriented magazines are 
used to treat significant 
health risks.  This finding 
differs from the work of 
previous researchers and 
represents a positive trend.  
However, the observed 
reduction in the amount of 
advertising for drugs used 
to treat medical conditions 
of particular concern to 
black Americans (such as 
cardiovascular disease) 
could negatively impact the 
health outcomes of ethnic 
and racial minorities. 
 
The FDA should enter into 
voluntary agreements with 
pharmaceutical companies 
to develop and implement 
help-seeking ad campaigns 
for medical conditions of 
particular concern to black 
Americans.  
RQ4:  Have the types of 
drugs advertised become 
more concordant with the 
health risks of the race of 
the magazine’s readers 
following the 2009 FDA 
report? 
DTCA published after the 
2009 FDA report was less 
concordant with the race of 
the magazine’s readers 
than DTCA published 
before the report.  In 
particular, cardiovascular 
drugs, which were the third 
most common drug 
advertised in black-
oriented magazines 
published before the 2009 
FDA report, were not 
advertised in any issue of 
the black-oriented 
magazines published in 
either 2011 or 2012.  
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Table 5-1: (continued) 
 
Research Question Findings Policy Recommendations 
RQ5:  Does the race of the 
models used in DTCA vary 
based on the racial 
orientation of the 
magazine? 
The race of the models 
used in DTCA varies based 
on the racial orientation of 
the magazine.  White 
models were more likely to 
be featured in ads placed in 
white-oriented magazines, 
and black models were 
more likely to be featured 
in ads placed in black-
oriented magazines. 
Social cognitive theory 
suggests that consumers 
are more likely to 
positively react to ads that 
feature models of the same 
race.  Thus, seeing a drug 
ad that features a black 
model is more likely to 
motivate a black reader to 
seek treatment than an ad 
featuring a white model, all 
else being equal.  Positive 
alignment between model 
ads and the race of a 
magazine’s readers may 
reduce health disparities.  
 
No change in policy is 
needed. 
RQ6:  Did the percentage 
of advertisements featuring 
black models increase 
following the FDA report? 
No statistically significant 
change in the percentage of 
ads featuring black models 
was detected in DTCA 
published before the FDA 
report versus that published 
after the report. 
It appears that the 
pharmaceutical industry 
has not increased its 
outreach to black readers 
of women’s magazines, 
regardless of their racial 
orientation.   
 
The FDA should 
implement voluntary 
agreements with the 
pharmaceutical industry to 
increase its outreach to 
black Americans.  These 
agreements could include a 
commitment to increase the 
use of black models in ad 
campaigns.  
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Table 5-1: (continued) 
 
Research Question Findings Policy Recommendations 
RQ7:  Does the provision 
of information about 
nondrug interventions vary 
based on the racial 
orientation of the 
magazine? 
Fewer than 50 percent of 
the ads reviewed included 
information about nondrug 
interventions.  The 
provision of this 
information varied based 
on the type of drug 
advertised rather than the 
racial orientation of the 
magazine in which the 
drug appeared.  Ads for 
drugs used to treat high 
cholesterol, diabetes, and 
depression were more 
likely to include this 
information than ads for 
other types of drugs.  
However, this information 
was not consistently 
provided—an ad for one 
antidepressant medication 
mentioned nondrug 
therapies while an ad for 
another did not.   
Despite the FDA 
recommendation to include 
this information, as well its 
own guiding principles, the 
industry has not been 
successful in alerting 
consumers to possible 
nondrug interventions in its 
advertising.  Such 
information can be an 
important cue to action and 
has important educational 
value. 
 
The FDA should mandate 
that this information be 
included in all 
pharmaceutical advertising.   
RQ8:  Did the percentage 
of advertisements that 
include information about 
nondrug interventions 
increase following the 
2009 FDA study? 
No statistically significant 
increase in the percentage 
of advertisements 
including information 
about nondrug 
interventions was detected.   
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Table 5-1: (continued) 
 
Research Question Findings Policy Recommendations 
RQ9:  Does the provision 
of information about 
available discounts or 
patient assistance programs 
vary based on the racial 
orientation of the 
magazine? 
The majority of ads 
evaluated included some 
form of discount or patient 
assistance program, 
whether it be a free trial, a 
discounted prescription 
rate, or referral to a 
program to assist low 
income or uninsured 
individuals in getting their 
medications.  The 
provision of this 
information did not vary 
based on the racial 
orientation of the 
magazine. 
These findings suggest that 
the pharmaceutical 
industry has is following 
both the FDA 
recommendations and its 
own guiding principles in 
with regard to this 
information.  In addition, it 
appears that the industry 
has increased its outreach 
to readers of black-oriented 
magazines through 
prescription discounts and 
other financial assistance.  
However, it is impossible 
to conclude whether this 
finding represents an 
intended effort to make 
drugs more accessible to 
these readers or a tool to 
promote a particular drug. 
 
Lack of financial resources 
can be a key barrier in 
obtaining medication and 
continuing a medication 
regime.  The FDA should 
mandate that drug ads 
include information to 
assist low-income 
individuals in obtaining 
their prescribed 
medications. 
RQ10:  Did the percentage 
of advertisements that 
include information about 
available discounts or 
patient assistance programs 
increase following the 
2009 FDA study 
A statistically significant 
increase in the number of 
advertisements placed in 
black-oriented magazines 
that offered financial 
assistance was observed 
over time. 
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APPENDIX A:  CODE SHEETS 
 
 
MAGAZINE CODE SHEET 
 
ID #: _________________________________________________________________________  
 
Magazine Name: _______________________________________________________________  
 
Publication Date: _______________________________________________________________  
 
Number of Pages: ______________________________________________________________  
 
Number of Advertising Pages: _____________________________________________________  
 
Number of DTCA Pages: __________________________________________________________  
 
Percent of Advertising Pages: _____________________________________________________  
 
Percent of DTCA: _______________________________________________________________  
 
NON-DTCA ADVERTISING 
 
Full Page Half Page 
 
 
 
 
 
 
DTCA ADVERTISING 
 
Full Page Half Page 
 
187 
 
 
ADVERTISEMENT CODE SHEET 
 
Coder Name: __________________________________________________________________  
 
Advertisement ID # _____________________________________________________________  
 
 
TYPE OF DRUG 
 
 
Drug Name: ___________________________________________________________________  
 
 
Medical Condition Used to Treat: __________________________________________________  
 
 
Manufacturer: _________________________________________________________________  
 
 
SIZE OF AD 
 
# Pages (Promotional): ___________________________________________________________  
 
# Pages (Brief Summary): _________________________________________________________  
 
AD APPEARANCE 
 
 
Does the ad use human models? 
 
  Y  N 
 
Does the ad use a cartoon character? 
 
  Y  N 
 
Does the ad use an inanimate object? 
 
  Y  N 
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ADVERTISEMENT CODE SHEET (continued) 
 
DEMOGRAPHICS OF HUMAN MODELS 
 
 
How many human models does the ad feature: _______________________________________  
 
 
Is the race of the models distinguishable? 
 
 
  Y  N 
 
 
For each model used, identify the race, gender, and approximate age in the table below.  Code 
models from left to right.  Circle the number of the primary model used in the ad. 
 
 
Model Race Gender Age 
 W B O M F Child Adult Senior 
1         
2         
3         
4         
 
 
W = White 
B = Black 
O = Other 
U = Unknown 
 
M = Male 
F = Female 
U = Unknown 
 
Child = < 18 years of age 
Adult = 18 to 64 years of age 
Senior = 65+ year of age 
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ADVERTISEMENT CODE SHEET (continued) 
 
AD APPEALS 
 
Is there a rational appeal (e.g., does the ad describe how the drug is to be used, does the ad list 
the drugs benefits, does the ad compare one drug to another, does the ad include statistics)?  
 
  Y  N 
 
Using the following taxonomy, identify the types of rational appeals used based on the words 
that appear in the ad: 
 
Claimed Attribute Description of Drug Yes No 
Effectiveness 
Effective “effective,” has a “proven” therapeutic benefit, 
“works” 
  
Cure Provides a “cure” for condition   
Dependable “reliable,” “dependable”   
Innovative “advancement,” “breakthrough,” “a first,” “new,” 
“novel,” “only” drug of kind, “innovative” 
  
Powerful “potent,” “powerful,” “strong”   
Prevention “prevents,” offers “prevention of” condition   
Reduced mortality “prolongs life,” “saves lives,” “prevents death”   
Symptom control “controls” or “manages” symptoms, brings symptoms 
“under control” 
  
Social-Psychological Enhancements 
Lifestyle Allows for a more “active,” “regular,” “normal,” “free,” 
or “flexible” life 
  
Psychological Increases feelings of “confidence,” “sureness,” 
“happiness,” “hope,” “relieves fears” 
  
Social Enhances the “attractiveness” or “appearance” of the 
user 
  
Ease of Use 
Convenience “convenient,” “easy,” “simple” to use, “infrequent” 
dosage or “short-term” use required 
  
Easy on system “gentle” on the user, “good tasting”   
Economical “economical,” “cost-beneficial,” or “saves money”   
Quick acting works “quickly,” “fast,” “rapidly,” “speedily”   
Safety 
Safe “safe,” leaves the system quickly, is a “reversible” 
treatment, “approved,” “FDA-approved” 
  
Natural Works “naturally,” works like your own body does, 
made of natural agents 
  
Nonaddictive “nonhabit forming” or “nonaddictive”   
Nonmedicated Does not make one feel “drowsy,” “sleepy,” 
“medicated,” “drugged,” or “spacey 
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ADVERTISEMENT CODE SHEET (continued) 
 
Is there a positive appeal (e.g., does the ad convey a sense of happiness, warmth, pride, joy, 
caring, humor, sex, fantasy, or nostalgia)? 
 
 
  Y  N 
 
 
Is there a humor appeal (e.g., does the ad use puns or satire)? 
 
 
  Y  N 
 
 
Is there a nostalgic appeal (e.g., does the ad include images from earlier time periods, is the ad 
printed in black or white or use sepia tones)? 
 
 
  Y  N 
 
 
Is there sex appeal (e.g., are the characters portrayed in an intimate encounter, scantily clad, 
wearing revealing clothing, or using provocative gestures? 
 
 
  Y  N 
 
 
Is there a negative appeal (e.g., does the ad invoke a sense of fear, anger, regret, sadness, guilt, 
or shame? 
 
 
  Y  N 
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ADVERTISEMENT CODE SHEET (continued) 
 
OTHER INFORMATION 
 
Is the reader offered help in finding patient support services? 
 
  Y   N 
 
Is the reader referred to a Web site for additional information? 
 
  Y  N 
 
Is the reader given a telephone contact for additional information? 
 
  Y  N 
 
Is the reader encouraged to talk with a doctor or another individual? 
 
  Y  N 
 
Is the reader offered monetary incentives or other financial support? 
 
  Y  N 
 
Is the reader informed of nondrug interventions, such as diet and exercise, which might be 
helpful? 
 
Y  N 
 
Does the ad encourage the reader to report negative side effects of prescription drugs to the 
FDA?      
 
  Y  N 
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APPENDIX B:  SUMMARY OF PREVIOUS CONTENT ANALYSES OF  
DIRECT-TO-CONSUMER ADVERTISING IN MAGAZINES 
 
 
 This appendix summarizes the work of previous researchers that contributed to 
the design of the study reported in this dissertation.  With one exception (Kean & 
Prividera, 2007), this research examined direct-to-consumer advertising (DTCA) found in 
a broad range of magazine genres.  These studies evaluated the content of the 
advertisements and compared differences in their appearance, the types of drugs 
advertised, and the kinds appeals used.  Some studies specifically compared ads based on 
the racial orientation of the magazine, while others made more general comparisons.  
Taken together, these studies reveal trends in DTCA over a period of nearly 20 years. 
 The following paragraphs provide a brief overview of each study.  Table B-1 
includes more detailed information about the sample size, methods used, and conclusions 
reached.   
Abel, Lee, and Weeks (2007):  This study focused on the advertising of pharmaceuticals 
to treat cancer or the effects of chemotherapy in both patient-oriented oncology 
magazines, as well as the popular press.  Selected issues of 10 popular magazines and all 
issues of four cancer magazines published between January 2003 and January 2006 were 
reviewed.  Researchers looked at not only the advertising prevalence of cancer-related 
drugs, but also the readability of such advertisements.  Not surprisingly, fewer 
advertisements for cancer-related drugs appeared in the popular press than in the 
patient-oriented oncology magazines, and the ads that did appear tended to be placed in 
women’s magazines.  Abel et al. also found that all of the information provided in the 
advertisements was hard to understand.  While other researchers have considered this to
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 be a net negative of DTCA, Abel et al. advance the idea that such intelligibility could be 
considered an asset by encouraging patients to discuss more fully the advantages and 
disadvantages of certain treatment options.   
Bell, Kravitz, and Wilkes (2000):  This early content analysis reviewed DTCA in 
13 magazine categories, as well as five publications targeted to a particular population 
based on ethnicity, age, and sexual orientation.  Advertisements appearing in these 
magazines between the years 1989 and 1998 were evaluated for trends in the drugs 
advertised, inducements offered, and appeals used.  Not surprisingly, the researchers 
found a dramatic increase in the amount of advertising over the study period.  Nearly a 
third of the ads were for drugs used to treat life-threatening conditions, and the vast 
majority of ads were aimed at the potential user of the drug, rather than a parent, spouse, 
or adult child.  Nearly a quarter of the ads were directed at women exclusively.  Most 
advertisements offered additional information, and a few offered monetary incentives.  In 
terms of appeals used, two-fifths of the ads characterized the product as innovative, while 
the notion of cost savings was rarely mentioned. 
Cline and Young (2004):  This study focused on the visual cues found in print 
advertisements placed in 18 popular magazines during the two-year period between 
January 1998 and December 1999.  Variables included the presence or absence of people; 
the number of people depicted; the age, ethnicity, and gender of each person depicted; the 
way in which people were depicted—either in a photograph or as a drawing or cartoon 
figure; whether the person appeared friendly, healthy, or active, and the social and 
relational context of the people depicted.  The researchers found that the models used in 
advertising were likely to appear active, healthy, and friendly.  They also found that the 
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advertisements reinforced gender stereotypes, with half the ads focusing on a woman’s 
reproductive capacity.  Advertisements for psychiatric products also tended to feature 
women.  African Americans did not appear in ads for drugs to treat cancer- and 
cardiovascular-related conditions, respiratory ailments, or psychiatric-neurological 
illnesses.  They also did not appear in ads promoting smoking cessation products.  On the 
other hand, ads for HIV/AIDS drugs more often than not featured African American or 
Hispanic models.  Few ads featured older people.  These results led the researchers to 
conclude that the visual cues in DTCA may perpetuate existing disparities in access to 
health care and health information. 
Crawley, Hisaw, and Illes (2009):  In this study, the researchers examined six magazines, 
representing three genres, for a six-month period between September 2005 and February 
2006.  Magazines in each genre were matched in terms of their target audience:  general 
audience versus African American audience.  The analysis included both prescription 
drug and over-the-counter product advertisements.  Variables included magazine genre, 
magazine racial/ethnic orientation, medical condition, advertisement type, FDA 
regulatory designation, and ad size.  A multiple correspondence analysis was used to 
explore placement patterns of advertising between the general audience and African 
American magazines.  Crawley, Hisaw, and Illes found little difference between the two 
magazine groups in terms of the total volume of advertisements placed.  However, they 
did find significant differences in the types of products advertised, with drugs for mental 
health conditions and serious life-threatening conditions corresponding to the general 
audience magazines while drugs for chronic non-life-threatening conditions and 
infectious disease corresponding to the African American magazines.  
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Duerksen et al. (2005):  In this study, Duerksen et al. examined the health-related 
advertising that appeared in the June, July, and August 2002 issues of 12 separate 
women’s magazines.  Advertisements were grouped into 48 categories, including health 
promotion products, products that could negatively affect health, food and nonalcoholic 
beverages, and products with mixed health impact.  The race/ethnicity of the models 
appearing in each advertisement was noted.  The study found that magazines targeted to 
African American or Hispanic audiences included more ads promoting products with 
potentially negative health consequences (i.e., health-diminishing products) than did 
magazines targeted to a more general audience.  Furthermore, ads promoting such 
products were more likely to use African American models than Caucasian models.  In 
contrast, general audience magazines included more advertisements for health-promoting 
products than for health-diminishing products, and health-promoting products were more 
likely to be advertised using Caucasian models. 
Kean and Prividera (2007):  This study did not evaluate DTCA, but instead compared 
advertisements for consumables, such as food, drink, vitamins, and supplements, found in 
two selected magazine titles: one targeted to an African American audience and one 
targeted to a more general readership.  The researchers evaluated all issues of these two 
magazines published between January 2004 and December 2004.  Kean and Prividera 
were particularly interested in the types of products advertised, the product claims made, 
and the appearance of the models used in the ads.  They found differences in the types of 
products advertised (more fast food ads appeared in the African American audience 
magazine), the claims made (a greater number of advertisements for weight loss products 
or making weight loss claims appeared in the magazine aimed at a more general 
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readership), and models used (the advertisements placed in the magazine targeted to an 
African American audience included more African American models while 
advertisements appearing in the magazine aimed at a more general readership included 
more Caucasian models). 
Mackert and Love (2011):  In this study, Mackert and Love investigated the content of 
DTCA within the context of the health belief model and evaluated the challenges to 
health literacy posed by such content.  Twenty magazines, representing a broad range of 
topic areas and target audiences, were chosen, and the issues of those magazines 
published between January and March 2007 were examined.  Although this study did not 
look specifically at racial disparities in advertising, the researchers did note that nearly 
half the advertisements featured Caucasian models, while only 20 percent featured 
African American models.  The researchers also found that the messages included in the 
advertisements reviewed did provide valuable medical and social information, but lacked 
some equally important information, such as statements regarding disease prevalence.  
However, Mackert and Love raised a concern regarding the ability of low literacy 
audiences to fully understand an advertisement’s intended message, but offered strategies 
for increasing the educational potential of DTCA. 
Main, Argo, and Huhmann (2004):  This study focused on the types of appeal and the 
appearance of the models used in DTCA, as well as advertisements for over-the-counter 
remedies and dietary supplements.  Magazines from seven different categories were 
selected (for a total of 30 magazines), and the December issues for years 1998, 1999, and 
2000 were chosen for study.  In examining the visual images and headline of each 
advertisement, the researchers found that most DTCA relies on an emotional appeal 
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rather than a rational appeal.  They also found that the DTCA evaluated featured fewer 
women, more children, and more white models than the nonpharmaceutical advertising. 
Mastin, Andsager, Choi, and Lee (2007):  This study looked specifically at how DTCA 
targets particular audiences by evaluating pharmaceutical advertisements placed in four 
magazine genres (African American, entertainment, news, and women’s) published 
during the period 1992 to 2002.  Variables included drug purpose, model race/ethnicity, 
and model gender.  The researchers found that most of the ads featured Caucasian models 
only; however, those ads placed in African American magazines were more likely to 
feature African American models.  They also discovered that while DTCA increased 
dramatically during the time period, the vast majority of the increase was found in those 
magazines targeted to African Americans and women.  In terms of the types of drugs 
advertised, Mastin et al. found little connection between the products promoted and the 
conditions likely to be a concern for the targeted population.  For example, African 
Americans are more likely to die from heart disease than Caucasians, but there were far 
fewer ads for heart medication in the magazines aimed at an African American audience 
than there were in those magazines targeted at women.   
Omonuwa (2001):  Omonuwa evaluated the DTC advertising in 10 popular magazines 
during the period of June to August 2000.  Five of the magazines were oriented to 
African American audiences and five were oriented to white audiences.  Omonuwa found 
a significant difference in the number of DTC advertisements between the two sets of 
magazines.  Those magazines oriented to white audiences contained four to eight times 
more DTC advertisements than magazines oriented to black audiences. 
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Pinto (2000):  Another early content analysis of DTCA, this study examined the type of 
appeals used in DTCA found in a random sample of magazine issues published between 
March 1996 and February 1998.  Twenty-four popular magazines, representing 
12 publication categories, were included in the study.  Pinto found that DTCA uses all 
types of appeal (fear, humor, guilt, sex, relational, and information), and many ads rely 
on both informational and emotional appeals.  Furthermore, the type of appeal did not 
vary with the type of drug being advertised. 
Sokol, Wackowski, and Lewis (2010):  This study reviewed the monthly issues of five 
popular women’s magazines published between July 2005 and June 2006.  Variables 
were related to the target audience of the magazine (in terms of age), the type of 
advertisement (product claim, help seeking, or reminder), the health condition for which 
the advertised drug was intended, the type of appeal used in the advertisement (logic, 
fear, emotion, humor), the type of evidence presented (testimonials, quantitative or 
narrative information, and eyewitness statements), and the characteristics of the models 
used in the advertisement.  The researchers found that the frequency of advertising, the 
types of drugs advertised, and the types of appeals and information presented varied 
depending on whether the magazine was aimed at an older or younger audience.  Sokol et 
al. also found that those magazines targeted at an older audience included advertisements 
for medications to address not only women’s health conditions, but although those more 
common to men and children.  
Woloshin, Schwartz, Tremmel, and Welch (2001):  This early content analysis of DTCA 
reviewed DTCA in a total of 10 magazines within three categories of readers:  men, 
women, and the general population.  Seven issues of each magazine title were evaluated.  
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Publication dates ranges from July 1998 to July 1999.  The study looked at both 
advertisement frequency and advertisement content.  Researchers found that DTCA was 
least common in men’s magazines and most common in women’s magazines.  The types 
of products advertised also varied by magazine genre, with hair products advertised most 
frequently is men’s magazines and medications to relieve allergy symptoms advertised 
most often in women’s magazines and magazines with a general readership.  In terms of 
content, much of the DTCA evaluated provided quantitative data on a drug’s possible 
side effects, but very little provided quantitative data on a drug’s benefits. 
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is
in
g 
th
an
 m
ai
n
st
re
am
 m
ag
az
in
e
s.
 
 
 
In
 A
fr
ic
an
 A
m
er
ic
an
 m
ag
az
in
es
, a
d
ve
rt
is
em
en
ts
 p
ro
m
o
ti
n
g 
h
ea
lt
h
-
d
im
in
is
h
in
g 
p
ro
d
u
ct
s 
w
er
e 
m
o
re
 li
ke
ly
 t
o
 in
cl
u
d
e 
an
 A
fr
ic
an
 
A
m
er
ic
an
 m
o
d
el
 t
h
an
 a
 C
au
ca
si
an
 m
o
d
el
.  
 
 
C
au
ca
si
an
 m
o
d
el
s 
w
er
e 
ra
re
ly
 u
se
d
 t
o
 p
ro
m
o
te
 h
ea
lt
h
-d
im
in
is
h
in
g 
p
ro
d
u
ct
s,
 b
u
t 
w
er
e 
fr
e
q
u
en
tl
y 
u
se
d
 t
o
 a
d
ve
rt
is
e 
h
ea
lt
h
-p
ro
m
o
ti
n
g 
p
ro
d
u
ct
s.
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T
ab
le
 B
-1
: 
 (
co
n
ti
n
u
ed
) 
A
u
th
o
r 
Sa
m
p
le
 
M
et
h
o
d
 
D
is
cu
ss
io
n
 
K
ea
n
 a
n
d
 P
ri
vi
d
er
a 
(2
0
0
7
) 
O
n
e 
m
ag
az
in
e 
ta
rg
et
e
d
 t
o
 a
n
 
A
fr
ic
an
 A
m
er
ic
an
 a
u
d
ie
n
ce
 
m
at
ch
ed
 t
o
 o
n
e 
ge
n
er
al
 r
ea
d
e
rs
h
ip
 
(m
ai
n
st
re
am
) 
m
ag
az
in
e
 
**
*
 
O
n
ly
 a
d
ve
rt
is
em
e
n
ts
 f
o
r 
co
n
su
m
p
ti
o
n
 p
ro
d
u
ct
s 
co
n
si
d
er
e
d
 
**
*
 
Ja
n
u
ar
y 
2
0
0
4
–D
ec
em
b
er
 2
0
0
4
 
**
*
 
1
4
1
 a
d
s 
in
 t
h
e 
A
fr
ic
an
 A
m
er
ic
an
 
m
ag
az
in
e
 
2
1
5
 a
d
s 
in
 t
h
e 
m
ai
n
st
re
am
 
m
ag
az
in
e
 
A
ss
e
ss
e
d
 t
h
e 
ty
p
e 
o
f 
p
ro
d
u
ct
 
ad
ve
rt
is
ed
 a
n
d
 t
h
e 
cl
ai
m
s 
m
ad
e 
ab
o
u
t 
th
e 
p
ro
d
u
ct
. 
**
*
 
Ev
al
u
at
ed
 t
h
e 
ch
ar
ac
te
ri
st
ic
s 
o
f 
th
e 
m
o
st
 p
ro
m
in
en
t 
m
o
d
e
l u
se
d
 
in
 t
h
e 
ad
. 
 
M
o
re
 f
as
t 
fo
o
d
 a
d
s 
ap
p
ea
re
d
 in
 t
h
e 
A
fr
ic
an
 A
m
er
ic
an
 m
ag
az
in
e 
th
an
 in
 t
h
e 
m
ai
n
st
re
am
 m
ag
az
in
e
. 
 
 
M
o
re
 a
lc
o
h
o
l a
d
s 
ap
p
ea
re
d
 in
 t
h
e 
m
ai
n
st
re
am
 m
ag
az
in
e 
th
an
 in
 
th
e 
A
fr
ic
an
 A
m
er
ic
an
 m
ag
az
in
e;
 a
lc
o
h
o
l w
as
 t
h
e 
p
ro
d
u
ct
 m
o
st
 
ad
ve
rt
is
ed
 in
 t
h
e 
m
ai
n
st
re
am
 m
ag
az
in
e.
 
 
 
N
o
 a
d
s 
fo
r 
w
ei
gh
t 
lo
ss
 s
u
p
p
le
m
e
n
ts
 o
r 
p
ro
d
u
ct
s 
ap
p
ea
re
d
 in
 t
h
e 
A
fr
ic
an
 A
m
er
ic
an
 m
ag
az
in
e.
 
 
 
O
n
e-
th
ir
d
 o
f 
ad
s 
in
 t
h
e 
A
fr
ic
an
 A
m
er
ic
an
 m
ag
az
in
e 
m
ad
e 
h
ea
lt
h
 
cl
ai
m
s 
as
 c
o
m
p
ar
ed
 t
o
 4
1
%
 o
f 
ad
s 
in
 t
h
e 
m
ai
n
st
re
am
 m
ag
az
in
e.
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T
ab
le
 B
-1
: 
 (
co
n
ti
n
u
ed
) 
 
A
u
th
o
r 
Sa
m
p
le
 
M
et
h
o
d
 
D
is
cu
ss
io
n
 
M
ac
ke
rt
 a
n
d
 L
o
ve
 
(2
0
1
1
) 
 
1
0
 p
o
p
u
la
r 
m
ag
az
in
es
; 
1
0
 c
u
lt
u
ra
lly
 f
o
cu
se
d
 a
n
d
 o
th
er
 
sp
ec
ia
lt
y 
m
ag
az
in
es
 
**
*
 
Ja
n
u
ar
y 
2
0
0
7
–M
ar
ch
 2
0
0
7
 
**
*
 
8
2
 u
n
iq
u
e 
p
h
ar
m
ac
eu
ti
ca
l 
ad
ve
rt
is
em
en
ts
 
A
n
al
yz
ed
 a
d
 c
o
n
te
n
t 
fo
r 
th
e 
p
re
se
n
ce
 o
r 
ab
se
n
ce
 o
f 
in
fo
rm
at
io
n
 r
eg
ar
d
in
g 
a 
co
n
d
it
io
n
’s
 p
re
va
le
n
ce
, m
e
d
ic
al
 
an
d
 s
o
ci
al
 b
e
n
ef
it
s,
 b
ar
ri
e
rs
 t
o
 
u
se
, a
n
d
 s
ym
p
to
m
s.
 
**
*
 
Ev
al
u
at
ed
 t
h
e 
h
ea
lt
h
 li
te
ra
cy
 o
f 
th
e 
ad
 in
 t
er
m
s 
o
f 
fo
n
ts
 u
se
d
, 
in
fo
rm
at
io
n
 r
eg
ar
d
in
g 
re
se
ar
ch
 o
r 
cl
in
ic
al
 t
ri
al
s,
 a
n
d
 t
h
e 
ap
p
ea
ra
n
ce
 
o
f 
th
e 
m
o
d
el
s 
u
se
d
 (
cu
lt
u
ra
l 
lit
er
ac
y)
. 
 
M
an
y 
ad
s 
la
ck
e
d
 in
fo
rm
at
io
n
 a
b
o
u
t 
a 
co
n
d
it
io
n
’s
 p
re
va
le
n
ce
. 
 
 
V
ir
tu
al
ly
 a
ll 
in
fo
rm
at
io
n
 c
o
n
ta
in
e
d
 in
fo
rm
at
io
n
 a
b
o
u
t 
m
e
d
ic
al
 
b
en
ef
it
s;
 a
b
o
u
t 
4
0
 p
er
ce
n
t 
in
cl
u
d
ed
 in
fo
rm
at
io
n
 a
b
o
u
t 
so
ci
al
 
b
en
ef
it
s.
 
 
 
M
o
st
 o
f 
th
e 
ad
s 
in
cl
u
d
ed
 in
fo
rm
at
io
n
 a
b
o
u
t 
p
o
te
n
ti
al
 s
id
e 
ef
fe
ct
s 
an
d
 c
o
n
tr
ai
n
d
ic
at
io
n
s.
 
 
 
M
o
re
 t
h
an
 h
al
f 
o
f 
th
e 
ad
s 
p
ro
vi
d
ed
 in
fo
rm
at
io
n
 a
b
o
u
t 
fi
n
an
ci
al
 
as
si
st
an
ce
. 
 
 
Le
ss
 t
h
an
 h
al
f 
o
f 
th
e 
ad
s 
in
cl
u
d
e
d
 in
fo
rm
at
io
n
 a
b
o
u
t 
sy
m
p
to
m
s.
 
 
 
M
o
st
 a
d
s 
u
se
d
 n
o
n
st
an
d
ar
d
 t
ex
t 
fo
rm
at
ti
n
g.
 
 
 
N
ea
rl
y 
h
al
f 
th
e 
ad
s 
fe
at
u
re
d
 C
au
ca
si
an
 m
o
d
el
s;
 A
fr
ic
an
 A
m
er
ic
an
 
m
o
d
el
s 
ap
p
ea
re
d
 in
 a
b
o
u
t 
2
0
 p
er
ce
n
t 
o
f 
th
e 
ad
s 
an
d
 H
is
p
an
ic
 
m
o
d
el
s 
ap
p
ea
re
d
 in
 le
ss
 t
h
an
 1
0
 p
er
ce
n
t.
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T
ab
le
 B
-1
: 
 (
co
n
ti
n
u
ed
) 
 
A
u
th
o
r 
Sa
m
p
le
 
M
et
h
o
d
 
D
is
cu
ss
io
n
 
M
as
ti
n
 e
t 
al
. 
(2
0
0
7
) 
Fo
u
r 
m
ag
az
in
e 
ge
n
re
s 
**
*
 
1
9
9
2
–2
0
0
2
 
**
*
 
A
ll 
D
TC
A
 f
o
r 
p
re
sc
ri
p
ti
o
n
 d
ru
gs
 
**
*
 
1
3
2
 m
ag
az
in
es
; 2
8
2
 a
d
ve
rt
is
em
e
n
ts
 
Id
en
ti
fi
ed
 t
h
e 
p
u
rp
o
se
 o
f 
th
e 
d
ru
g,
 t
h
e 
ra
ce
/e
th
n
ic
it
y 
o
f 
th
e 
m
o
d
el
s,
 a
n
d
 t
h
e 
ge
n
d
er
 o
f 
th
e 
m
o
d
el
s.
 
**
*
 
C
o
m
p
ar
ed
 t
h
e 
ra
ce
/e
th
n
ic
it
y 
o
f 
m
o
d
el
s 
as
 a
 f
u
n
ct
io
n
 o
f 
m
ag
az
in
e
 
ge
n
re
. 
**
*
 
C
o
m
p
ar
ed
 t
h
e 
p
u
rp
o
se
 o
f 
th
e 
d
ru
g 
ad
ve
rt
is
ed
 a
s 
a 
fu
n
ct
io
n
 o
f 
m
ag
az
in
e 
ge
n
re
. 
**
*
 
C
o
m
p
ar
ed
 t
h
e 
p
u
rp
o
se
 o
f 
th
e 
d
ru
g 
ad
ve
rt
is
ed
 in
 A
fr
ic
an
 
A
m
er
ic
an
 a
n
d
 w
o
m
en
’s
 
m
ag
az
in
es
 o
ve
r 
th
e 
st
u
d
y 
p
er
io
d
. 
 
 
Th
e 
am
o
u
n
t 
o
f 
D
TC
A
 in
cr
ea
se
d
 o
ve
r 
th
e 
st
u
d
y 
p
er
io
d
.  
Th
e 
la
rg
e
st
 
in
cr
ea
se
 in
 D
TC
A
 o
cc
u
rr
ed
 in
 m
ag
az
in
es
 t
ar
ge
te
d
 t
o
 A
fr
ic
an
 
A
m
er
ic
an
s 
an
d
 w
o
m
en
. 
 
 
Th
re
e–
fo
u
rt
h
s 
o
f 
th
e 
ad
s 
in
 A
fr
ic
an
 A
m
er
ic
an
 m
ag
az
in
es
 u
se
d
 
A
fr
ic
an
 A
m
er
ic
an
 m
o
d
el
s;
 f
ew
 a
d
s 
in
 A
fr
ic
an
 A
m
er
ic
an
 m
ag
az
in
e
s 
fe
at
u
re
d
 C
au
ca
si
an
 m
o
d
el
s 
w
h
ile
 n
ea
rl
y 
al
l a
d
s 
p
la
ce
d
 in
 o
th
er
 
m
ag
az
in
es
 f
ea
tu
re
 C
au
ca
si
an
 m
o
d
el
s 
o
n
ly
. 
 
 
Th
e 
ty
p
es
 o
f 
d
ru
gs
 a
d
ve
rt
is
ed
 v
ar
ie
d
 b
y 
m
ag
az
in
e 
ge
n
re
.  
D
TC
A
 f
o
r 
d
ru
gs
 t
o
 t
re
at
 w
o
m
en
’s
 h
ea
lt
h
 is
su
es
, a
s 
w
el
l a
s 
se
xu
al
ly
 
tr
an
sm
it
te
d
 d
is
ea
se
s,
 w
er
e 
m
o
re
 li
ke
ly
 t
o
 a
p
p
ea
r 
in
 m
ag
az
in
es
 
ta
rg
et
e
d
 t
o
 A
fr
ic
an
 A
m
er
ic
an
s.
 
 
 
Th
e 
ty
p
es
 o
f 
d
ru
gs
 a
d
ve
rt
is
ed
 w
e
re
 n
o
t 
co
n
si
st
e
n
t 
w
it
h
 r
is
k 
o
f 
ill
n
e
ss
 a
ss
o
ci
at
ed
 w
it
h
 t
h
e 
m
ag
az
in
e’
s 
in
te
n
d
e
d
 a
u
d
ie
n
ce
.  
Fo
r 
ex
am
p
le
, t
h
e 
ra
ti
o
 o
f 
ad
s 
fo
r 
h
ea
rt
 m
ed
ic
at
io
n
 w
as
 1
:4
 in
 A
fr
ic
an
 
A
m
er
ic
an
 m
ag
az
in
es
 v
er
su
s 
w
o
m
en
’s
 m
ag
az
in
e
s 
al
th
o
u
gh
 A
fr
ic
an
 
A
m
er
ic
an
s 
ar
e 
m
o
re
 li
ke
ly
 t
o
 d
ie
 f
ro
m
 h
ea
rt
 d
is
ea
se
 t
h
an
 a
re
 
C
au
ca
si
an
s.
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T
ab
le
 B
-1
: 
 (
co
n
ti
n
u
ed
) 
 
A
u
th
o
r 
Sa
m
p
le
 
M
et
h
o
d
 
D
is
cu
ss
io
n
 
M
ai
n
, A
rg
o
, a
n
d
 H
u
h
m
an
n
 
(2
0
0
4
) 
3
0
 p
o
p
u
la
r 
m
ag
az
in
es
 r
e
p
re
se
n
ti
n
g 
se
ve
n
 c
at
e
go
ri
es
 
**
*
 
D
ec
em
b
er
 1
9
9
8
, 1
9
9
9
, a
n
d
 2
0
0
0
 
**
*
 
A
ll 
p
re
sc
ri
p
ti
o
n
 a
n
d
 n
o
n
p
re
sc
ri
p
ti
o
n
 
m
ed
ic
at
io
n
s 
(O
TC
 r
em
ed
ie
s 
an
d
 
d
ie
ta
ry
 s
u
p
p
le
m
e
n
ts
) 
ad
s 
**
*
 
3
6
5
 a
d
ve
rt
is
em
en
ts
—
1
9
5
 f
o
r 
p
re
sc
ri
p
ti
o
n
 d
ru
gs
, 1
3
7
 f
o
r 
O
TC
 
re
m
ed
ie
s,
 a
n
d
 3
3
 f
o
r 
d
ie
ta
ry
 
su
p
p
le
m
e
n
ts
 
D
et
er
m
in
ed
 t
h
e 
ty
p
e 
o
f 
ap
p
ea
l 
u
se
d
. 
**
*
 
Ev
al
u
at
ed
 t
h
e 
d
em
o
gr
ap
h
ic
 
ch
ar
ac
te
ri
st
ic
s 
o
f 
th
e 
m
o
d
el
s 
u
se
d
. 
**
*
 
C
o
m
p
ar
ed
 t
h
e 
ty
p
e 
o
f 
ap
p
ea
l 
u
se
d
 a
n
d
 t
h
e 
ap
p
ea
ra
n
ce
 o
f 
th
e 
m
o
d
el
s 
u
se
d
 in
 p
re
sc
ri
p
ti
o
n
 d
ru
g 
ad
s 
to
 t
h
o
se
 u
se
d
 in
 
n
o
n
p
re
sc
ri
p
ti
o
n
 d
ru
g 
ad
s.
 
 
D
TC
A
 d
o
es
 in
cl
u
d
e 
in
fo
rm
at
io
n
 a
b
o
u
t 
th
e 
d
ru
g,
 t
h
e 
d
is
ea
se
, a
n
d
 
th
e 
ri
sk
s 
an
d
 b
e
n
ef
it
s.
 
 
 
Th
e 
p
ro
m
o
ti
o
n
al
 p
ar
t 
o
f 
th
e 
ad
s 
re
lie
s 
o
n
 a
n
 e
m
o
ti
o
n
al
 r
at
h
er
 
th
an
 a
 r
at
io
n
al
 a
p
p
ea
l. 
 
 
Em
o
ti
o
n
al
 a
p
p
ea
ls
 c
an
 b
e 
b
o
th
 p
o
si
ti
ve
 a
n
d
 n
eg
at
iv
e.
 
 
 
P
re
sc
ri
p
ti
o
n
 d
ru
g 
ad
s 
fe
at
u
re
d
 f
e
w
er
 w
o
m
en
, m
o
re
 c
h
ild
re
n
, a
n
d
 
m
o
re
 W
h
it
es
.  
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T
ab
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 B
-1
: 
 (
co
n
ti
n
u
ed
) 
 
A
u
th
o
r 
Sa
m
p
le
 
M
et
h
o
d
 
D
is
cu
ss
io
n
 
O
m
o
n
u
w
a 
(2
0
0
1
) 
5
 b
la
ck
-o
ri
en
te
d
 m
ag
az
in
e
s;
 
5
 w
h
it
e-
o
ri
en
te
d
 m
ag
az
in
es
 
**
*
 
Ju
n
e 
2
0
0
0
–
A
u
gu
st
 2
0
0
0
 
**
*
 
A
ll 
D
TC
A
 f
o
r 
p
re
sc
ri
p
ti
o
n
 d
ru
gs
 
C
o
m
p
ar
ed
 t
h
e 
n
u
m
b
er
 a
n
d
 t
yp
e 
o
f 
D
TC
A
 a
p
p
ea
ri
n
g 
b
la
ck
-o
ri
en
te
d
 
m
ag
az
in
es
 v
er
su
s 
w
h
it
e-
o
ri
e
n
te
d
 
m
ag
az
in
es
. 
 
Th
e 
am
o
u
n
t 
o
f 
D
TC
A
 w
as
 s
u
b
st
an
ti
al
ly
 g
re
at
er
 (
fo
u
r 
to
 e
ig
h
t 
ti
m
es
) 
in
 w
h
it
e-
o
ri
en
te
d
 m
ag
az
in
es
 t
h
an
 in
 b
la
ck
-o
ri
en
te
d
 
m
ag
az
in
es
. 
 
 
Th
e 
ty
p
es
 o
f 
d
ru
gs
 a
d
ve
rt
is
ed
 v
ar
ie
d
 b
et
w
ee
n
 w
h
it
e
-o
ri
e
n
te
d
 
m
ag
az
in
es
 a
n
d
 b
la
ck
-o
ri
e
n
te
d
 m
ag
az
in
es
. 
 
 
N
o
 a
d
s 
ap
p
ea
re
d
 in
 w
h
it
e
-o
ri
en
te
d
 m
ag
az
in
e
s 
fo
r 
o
ra
l 
co
n
tr
ac
ep
ti
o
n
 o
r 
H
IV
/A
ID
S.
 
 
 
N
o
 a
d
s 
ap
p
ea
re
d
 in
 b
la
ck
-o
ri
en
te
d
 m
ag
az
in
es
 f
o
r 
ch
o
lin
es
te
ra
se
 
in
h
ib
it
o
rs
 (
fo
r 
th
e 
tr
ea
tm
en
t 
o
f 
d
em
en
ti
a)
, c
al
ci
u
m
 s
u
p
p
le
m
en
ts
, 
C
O
X
-I
I i
n
h
ib
it
o
rs
 (
p
ai
n
 r
e
lie
f)
, i
n
tr
an
as
al
 s
te
ro
id
s,
 a
n
o
re
xi
an
ts
 
(a
p
p
et
it
e 
su
p
p
re
ss
io
n
),
 p
ro
to
n
 p
u
m
p
 in
h
ib
it
o
rs
 (
re
d
u
ct
io
n
 o
f 
ga
st
ri
c 
ac
id
 p
ro
d
u
ct
io
n
),
 a
n
d
 s
m
o
ki
n
g 
d
et
er
re
n
t 
ag
en
ts
. 
P
in
to
 
(2
0
0
0
) 
2
4
 p
o
p
u
la
r 
m
ag
az
in
es
 r
e
p
re
se
n
ti
n
g 
1
2
 c
at
eg
o
ri
es
 
**
*
 
M
ar
ch
 1
9
9
6
–F
e
b
ru
ar
y 
1
9
9
8
 
**
*
 
4
8
 m
ag
az
in
e 
is
su
e
s 
ra
n
d
o
m
ly
 
se
le
ct
e
d
 
**
*
 
A
ll 
D
TC
A
 o
f 
at
 le
as
t 
o
n
e-
h
al
f 
p
ag
e
 in
 
si
ze
 
**
*
 
5
8
 u
n
iq
u
e 
p
h
ar
m
ac
eu
ti
ca
l 
ad
ve
rt
is
em
en
ts
 
C
at
eg
o
ri
ze
d
 d
ru
gs
 a
d
ve
rt
is
e
d
 
w
it
h
in
 s
ix
 c
at
eg
o
ri
es
. 
**
*
 
Ev
al
u
at
ed
 t
h
e 
ty
p
e 
o
f 
ap
p
ea
l 
u
se
d
 in
 e
ac
h
 a
d
 (
fe
ar
, h
u
m
o
r,
 
gu
ilt
, s
ex
, r
el
at
io
n
al
, a
n
d
 
in
fo
rm
at
io
n
).
 
 
C
o
m
p
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APPENDIX C:  FREQUENCY OF INDIVIDUAL DRUG ADVERTISEMENTS BY 
MAGAZINE GENRE AND PUBLICATION DATE 
 
 The following table provides a complete inventory of the 1,090 product claim 
advertisements found in the five magazines providing data for this research.  Individual 
drugs are grouped within 16 categories:  Allergies, Cancer, Cardiovascular, Cosmetic, 
Dermatologic, Diabetes, Gastrointestinal/Nutritional, Infectious (Non-HIV), 
Musculoskeletal, Obstetric/Gynecological, Ophthalmological, Psychiatric/Neurologic, 
Respiratory, Tobacco Addiction, and Urological (e.g., the category “Allergies” includes 
the drugs EpiPen and Singulair).  The number of ads for each drug is reported, as well as 
the relative percentage within a given category.  For example, 13 ads for cardiovascular 
drugs appeared in black-oriented magazines published before the 2009 FDA report.  Five 
of these ads (or 38.5 percent) were for Caduet and eight (or 61.5 percent) were for Plavix.    
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Table C-1:  Name of Drug Advertised by Racial Orientation of Magazine 
(No. of Ads/Percent of Disease Category) 
 
DRUG NAME BEFORE AFTER 
 Black White Cross-
over 
Black White Cross-
over 
Allergies --- 1/100.0 --- --- 3/100.0 --- 
EpiPen --- --- --- --- 3/100.0 --- 
Singulair --- 1/100.0 --- --- --- --- 
Cancer 1/100.0 1/100.0 --- --- --- --- 
Arimidex --- 1/100.0 --- --- --- --- 
Femara 1/100.0 --- --- --- --- --- 
Cardiovascular 13/100.0 56/100.0 8/100.0 --- 30/100.0 2/100.0 
Caduet 5/38.5 5/8.9 --- --- --- --- 
Crestor --- 12/21.4 4/50.0 --- --- --- 
Lipitor --- 4/7.1 --- --- 3/10.0 2/100.0 
Livalo --- --- --- --- 8/26.7 --- 
Lovaza --- 2/3.6 --- --- 1/.33 --- 
Niaspan --- 2/3.6 --- --- 2/6.7 --- 
Plavix 8/61.5 13/23.2 4/50.0 --- --- --- 
Pradaxa --- --- --- --- 12/40.0 --- 
TriCor --- 2/3.6 --- --- --- --- 
Vytorin --- 5/8.9 --- --- --- --- 
Xarelto --- --- --- --- 2/6.7 --- 
Zetia --- 11/19.6 ---  2/6.7 --- 
Cosmetic --- --- 17/100.0 --- 8/100.0 13/100.0 
ArteFill --- --- 2/11.8 --- --- --- 
Botox Cosmetic --- --- 3/17.7 --- 3/37.5 6/46.2 
Dysport --- --- 1/5.9 --- --- --- 
Juvederm --- --- 3/17/7 --- --- 3/23.1 
Latisse --- --- 3/17.7 --- 5/62.5 3/23.1 
Restylane --- --- 3/17.7 --- --- --- 
SculptraAesthetic --- --- --- --- --- 1/7.7 
Vivite --- --- 2/11.8 --- --- --- 
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Table C-1:  (continued) 
 
DRUG NAME BEFORE AFTER 
  
Black 
 
White 
Cross-
over 
 
Black 
 
White 
Cross-
over 
Dermatologic --- 6/100.0 3/100.0 --- 3/100.0 11/100.0 
Asclera --- --- --- --- --- 5/45.5 
Enbrel --- 3/50.0 --- --- --- --- 
Humira --- --- --- --- 3/100.0 3/27.3 
Oracea --- 3/50.0 --- --- --- 3/27.3 
Diabetes 20/100.0 3/100.0 1/100.0 17/100.0 12/100.0 --- 
FlexPen 2/10.0 --- --- --- --- --- 
Januvia 16/80.0 2/66.7 1/100.0 14/82.4 --- --- 
Lantus 2/20.0 1/33.3 --- --- 1/8.3 -- 
Victoza --- --- --- 3/17.6 11/91.7 --- 
Gastrointestinal/ 
Nutritional 
--- 17/100.0 2/100.0 --- --- --- 
AcipHex --- 11/64.7 --- --- --- --- 
Amitiza --- 4/23.5 --- --- --- --- 
Transderm Scop --- 2/11.8 2/100.0 --- --- --- 
Infectious  
(Non-HIV) 
5/100.0 17/100.0 6/100.0 20/100.0 20/100.0 --- 
FluMist --- --- --- --- 3/15.0 --- 
FluZone --- --- --- --- 2/10.0 --- 
Gardasil 2/40.0 10/58.8 6/100.0 12/60.0 8/40.0 --- 
Incivek --- --- --- 3/15.0 --- --- 
Prevnar 13 --- --- --- 5/25.0 2/10.0 --- 
Tamiflu --- --- --- --- 2/10.0 --- 
Valtrex 3/100.0 --- --- --- --- --- 
Zostavax --- 7/41.2 --- --- 3/15.0 --- 
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Table C-1:  (continued) 
 
DRUG NAME BEFORE AFTER 
  
Black 
 
White 
Cross-
over 
 
Black 
 
White 
Cross-
over 
Musculoskeletal 8/100.0 76/100.0 13/100.0 5/100.0 79/100.0 7/100.0 
Actonel --- 22/29.0 --- --- --- --- 
Boniva --- 11/14.5 3/23.1 --- 11/13.9 --- 
Celebrex --- 8/10.5 --- --- 7/8.9 --- 
Cimzia --- --- --- --- 8/10.1 --- 
Enbrel --- --- --- --- 2/2.5 --- 
Evista --- 11/14.5 4/30.8 --- 4/5.1 --- 
Humira --- 1/1.3 --- --- 4/5.1 --- 
Orencia 8/100.0 8/10.5 3/23.1 5/100.0 6/7.6 3/42.9 
Prolia --- --- --- --- 14/17.7 --- 
Reclast --- 13/17.1 3/23.1 --- 5/6.3 --- 
Remicade --- 1/1.3 --- --- --- --- 
Simponi --- --- --- --- 6/7.6 --- 
Synvisc-One --- 1/1.3 --- --- 2/2.5 --- 
Vimovo --- --- --- --- 10/12.7 4/57.1 
Obstetric/ 
Gynecological 
11/100.0 7/100.0 2/100.0 5/100.0 18/100.0 8/100.0 
Estring --- --- --- --- 1/5.6 --- 
Mirena 1/9.1 --- 2/100.0 --- --- --- 
NuvaRing --- --- --- 5/100.0 --- --- 
Plan B 2/18.2 --- --- --- --- --- 
Premarin Vaginal 
Cream 
--- 7/100.0 --- --- 17/94.4 7/87.5 
VagiFem --- --- --- --- --- 1/12.5 
Yaz 8/72.7 --- --- --- --- --- 
Ophthalmological --- --- --- --- 8/100.0 6/100.0 
Restasis --- --- ---  8/100.0 6/100.0 
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Table C-1:  (continued) 
 
DRUG NAME BEFORE AFTER 
 Black White Cross-
over 
Black White Cross-
over 
Psychiatric/ 
Neurologic 
22/100.0 125/100.0 25/100.0 18/100.0
0 
109/100.0 33/100.0 
Abilify --- 17/13.6 6/24.0 --- 14/12.8 11/33.3 
AmbienCR 1/4.5 11/8.8 --- --- --- --- 
Aricept --- --- --- --- 11/10.1 --- 
Botox --- --- --- --- 4/3.7 3/9.1 
Concerta --- 8/6.4 1/4.0 --- --- --- 
Cymbalta 3/13.6 18/14.4 8/32.0 --- 29/26.6 5/15.2 
Exelon Patch --- --- --- --- 6/5.5 --- 
Horizant --- --- --- --- 1/0.9 --- 
Keppra --- 4/3.2 --- --- --- --- 
Lunesta --- 2/1.6 --- --- 3/2.6 --- 
Lyrica 11/50.0 11/8.8 6/24.0 9/50.0 16/14.7 8/24.2 
Mirapex --- 2/1.6 --- --- --- --- 
Nuedexta --- --- --- --- 1/0.9 --- 
Pristiq --- 6/4.8 --- 9/50.0 13/11.9 3/9.1 
Provigil --- 1/0.8 --- --- --- --- 
Rozerem --- 1/0.8 1/4.0 --- --- --- 
Seroquel XR --- --- --- --- 11/10.1 3/9.1 
Topamax --- 3/2.4 3/12.0 --- --- --- 
Treximet --- 8/6.4 --- --- --- --- 
Ultram ER --- 1/0.8 --- --- --- --- 
Vyvanse 7/31.8 32/25.6 --- --- --- --- 
Respiratory 16/100.0 41/100.0 4/100.0 10/100.0 48/100.0 4/100.0 
Advair 
Diskus 
9/56.3 17/41.5 --- 2/20.0 18/37.5 1/25.0 
Dulera --- --- --- --- 12/25.0 --- 
Flovent 
Diskus 
--- --- --- 4/40.0 2/4.2 1/25.0 
Pulmicort 
Respules 
3/18.8 1/2.4 4/100.0 --- --- --- 
Singulair --- 7/17.1 --- --- --- --- 
Spiriva 
HandiHaler 
4/25.0 4/9.8 --- --- 7/14.6 --- 
Symbicort --- 12/29.3 --- 4/40.0 9/18.8 2/50.0 
Tobacco 
Addiction 
--- 7/100 --- --- --- --- 
Chantix --- 7/100 --- --- --- --- 
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Table C-1:  (continued) 
 
DRUG NAME BEFORE AFTER 
  
Black 
 
White 
Cross-
over 
 
Black 
 
White 
Cross-
over 
Urological --- 40/100.0 2/100.0 --- 13/100.0 4/100.0 
Detrol LA --- 11/27.5 --- --- --- --- 
Enablex --- 17/42.5 --- --- --- --- 
Toviaz --- 4/10.0 2/100.0 --- 9/69.2 4/100 
VESIcare --- 8/20.0 --- --- 4/30.8 --- 
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APPENDIX D:  ANALYSIS OF APPEALS USED IN  
DIRECT-TO-CONSUMER ADVERTISING 
 
 The following analysis examines the type of appeals used in DTCA as a function 
of magazine genre and time.  As discussed in Chapter 4, the primary driver behind the 
type of appeal used in DTCA is the actual drug advertised and not the magazine in which 
the ad appeared (see Tables D-1 and D-2).  Hence, the data reported in this appendix 
should be considered with this in mind.  There is no evidence to suggest that 
pharmaceutical manufacturers altered the appeals used in their advertising based either on 
magazine genre or publication date. 
Virtually all DTCA examined used a rational appeal (less than 1 percent did not).  
Nearly all ads made a claim about their effectiveness; roughly one-third claimed some 
sort of social or psychological enhancement, such as allowing the user to lead a more 
active lifestyle.  Between 30 and 45 percent of ads claimed to be easy to use and safe.  
There was some variation in these latter two attributes between the two time periods 
studied, with the number of ads claiming to be easy to use decreasing over time and the 
number of ads claiming to be safe increasing.  Table D-3 presents these results. 
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Table D-1:  Relationship of ads using a rational appeal to magazine genre 
 Rational Appeal?  
Magazine Genre Yes No Total 
White 
N 
% 
 
296 
99.0 
 
3 
1.0 
 
299 
100.0 
Black 
N 
% 
 
89 
100.0 
 
0 
0.0 
 
89 
100.0 
Crossover 
N 
% 
 
51 
100.0 
 
0 
0.0 
 
51 
100.0 
Total 
% 
436 
99.3 
3 
0.7 
439 
100.0 
χ2 (2, n=439) = 1.41, p=.493 
Table D-2:  Relationship of ads using an emotional appeal to magazine genre 
 Emotional Appeal?  
Magazine Genre Yes No Total 
White 
N 
% 
 
256 
85.6 
 
43 
14.4 
 
299 
100.0 
Black 
N 
% 
 
77 
86.5 
 
12 
13.5 
 
89 
100.0 
Crossover 
N 
% 
 
46 
90.2 
 
5 
9.8 
 
51 
100.0 
Total 
% 
379 
86.3 
60 
13.7 
439 
100.0 
χ2 (2, n=439) = .777, p=.678 
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Table D-3:  Distribution of rational appeal claims in DTCA 
published before and after FDA report 
 
 BEFORE AFTER 
Attribute Frequency Percent Frequency Percent 
Effectiveness 198 96.1 230 98.7 
Social-Psychological 
Enhancement 
68 33.0 79 34.6 
Ease of Use 83 40.3 78 34.2 
Safety 71 34.5 99 43.4 
 
 
Table D-4 reports the percentage of ads using a rational appeal as a function of 
magazine genre for both time periods studied.  Claims about a drug’s effectiveness were 
by far the most common rational appeal used regardless of magazine genre or publication 
date.  A greater proportion of ads appearing in the black-oriented magazines than in the 
white-oriented magazines claimed a social-psychological enhancement, such as weight 
loss, or advertised its product as being easy to use.  This was true for all publication dates 
studied.  For example, 29.2 percent of ads appearing in white-oriented magazines 
published before the FDA report claimed some sort of social-psychological enhancement.  
During this same time period, 50.9 percent of ads appearing in black-oriented magazines 
made such a claim.  Besides being effective, the most likely product claim made by 
medications advertised in the crossover magazine was safety (65.2 percent of ads 
published before the FDA report and 50.0 percent of ads published after the FDA report 
made such a claim).   
  
219 
 
 
Table D-4:  Percent of DTCA published before and after FDA report using 
rational appeals as a function of magazine genre 
 
 BEFORE AFTER 
Rational 
Appeal 
Magazine Genre Magazine Genre 
White Black Crossover White Black Crossover 
Effectiveness 97.7 
(n=127) 
96.2 
(n=51) 
87.0 
(n=20) 
97.0 
(n=161) 
100.0 
(n=36) 
96.4 
(n=27) 
Social-
Psychological 
Enhancement 
29.2 
(n=38) 
50.9 
(n=27) 
13.0 
(n=3) 
33.7 
(n=56) 
61.1 
(n=22) 
3.6 
(n=1) 
Ease of Use 30.8 
(n=40) 
64.2 
(n=34) 
39.1 
(n=9) 
32.5 
(n=54) 
50.0 
(n=18) 
25.0 
(n=7) 
Safety 23.8 
(n=31) 
20.8 
(n=11) 
65.2 
(n=15) 
44.0 
(n=73) 
36.1 
(n=13) 
50.0 
(n=14) 
 
 
The use of product claims varied depending on the type of drug advertised as 
illustrated in Table D-5.  This table reports the distribution of ads using rational appeals 
across the six disease categories of interest for all magazines and both time periods 
studied.  From this table, we can see that nearly 61 percent of the ads for drugs used to 
treat respiratory illness claimed a social-psychological enhancement and nearly 
33 percent claimed to be safe.  As an example, an advertisement for Advair, used to treat 
asthma, claimed that the drug would help you “breathe better” (social-psychological 
enhancement) and promised symptom control for up to “24 hours” (easy to use).  Lipitor, 
a drug used to lower cholesterol, touted the results of clinical trials (effectiveness) and 
noted that it had been “extensively studied with over 18 years of research…backed by 
over 400 ongoing or completed clinical trials” (safety).  One hundred percent of ads for 
cardiovascular drugs claimed to be effective.  Most of the DTCA in the diabetes drugs 
were for injection pens, hence the large percentage (94.3%) of ads claiming ease of use. 
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Table D-5:  The distribution of DTCA using rational appeals by disease category 
 
Disease 
Category 
Type of Rational Appeal 
Effectiveness  Enhancement Easy to Use Safety 
Alzheimer’s 17 
(100.0%) 
6 
(35.3%) 
6 
(35.3%) 
4 
(23.5%) 
Cancer 2 
(100.0%) 
0 
(0.0%) 
1 
(50.0%) 
2 
(100.0%) 
Cardiovascular 108 
(100.0%) 
20 
(18.5%) 
33 
(30.6%) 
29 
(26.9%) 
Depression 126 
(92.0%) 
4 
(2.9%) 
30 
(21.9%) 
92 
(67.5%) 
Diabetes 48 
(90.6%) 
43 
(81.1%) 
50 
(94.3%) 
4 
(7.6%) 
Respiratory 121 
(99.2%) 
74 
(60.6%) 
42 
(34.4%) 
40 
(32.8%) 
 
 
In the ads published before the FDA report, 81 percent (n=166) included an 
emotional appeal.  For ads published after the FDA report, that proportion increased to 
91 percent (n=213).  Of the 166 ads published before the 2009 FDA report, nearly 
50 percent included a positive appeal.  That percentage increased to over 60 percent in 
ads published after the FDA report.  Only one ad published in 2008 and 2009 included a 
humorous appeal; that number rose to 33 in the 2011/2012 timeframe.  Less than 
10 percent of the ads examined included a nostalgic appeal.  A negative appeal was used 
in just over 60 percent of the ads published in 2008 and 2009; this proportion rose to 
65 percent in ads published in 2011 and 2012.  Some ads included both a positive and 
negative appeal.  (Recall the tag line for the Cymbalta ad in Figure 4-3—“Depression 
Hurts.  Cymbalta can help.”)  Table D-6 summarizes these results. 
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Table D-6:  Distribution of emotional appeals in DTCA 
published before and after FDA report 
 
 BEFORE AFTER 
Type of Appeal Frequency Percent Frequency Percent 
Positive 81 48.8 134 62.9 
Humorous 1 0.6 33 15.4 
Nostalgic 12 7.2 18 8.5 
Negative 101 60.8 138 64.8 
 
 
Table D-7 reports the percentage of ads using an emotional appeal as a function of 
magazine genre for both time periods studied.  The most common types of emotional 
appeal were either a positive appeal or negative appeal.  Few ads took a humorous 
approach and those that did often coupled it with a negative appeal.  For example, an ad 
for Spiriva, a medication used to treat COPD, shows an elephant sitting on a woman’s 
chest.  While the graphic image could be considered humorous, the tag line is not:  “Does 
Breathing With COPD Weigh You Down?”  Nostalgic appeals were prompted by 
images, such as photos of the ad’s model at an earlier period of life, and the use of tag 
lines such as this:  “throughout my life, mom has always been there for me, now it’s my 
turn,” found in an ad for the Exelon Patch used to treat Alzheimer’s disease.   
Table D-7:  Percent of DTCA published before and after FDA report using 
emotional appeals as a function of magazine genre 
 
 BEFORE AFTER 
Emotional 
Appeal 
Magazine Genre Magazine Genre 
White Black Crossover White Black Crossover 
Positive 46.5 
(n=47) 
64.4 
(n=29) 
25.0 
(n=5) 
57.4 
(n=89) 
93.8 
(n=30) 
42.3 
(n=11) 
Humorous 1.0 
(n=1) 
0.0 
(n=0) 
0.0 
(n=0) 
14.8 
(n=23) 
0.0 
(n=0) 
38.5 
(n=10) 
Nostalgic 8.9 
(n=9) 
0.0 
(n=0) 
15.0 
(n=3) 
11.6 
(n=18) 
0.0 
(n=0) 
0.0 
(n=0) 
Negative 65.3 
(n=66) 
35.6 
(n=10) 
95.0 
(n=19) 
63.2 
(n=98) 
46.9 
(n=15) 
96.2 
(n=25) 
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It is important to note that many ads used both a positive and negative appeal.  
Therefore, caution should be exercised in interpreting the results reported in Table D-7.  
For example, it would not be correct to conclude that ads placed in black-oriented 
magazines were more likely to use a positive appeal than ads place in white-oriented 
magazines or that ads placed in white-oriented magazines were more likely to use a 
negative appeal than ads placed in black-oriented magazines.   
However, it is interesting that the overwhelming majority of DTCA found in O, 
The Oprah Magazine (95.0 percent of ads published before the FDA report and 
96.2 percent of ads published after the report) used a negative appeal.  Looking more 
closely at the data revealed that 39 of the 46 ads (approximately 85 percent) that appeared 
in the magazine during the study period promoted drugs used to treat either depression or 
cardiovascular disease.  Drugs in both of these disease categories tend to use negative 
appeals, such as the ad for Crestor which uses the tag line:  “While you’ve been building 
your life, plaque may have been building in your arteries.”  This trend can be seen in 
Table D-8 which reports the distribution of ads using emotional appeals across the six 
disease categories of interest for all magazines and both time periods studied.  For 
example, 86.1 percent of ads for antidepressant medications and 65.7 percent of ads for 
cardiovascular medications used a negative emotional appeal. 
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Table D-8:  The distribution of DTCA using emotional appeals by disease category 
 
Disease 
Category 
Type of Emotional Appeal 
Positive  Humorous Nostalgic Negative 
Alzheimer’s 0 
(0.0%) 
0 
(0.0%) 
17 
(100.0%) 
0 
(0.0%) 
Cancer 2 
(100.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
Cardiovascular 43 
(39.8%) 
1 
(0.9%) 
13 
(12.0%) 
71 
(65.7%) 
Depression 37 
(27.0%) 
21 
(15.3%) 
0 
(0.0%) 
118 
(86.1%) 
Diabetes 53 
(100%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
Respiratory 59 
(48.4%) 
12 
(9.8%) 
0 
(0.0%) 
33 
(27.1%) 
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